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Abstract 
 
This study was directed at characterising the cannabinoid receptor activity modulating 
the electrical field stimulation (EFS) evoked contractions of the rat isolated ileum 
myenteric plexus longitudinal muscle (MPLM) preparation, and the capsaicin, 
nicotine and veratridine evoked secretory responses of the rat isolated colonic 
submucosal plexus-mucosal (SPM) preparation.  
 
EFS of the MPLM preparation with single pulses at a repetition frequency of 0.05 Hz 
elicited a transient twitch contraction immediately in response to each electrical pulse. 
In contrast, stimulation of the MPLM preparation with 2 second trains of pulses every 
minute at a frequency of 30 Hz elicited a rapid transient rebound contraction on 
termination of each train of EFS. The non-selective cannabinoid receptor agonists 
AEA, CP 55,940, Δ9-THC and WIN 55,212-2 inhibited both EFS-evoked twitch and 
rebound contractions of the rat ileum MPLM elicited by 0.05 Hz and 30 Hz EFS 
respectively. The inhibition of the twitch contractions was competitively antagonised 
by the cannabinoid CB1 receptor antagonist / inverse agonist SR 141716 with pKB 
values of 8.60. In contrast, SR 141716 only antagonised the ability of AEA, Δ9-THC 
and WIN 55,212-2 but not CP 55,940 to inhibit the rebound contractions with pA2 
values of 6.60.  These observations extended to the inhibitory effect of WIN 55,212-2 
on the twitch and rebound contractions of the guinea-pig ileum MPLM. The CB2 
antagonist / inverse agonist SR 144528 did not alter the effects of the agonists. 
Additionally, the inhibitory effect of AEA was refractory to the vanilloid TRPV1 
receptor antagonist capsazepine. WIN 55,212-3 a stereoisomer of WIN 55,212-2 was 
without effect on the rat MPLM. SR 141716 alone concentration-dependently 
increased the twitch contractions but inhibited the rebound contractions. Both types of 
the EFS-evoked contractions were abolished by the Na+ channel blocker tetrodotoxin 
or the muscarinic acetylcholine (ACh) receptor antagonist atropine but not the 
nicotinic ACh receptor antagonist hexamethonium. None of the cannabinoids altered 
the contractions to exogenously applied ACh. 
 
These data suggested that the cannabinoid agonists inhibited the twitch contractions 
through a stereospecific presynaptic CB1 receptor-mediated reduction in the release of 
 ii
ACh. Additionally, the inhibition of the rebound contractions occurred because of an 
inhibition of ACh release by a novel stereospecific presynaptic non-CB1 -non CB2 -
non -TRPV1 site. The ability of SR 141716 to inhibit the rebound contractions and 
antagonise AEA, Δ9-THC and WIN 55,212-2 may be though partial agonism at the 
non-CB1-non CB2-non-TRPV1 site.  
 
The ability of SR 141716 to potentiate the twitch contractions by increasing the 
release of ACh suggested that the CB1 receptor was constitutively active or was 
subjected to a tonic activation by endocannabinoid agonists. A comparison between 
the maximal enhancement of the twitch contractions of the rat and the guinea-pig 
ileum MPLM caused by three CB1 receptor antagonists / inverse agonists AM 251, 
SR 141716 and O-2050 showed that each cannabinoid had a different maximum. This 
suggested inverse agonism. These data were supported with studies showing the lack 
of effect of three fatty acid amide hydrolase (FAAH) inhibitors AA-5HT, PMSF, 
URB–597 and VDM-11, an inhibitor of the AEA uptake transporter on EFS-evoked 
contractions. These studies showed that all three FAAH inhibitors increased the 
potency of exogenously applied AEA but not WIN 55,212-2, and that VDM-11 had 
no effect on the potency of exogenously applied AEA. This data suggested that a 
functional endocannabinoid tone and the uptake transporter were not present in the 
MPLM, but FAAH was present. These data provide supporting evidence that SR 
141716 behaved as an inverse agonist in the MPLM to augment twitch contractions. 
 
The interaction between CP 55,940 or WIN 55,212-2 with SR 141716 was 
investigated using the rat colonic SPM sheet. Both CP 55,940 and WIN 55,212-2 
attenuated the secretory responses to capsaicin and nicotine in a SR 141716 sensitive 
manner. SR 140333, a neurokinin 1 receptor antagonist, abolished the capsaicin and 
nicotine. This suggested that CP 55,940 and WIN 55,212-2 inhibited the capsaicin and 
nicotine response through a CB1 receptor-mediated inhibition of the release of 
substance P or neurokinin A. The sensitivity of the veratridine response to TTX and 
α-chymotrypsin and the failure of the cannabinoids to attenuate the response 
suggested the absence of the CB1 receptor on the neurones releasing the undetermined 
neuropeptide.  
 
 iii
Together, these data suggest that both the CB1 receptor and non-CB1-non-CB2 -non-
TRPV1 receptor can mediate the inhibitory effects of cannabinoid agonists in the rat 
ileum MPLM depending on the frequency of EFS. These data also show that SR 
141716 is an inverse agonist in the MPLM. In the SPM preparation, the CB1 receptor 
appears to be involved in the modulation of some forms of peptidergic transmission. 
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CHAPTER 1: 
GENERAL INTRODUCTION 
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1.1. Cannabis sativa 
 
1.1.1. Botany 
The Indian hemp represents one of mankind’s oldest cultivated Old World plants 
originating from the plains of Central Asia, but through man’s activities has been 
distributed widely around the world (Grinspoon & Bakalar, 1993; Peters & Nahas, 
1999). The plant has been exploited through the process of selection for thousands of 
years for multiple desirable characteristics, some grown exclusively for their fibre and 
oil content, while others for their content of psychoactive chemicals (Grinspoon & 
Bakalar, 1993; Peters & Nahas, 1999). All of these varieties are generally classified 
under the Linnaeus system as a single species, Cannabis sativa L. (Schultes, 1970). 
 
The cannabis plant is a fast growing annual with characteristic finely branched leaves, 
each of which are subdivided into at least five spear shaped leaflets with a saw tooth 
edge (Figure 1.0). The plant is either male or female, and under normal temperate 
growing conditions these are generated in roughly equal numbers (Iversen, 2000; 
Stearn, 1970).  
 
A vast number of constituents representing almost all of the chemical classes, e.g. 
amino acids, flavonoids, nitrogenous compounds, hydrocarbons, steroids, sugars, are 
present in the plant. However, to date, at least seventy 21–carbon-containing 
terpenophenolic alkaloids which are unique to the plant have been identified (ElSohly 
& Slade, 2005; Lambert & Fowler, 2005). These compounds are commonly referred 
to as cannabinoids, or more specifically phytocannabinoids because of their plant 
origin.  
 
Although a large variability exists in the amount and ratio of the chemical constituents 
of the plant, which is dependent on botanical and cultivation factors, Δ9-
tetrahydrocannabinol (Δ9-THC; Figure 1.1) is the principal psychoactive 
phytocannabinoid (Gaoni & Mechoulam, 1964). Δ9-THC is present in larger amounts, 
usually 1 - 5 % by weight, than other phytocannabinoids (Grinspoon & Bakalar, 
1993). It is present in most parts of the plant including the leaves and flowers, but is 
most highly concentrated in fine droplets of resin produced by glands at the base of 
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the fine hairs that coat the leaves and the bracts of the female flower head (Stearn, 
1970). Other major phytocannabinoids that are present in similar or lesser amounts 
than Δ9-THC include cannabinol, cannabidiol, cannabingerol etc. The later 
phytocannabinoids are essentially non-psychoactive, but may possess 
pharmacological activity (ElSohly & Slade, 2005; Mechoulam, 1970).  
 
 
A 
B 
 
 
 
Figure 1.0: Cannabis sativa. L. The (A) male and (B) female plants. Modified from 
Köhler FE (1887). Cannabis sativa (Cannabaceae). Available at http://caliban.mpiz-
koeln.mpg.de/~stueber/koehler/CANNABIS.jpg 
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1.1.2. Historical uses and current legislation 
Cannabis was possibly one of the most versatile plants cultivated not specifically for 
its herbal contents, but as a valuable source of natural fibre and oil. The strong 
structural fibres in its stalk and stems provided material for cloth and rope making, 
whilst the oil in its seeds was used as a lubricant, paint ingredient and for cooking 
(Grinspoon & Bakalar, 1993; Schultes, 1970). 
 
Although the first descriptions of its medicinal properties were included by the Greek 
physician Dioscorides in his classic textbook of pharmacology, De Materia Medica 
(“The Materials of Medicine”) in 60 AD, the curative properties of the plant were 
popularised into Western medicine by the British physician William O’Shaughnessy 
in 1830 (Iversen, 2000). O’Shaughnessy reported, observing the medicinal use of the 
drug in India for its effectiveness in the treatment of a variety of ailments such as 
asthma, constipation, convulsions, diarrhoea, epilepsy, nausea, rheumatic pain, 
tetanus and vomiting (O’Shaughnessy, 1842). Soon afterwards, both an extract and a 
tincture of cannabis were introduced into the British Pharmacopoeia in 1845, and 
were available for more than a hundred years (Iversen 2000). However, by the middle 
of the twentieth century, the availability of alternative treatments, increased 
recreational use of cannabis and difficulties in obtaining standardised supplies of the 
medicine led to the removal of both herbal preparations from the British 
Pharmacopoeia as the Misuse of Drugs Act (1971) declared that it was of no medical 
benefit and its use was illegal (Baker et al., 2003). 
 
Today, despite the illegal possession, supply and use of cannabis for self–medication 
in the United Kingdom (U.K.), cannabis is a schedule C drug, as recognition that it 
does not carry the same risks as schedule B drugs such as amphetamine and 
barbiturates (Baker et al., 2003). 
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1.1.3. Modern therapeutic applications 
The interest in the therapeutic properties of cannabis was renewed after the discovery 
and isolation of Δ9-THC (Gaoni & Mechoulam, 1964). The chemical synthesis of the 
phytocannabinoid was followed by research into basic structure activity relationships 
(Razdan, 1986) and their metabolic routes (Agurell et al., 1986) with the aim of 
developing more potent and less lipophilic analogues, or compounds that separated 
the desirable medicinal properties from the psychoactive effects. 
 
The first potent synthetic Δ9-THC analogue to be used in man was nantradol, 
synthesised in the early 1980s by Pfizer Inc. in the United States of America (U.S.A), 
but this was subsequently replaced by levonantradol (Nantrodolum®) (Iversen, 2000). 
The synthetic cannabinoids had an advantage over Δ9-THC as they were slightly 
water soluble and thus easier to formulate and deliver. In spite of proving more potent 
than morphine as analgesics and effective in blocking nausea and vomiting in patients 
undergoing cancer chemotherapy, the inability to separate the psychoactive property 
was a drawback to their use (Iversen, 2000). However, since levonantradol, a number 
of clinically useful cannabinoid based medicines have been developed and are 
currently available by prescription both in the U.K and U.S.A., whilst others are in 
clinical trials. Some Δ9-THC based drugs that are already used clinically include 
dronabinol (Marinol®), which is available under prescription to counteract the AIDS 
wasting syndrome and nabilone (Cesamet®) another potent synthetic analogue of Δ9-
THC, with low psychotomimetic activity, which is marketed to curtail nausea and 
vomiting experienced by patients undergoing cancer chemotherapy (Pertwee, 2000). 
More recently, two other cannabinoid medicines have become available. These 
include rimonabant or Acomplia®, synthesised by Sanofi Recherchē in France, and 
Sativex®, developed by GW Pharmaceuticals in the U.K. Rimonabant®, an antagonist 
/ inverse agonist of the central cannabinoid CB1 receptor has been indicated as an 
anti-obesity drug and for the suppression of the reinforcing and rewarding properties 
of a number of drugs of abuse, such as alcohol, cocaine, heroin and nicotine (Carai et 
al., 2005), whereas Sativex®, a whole cannabis plant extract containing an equal 
proportion of Δ9-THC and cannabidiol is being tested for clinical efficacy for the 
alleviation of symptoms of debilitating conditions such as multiple sclerosis, spinal 
cord injury and neurogenic pain (Smith, 2004). 
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1.2. Cannabinoid receptor subtypes 
 
One of the earliest hypothesis concerning the mechanism of action of Δ9-THC was 
attributed to its high lipophilicity, which could perturb the phospholipid bilayer of the 
cell plasma membrane and result in relatively non-specific disruption of cellular 
function (Hillard et al., 1985; Paton, 1975; Roth & Williams, 1979). 
 
There is now convincing evidence for the existence of specific cannabinoid receptors, 
with two subtypes being described i.e. the CB1 receptor (Section 1.2.1) and CB2 
receptor (Section 1.2.2), as defined by the IUPHAR Committee on Receptor 
Nomenclature (Howlett et al., 2002). Both receptors share common characteristics 
with other members of the G protein-coupled receptor family in their amino acid 
sequences and the seven transmembrane helical structures (Matsuda et al., 1990; 
Munro et al., 1993). Between them, both receptors mediate the majority of the 
pharmacological actions of Δ9-THC. 
 
Recent data have pointed to the existence of additional novel pharmacological targets 
for cannabinoids because of the observation of non-CB1-non-CB2-receptor mediated 
effects by number of established cannabinoid receptor agonists, either after blockade 
of the CB1 and CB2 receptors with selective antagonists or in transgenic CB1-/-, CB2-/- 
and CB1-/- / CB2-/- receptor gene knockout animals and their tissues (for review see 
Pertwee, 2004). 
 
1.2.1. Cannabinoid CB1 receptor 
The earliest evidence that a specific stereo-selective cannabinoid binding site 
mediated the pharmacological actions of Δ9-THC and its analogues was provided by 
Howlett and co-workers using rat brain neuroblastoma N18TG2 cells (Howlett, 1984; 
Howlett et al., 1986). The authors of these studies proposed the existence of a stereo-
specific Gi/o protein-coupled cannabinoid receptor on the observation that pairs of 
enantiomeric psychotropic cannabinoids inhibited the activity of the enzyme 
adenylate cyclase in a concentration-dependent, stereo-selective and pertussis-toxin 
sensitive manner. Soon afterwards, this hypothesis was validated by radioligand-
binding assays performed on rat brain membranes with the demonstration of a 
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saturable, stereo-selective and high affinity membrane binding site for a range of 
psychotropic cannabinoids (Devane et al., 1988).  
 
The first cannabinoid receptor, designated as the CB1 receptor, was eventually cloned 
from the rat brain (Matsuda et al., 1990) and thereafter from the human brain and 
testis (Gerard et al., 1991) and subsequently from the mouse brain (Abood et al., 
1997; Chakrabarti et al., 1995). This receptor has been noted to be highly conserved 
across the human, rat and mouse. Specifically, the nucleotide sequences of human and 
rat CB1 receptor share 93 % homology, whereas those of human and mouse are 90 % 
similar and those of rat and mouse are 95 % identical (Gerard et al., 1991; Chakrabati 
et al., 1995).  
 
The anatomical distribution of this receptor extends primarily to neuronal tissues such 
as the brain, spinal cord and nerves of the autonomic nervous system, where it is 
localised on the soma and axon terminals to modulate neuronal excitability and 
neurotransmitter release respectively. In the central nervous system (CNS), the CB1 
receptor has been detected in high abundance in the hippocampus, cerebral and 
cerebellar cortices and basal ganglia (Herkenham et al., 1991; Glass et al., 1997). The 
heterogeneous receptor distribution in these discrete areas correlates well with the 
known effects of cannabinoids on memory, perception and motor function. The 
peripheral distribution pattern of the CB1 receptor extends mainly to nerve terminals 
innervating visceral organs such as the adrenal glands, heart, lungs, gastrointestinal 
tract and genitourinary tract (Howlett et al., 2002; Pertwee, 1997). 
  
The existence of subtypes of the CB1 receptor has also been reported. For example, 
the minor splice variant CB1A and CB1B receptor have been detected in the human 
lung (Shire et al., 1995; Rinaldi-Carmona et al., 1996) and foetal human brain 
(Ryberg et al., 2005) respectively. Although these subtypes of the human CB1 
receptor appear to have a matching distribution pattern to that of the conserved CB1 
receptor in the human brain and peripheral tissues, their biological significance 
remains unknown (Shire et al., 1995). Other distinct CB1 receptor mRNAs have also 
been detected in the C57BL/6 mouse brain, but again their significance remains 
unknown (Onaivi et al., 1996).  
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1.2.2. Cannabinoid CB2 receptor 
In 1993, the second cannabinoid receptor type, named as the CB2 receptor, was 
isolated from the human promyelocytic leukaemia HL60 cells (Munro et al., 1993). In 
addition to it being a pertussis toxin-sensitive Gi/o protein-coupled receptor, this 
receptor was revealed to exhibit 68% identity to the CB1 receptor within the 
transmembrane regions and 44% identity throughout the whole CB1 protein (Munro et 
al., 1993). Since then, the receptor has been further isolated from the mouse and rat 
spleen and a myeloid leukaemia cell line (Brown et al., 2002; Griffin et al., 2000; 
Shire et al., 1996; Valk et al., 1997). 
 
Unlike the CB1 receptor nucleotide sequence, which appears to be highly conserved 
between the human, mouse and rat, the nucleotide sequence of the CB2 receptor 
exhibits less homology between these mammalian species. For example, the human 
and mouse CB2 receptor share 82% amino acid identity (Shire et al., 1996) whereas 
the mouse and rat 93% homologous (Brown et al., 2002; Griffin et al., 2000). 
 
The distribution of the CB2 receptor appears to be predominantly restricted to the 
periphery e.g. in cells of the immune system such as B and T lymphocytes, natural 
killer cells and monocytes (Galiegue et al., 1995). Given their location on these cells 
they are thought to be involved in chemotaxis and the modulation of the release of 
pro-inflammatory and anti-inflammatory mediators (Bouaboula et al., 1993). Visceral 
regions where CB2 receptor mRNA expression has also been detected include the 
adrenal glands, small intestine, heart, lungs, pancreas, prostate, spleen, testis, tonsils 
and uterus (Munro et al., 1993; Galiegue et al., 1995; Walter et al., 2003). More 
recent studies have provided functional evidence for a presence of the CB2 receptor 
on neurones of the brainstem, where its activation can inhibit emesis (Van Sickle et 
al., 2005). The later results suggest that the CB2 receptor could represent an 
alternative non-psychotropic therapeutic site of action of cannabinoid receptor 
agonists. 
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1.3. Cannabinoid receptor ligands 
 
Since the isolation and elucidation of the chemical structure of Δ9-THC in 1964, many 
potent, stereo-isomeric, high affinity, selective and non-selective cannabinoid receptor 
ligands have been both synthesised and assayed in vivo and in vitro. This sub-section 
briefly introduces the classes of cannabinoid receptor ligands with regard to their 
chemical class and pharmacological activity. 
 
1.3.1. Agonists 
These have been classified according to their chemical structures into at least four 
main groups: classical (Section 1.3.1.1), non-classical (Section 1.3.1.2), 
aminoalkylindole (Section 1.3.1.3) and eicosanoid (Section 1.3.1.4).  
 
1.3.1.1. Classical agonists  
Members of this group are characterised by a dibenzopyran ring system in their 
structure (Howlett et al., 2002). This class include the phytocannabinoids e.g. Δ9-THC 
(Figure 1.1) and its synthetic analogues such as HU-210 (Mechoulam et al., 1988) and 
the clinically tested dronabinol, nantradol, levonantradol, nabilone and the two 
components of Sativex® i.e. Δ9-THC and cannabidiol (Section 1.1.3). Other unique 
cannabinoids belonging to this class are the water-soluble compounds O-1057 and O-
2545 from Organix (Pertwee et al., 2000, Litchman et al., 2000; Martin et al., 2006).  
 
Like Δ9-THC, most classical cannabinoids that bind to the CB1 receptor also have 
affinity for the CB2 receptor. However, there are significant differences in the 
magnitude of potencies and efficacies between the various compounds, which are 
suggested to be related to the intrinsic efficacy of the ligand, stimulus-response 
coupling capacity of the bioassay and the density of the cannabinoid receptor 
(Howlett et al., 2002). The affinity values (equilibrium dissociation constant, pKI) of 
Δ9-THC for the in vitro displacement of [3H]-CP 55,940 from CB1 and CB2 receptor 
binding sites range from 7.80 to 8.41 respectively (Bayewitch et al.,  1996; Felder et 
al., 1995; Showalter et al., 1996; Rhee et al., 1997; Rinaldi-Carmona et al., 1994). 
 
 9
Structure-activity relationship studies have revealed that the phenolic hydroxyl group 
and the aliphatic side chain are crucial for potency and affinity for this class of 
cannabinoids (Goutopoulous & Makriyannis, 2002). The presence of chiral centres in 
classical cannabinoids such as Δ9-THC and HU210 has made it possible to develop 
enantiomers of this class of cannabinoids. These stereo-chemical changes have shown 
that the pharmacological activity of the (-) enantiomers is greater than that of the (+) 
enantiomers in terms of receptor affinity and potency (Howlett et al., 2002) at both 
cannabinoid receptor subtypes. 
 
1.3.1.2. Non-classical agonists 
This class of synthetic cannabinoids consists of bicyclic and tricyclic analogues of Δ9-
THC that lack the dibenzopyran ring found in the classical cannabinoids. The 
prototypical compound of this class is the Pfizer Inc. compound CP 55,940 (Johnson 
& Melvin, 1986; Melvin et al., 1993; Figure 1.1), of which the tritiated radioactive 
form was used to demonstrate the existence of cannabinoid binding sites in the rat 
brain (Devane et al., 1988). 
 
In many bioassays, CP 55,940 behaves as a full agonist and displays high affinity and 
potency at both cannabinoid receptor subtypes with pKI and potency (pEC50) values 
between 8.30 and 9.30 respectively (Felder et al., 1995; Rinaldi-Carmona et al., 1994; 
Ross et al., 1999; Showalter et al., 1996). The presence of chiral centres and the 
development of the (+)-enantiomer of CP 55,940 i.e. CP 56,667 has been exploited to 
demonstrate the stereo-selective property of the cannabinoid receptor (Pertwee et al., 
1993). Like classical cannabinoids, the phenolic hydroxyl group and the aliphatic side 
chain of the non-classical cannabinoids are considered to be essential for cannabinoid 
receptor activity (Goutopoulous & Makriyannis, 2002). 
 
1.3.1.3. Aminoalkyindole agonists  
Although structurally unrelated to the other classes of cannabinoid receptor agonists, 
members of this class typified by the Sterling Winthrop Inc. compound R-(+)-WIN 
55,212-2 (WIN 55,212-2; Figure 1.1) display the full spectrum of cannabinoid effects 
both in vivo and in vitro (Pacheco et al., 1991; Compton et al., 1992). 
 
 10
Site-directed mutagenesis studies on the cannabinoid receptor genes and molecular 
modelling studies of the receptor proteins have revealed that WIN 55,212-2 binds 
differently to receptor than the other three classes of cannabinoids. However, the 
receptor binding has been suggested to occur in a manner that allows mutual 
displacement of WIN 55,212-2 by other classes of cannabinoid receptor ligands 
(Houston & Howlett, 1998).  
 
WIN 55,212-2 behaves as a full agonist and displays high affinity and potency at both 
cannabinoid receptor types (Howlett et al., 2002), whereas its S-(-)-enantiomer i.e. 
WIN 55,212-3 is inactive. Typical pKI and pEC50 values for WIN 55,212-2 at both 
receptor subtypes range between 7.80 and 9.55 respectively (Felder et al., 1995; 
Rinaldi-Carmona et al., 1994; Showalter et al., 1996).  
 
The tritiated form of WIN 55,212-2 has been used to characterise and map the 
distribution of the cannabinoid receptor in the rat brain (Jansen et al., 1992; Kuster et 
al., 1993). A structural requirement for this class of cannabinoids to exhibit 
cannabimimetic activity is the presence of the 3-aroyl moiety (Goutopoulous & 
Makriyannis, 2002). 
 
1.3.1.4. Eicosanoid agonists 
These are a series of arachidonic acid derivatives that often referred to as the 
endogenous cannabinoids or endocannabinoids. Of the endocannabinoids, 
arachidonyl-ethanolamide (anandamide, AEA; Figure 1.1), isolated from the pig brain 
(Devane et al., 1992), and 2-arachidonoly glycerol (2-AG), discovered in the canine 
gut (Mechoulam et al., 1995) and rat brain (Sugiura et al., 1995), are the most widely 
investigated. 
 
Other major endocannabinoids include nolandin-ether isolated from the pig brain 
(Hanus et al., 2001), virodhamine, discovered in the rat brain (Porter et al., 2002) and 
N-arachidonoyl-dopamine, detected in both rat and bovine brain (Huang et al., 2002). 
 
Studies with AEA have shown that this cannabinoid binds marginally more readily to 
the CB1 receptor than to the CB2 receptor with pKI values of around 7.05 and 5.71 
respectively (Felder et al., 1995; Showalter et al., 1996). 
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In some CB1 receptor-expressing systems, AEA and 2-AG resemble Δ9-THC in 
demonstrating different degrees of efficacy. For example, Mackie et al., (1993) 
showed that AEA at maximally active concentrations produced a sub-maximal 
inhibition of N-type Ca2+ currents in N18 mouse neuroblastoma cells relative to that 
obtained with WIN55212-2. Furthermore, AEA was able to antagonise the response 
to WIN55212-2, indicating that the both agonists were likely to be acting at the same 
receptor and that AEA was behaving as a partial agonist. By contrast, in cultured rat 
hippocampal neurones, Twitchell et al., (1997) have shown that the maximal 
inhibition of Ca2+ currents carried by N- and P/Q-type channels in response to AEA 
was similar to that of WIN55212-2 and CP 55,940. The differences in efficacy of 
AEA between these experimental cell types could be attributed to differences in the 
density of the CB1 receptor, the stimulus-response coupling capacity of the cells or the 
susceptibility of AEA to metabolic degradation in these cells.  
 
Far fewer structure-activity relationship studies have been performed with 2-AG 
compared to AEA. For a molecule such as AEA that lacks chiral centres, structural 
modifications have yielded potent chiral centre containing CB1 receptor selective 
analogues such as the fatty acid amide hydrolase (FAAH) enzyme resistant R-(+)-
methanandamide (Abadji et al., 1994). Other notable selective CB1 receptor agonists 
derived from AEA include the commercially available arachidonoyl-2’-
chloroethanolamide and arachidonoyl-cyclopropylamide (Hillard et al., 1999). It has 
been proposed that the hexyl saturated carbon chain and the amide moiety are 
essential for activity (Howlett et al., 2002). 
 
Although AEA has been commonly referred to as a cannabinoid, a large body of 
evidence has emerged since its discovery that it is also capable of eliciting a number 
of non-CB1-non-CB2 receptor-mediated effects, for example, through activation of the 
transient receptor potential vanilloid type 1 receptor (TRPV1) (Zygmunt et al., 1999) 
(Section 1.5) 
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Figure 1.1: Chemical structures of the cannabinoid receptor agonists used in the 
present study.  
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1.3.2. Antagonists 
Since the most widely used cannabinoid receptor agonists i.e. Δ9-THC, CP 55,940, 
WIN 55,212-2 and AEA are capable of activating both subtypes of the cannabinoid 
receptor, selective, high affinity, potent and reversible competitive antagonists have 
been developed to pharmacologically block the effect of the agonists and to 
distinguish between the receptor subtypes. 
 
However, in addition to their antagonist activity, a consistent observation with the 
majority of these antagonists is their ability to independently elicit effects that are 
opposite in direction to those produced by the agonists in a number of in vitro and in 
vivo bioassays. These antagonist-mediated effects have been interpreted as evidence 
for either inverse agonism via an agonist-independent reduction in the constitutive 
activity of the receptor, or an antagonism of the endogenous agonist-mediated tonic 
activation of the receptor (Pertwee, 2005b).  
 
1.3.2.1. CB1 receptor antagonists / inverse agonists 
Several classes of structurally unrelated, potent and surmountable antagonists/inverse 
agonists have been developed since the cloning of the CB1 receptor protein. These 
include the diarylpyrazoles such as the widely used Sanofi Recherché compound SR 
141716, which is known as rimonabant and Acomplia® (Section 1.1.3, Rinaldi-
Carmona et al., 1994), its analogue AM251 (Gatley et al., 1997), the benzofuran LY 
320135 from Eli Lilly (Felder et al., 1998) and the aminoalkylindole WIN 56,098 
(Pacheco et al., 1991). 
 
Tritium-labelled SR 141716 and AM 251 have also been synthesised for use in 
radioligand binding studies to test novel cannabimimetic ligands for CB1 receptor 
binding (Pertwee, 1999). Structure-activity relationship studies with SR 141716 have 
indicated that the 2,4-dichlorophenyl and amide moieties are essential for CB1 
receptor affinity whereas the 5-position of the pyrazole ring is important for receptor 
potency.  
 
Several radioligand binding and functional assays have shown that pKI value of SR 
141716 ranges between 7.93 and 8.74 at the CB1 receptor (Felder et al., 1995; 
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Rinaldi-Carmona et al., 1994; Showalter et al., 1996) and around 4.88 at the CB2 
receptor (Felder et al., 1998).   
 
Recently, a number of CB1 receptor antagonists have been developed and claimed to 
behave as neutral antagonists i.e. ligands devoid of intrinsic efficacy. But, because 
very few studies have been performed with these compounds, the full spectrum of 
their pharmacological effects remains to be characterised. Some examples of putative 
neutral antagonists are: O-1184, a derivative of Δ8-THC (Ross et al., 1999), O-2050 a 
sulphonamide analogue of Δ9-THC (Martin et al., 2002) and O-2654 derived from 
cannabidiol (Thomas et al., 2004)  
 
1.3.2.2. CB2 receptor antagonists / inverse agonists 
Ligands in this group are structurally dissimilar from the CB1 antagonists / inverse 
agonists (Section 1.3.2.1). Some widely used CB2 antagonists / inverse agonists 
include the diarylpyrazoles such as SR 144528 from Sanofi Recherchē (Rinaldi-
Carmona et al., 1998) and the aminoalkylindole, AM630 (Ross et al., 1999). These 
compounds demonstrate affinities of around 9.50 and 7.50 at the CB2 respectively and 
around 5.00 and 5.29 at the CB1 receptor respectively (Ross et al., 1999; Rinaldi-
Carmona et al., 1998). 
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Figure 1.2: Chemical structures of the cannabinoid receptor antagonists used in the 
present study. The selectivity of the receptor subtype is indicated in brackets.  
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1.3.3. Allosteric modulators 
In addition to the presence of the primary (orthosteric) binding site on the cannabinoid 
receptor with which agonists / antagonists / inverse agonists interact, two recent 
studies have provided evidence for the existence of an allosteric binding site on the 
CB1 receptor through which certain compounds interact and cause a conformational 
change in the receptor structure, and hence alter the affinity and/or intrinsic efficacy 
of cannabinoids acting at the primary binding site (Price et al., 2005; Horswill et al., 
2007).  
 
Org 27569, Org 27759 and Org 29647, developed by Organon Research U.K., and 
PSNCBAM-1 developed by Prosidion U.K., have been demonstrated to separately 
modulate the affinity and stimulus response coupling capacity of the CB1 receptor in 
an allosteric manner. For example, these compounds have been reported to augment 
the binding of [3H]-CP 55,940 and [3H]-SR 141716 to the CB1 receptor in mouse 
brain membranes and human CB1 receptor-transfected human embryonic kidney 
HEK-293 cells, but non-competitively reduce the tissue maxima of the CP 55,940 in 
functional assays such as the [35S]-guanosine-5'-triphosphate-γS ([35S]-GTPγS) assay 
on mouse brain membranes and attenuation of the electrically evoked contractions of 
the mouse isolated vas deferens. 
 
Because these compounds do not compete with cannabinoids for the primary binding 
site, nor do they display an inherent effect of their own, these observations have led to 
the suggestion that the Organon and Prosidion compounds behave as allosteric 
enhancers of cannabinoid binding but inhibitors of efficacy. In vivo studies with 
PSNCBAM-1 in rat model of acute food intake have shown that this compound 
significantly reduced food intake and body weight in a manner similar to SR 141716 
(Horswill et al., 2007). These early studies have pointed to a possible usefulness of 
targeting the allosteric site as a novel target for therapeutic exploitation. 
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1.4. Cannabinoid receptor signal mechanisms 
 
Depending on the bioassay system, the cannabinoid receptor can couple to either Gi/o 
or Gs family of G proteins to transduce intracellular signals (Abaji et al., 1994; 
Calandra et al., 1999). The G protein isoform utilised can be distinguished 
pharmacologically with pertussis toxin to which the former is sensitive. 
 
The [35S]GTPγS assay is one of the most common in vitro functional bioassays used 
for demonstrating the activation of the cannabinoid receptor in whole cells or cell 
membranes either naturally expressing, or transfected with, one or both cannabinoid 
receptor subtypes (Howlett et al., 2002). The assay measures the ability of 
cannabinoid receptor agonists to stimulate the coupling of the α-subunit of the G 
protein to the agonist-occupied receptor, whilst the membrane bound guanosine-
diphosphate is exchanged with the metabolically stable analogue of GTP 
([35S]GTPγS). The α-[35S]GTPγS complex regulates the activity of ion channels and 
intracellular enzymes e.g. adenylate cyclase and mitogen activated protein kinases 
that regulate important cell functions (Howlett & Mukhopadhyay, 2000). Figure 1.3 
shows a diagrammatic representation of the signal transduction pathways of the 
cannabinoid receptor.  
 
1.4.1. Modulation of adenylate cyclase activity 
Both cannabinoid receptor subtypes can alter cellular function by modulating cellular 
levels of the intracellular signalling molecule cyclic adenosine monophosphate 
(cAMP) with which they do by coupling to adenylate cyclase through Gi/o and Gs 
proteins. 
 
The negative coupling of the receptor to adenylate cyclase through Gi/o proteins is 
associated with an inhibition of the synthesis of cAMP (Howlett et al., 1984; Howlett 
et al., 1986) whereas positive coupling with adenylate cyclase through Gs proteins 
results in the stimulation of the synthesis of cAMP (Felder et al., 1998). The ability of 
cannabinoids to modulate cellular levels of cAMP has been demonstrated to regulate 
many aspects of cellular function, such as the contractile activity of smooth muscle, 
the gating properties of ion channels on neurones etc. (Childers & Deadwyler, 1996).  
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In vitro functional evidence that the CB1 receptor-induced inhibition of electrically 
evoked contractions of myenteric plexus longitudinal muscle (MPLM) preparation of 
guinea-pig small intestine, and the mouse vas deferens can be modulated by 
manipulating the cellular levels of cAMP has been demonstrated by Coutts and 
Pertwee, (1998) and Pertwee et al., (1996b). In the guinea-pig ileum MPLM, pre-
incubation of the tissue with drugs that mimicked the action of cAMP, e.g. 8-bromo-
cyclic-AMP, or increased intracellular levels of cAMP by stimulating its production, 
e.g. with forskolin, or inhibiting its catabolism, e.g. with 3-isobutyl-1-methylxanthine, 
significantly attenuated the maximal inhibitory response to WIN 55,212-2 (Coutts & 
Pertwee, 1998). In the mouse isolated vas deferens, in the presence of forskolin, 
concentrations of CP 55,940 that inhibited electrically-evoked contractions produced 
a concentration-related inhibitory effect on cAMP production via a SR 141716-
sensitive manner presumably due to an action at the CB1 receptors (Pertwee et al., 
1996b).  
 
1.4.2. Modulation of mitogen activated protein kinases 
The activation of both cannabinoid receptor subtypes is known to cause the 
phosphorylation and activation of p42/44 and p38 mitogen-activated protein kinases 
(MAPK) through an interaction with Gi/o proteins. These enzyme-signalling pathways 
regulate gene transcription and expression of factors involved in important cellular 
functions associated with synaptic plasticity, cell division, growth, differentiation and 
apoptosis (Bouaboula et al., 1995; Rueda et al., 2000). 
 
1.4.3. Modulation of ion channel function  
Data from electrophysiological studies have shown that the CB1 receptor, but not the 
CB2 receptor, couples predominantly through Gi/o proteins to certain subtypes of 
voltage-gated calcium (Ca2+) and potassium (K+) channels. The CB1 receptor has been 
reported to couple negatively to the N, P, Q and L-types of the Ca2+ channel (Caufield 
& Brown, 1992; Gebremedhin et al., 1999; Mackie et al., 1993; 1995), but positively 
to A-subtype and inward-rectifying K+ channels (Mackie et al., 1995; McAllister et 
al., 1999).  
 
For example, in neuronal cells such as rat cortical and cerebellar brain slices and N18 
and NG108-15 brain neuroblastoma-glioma hybrid cells, the negative coupling of the 
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CB1 receptor with N, P and Q-types of the Ca2+ channel has been implicated in the 
inhibition of neurotransmitter release as a consequence of a reduction in the influx of 
Ca2+ ions into nerve terminals. The inhibition of the L-subtype Ca2+ currents in cat 
brain arterial smooth muscle cells has suggested as a mechanism by which 
cannabinoids produce vasodilatation (Gebremedhin et al., 1999). 
 
The positive coupling of the CB1 receptor to the A- and inward-rectifying types of the 
K+ channel in neuronal cells has also been suggested to be a mechanism by which 
cannabinoids inhibit neuronal excitability. A possible mechanism by which the 
activation of the CB1 receptor would inhibit neurotransmitter release would through 
an activation of these K+ channels to increase the efflux of K+ ions from the neurones 
thereby raising the threshold potential for the generation and propagation of an action 
potential.  
 
Figure 1.3: Signal transduction pathways of the CB1 receptor. The presence of Δ9-
THC causes the CB1 receptor to couple through the Gi/o proteins negatively to 
adenylate cyclase (AC) to reduce the formation of cyclic adenosine monophosphate 
(cAMP), decrease Ca2+ conductance by inhibition of the voltage-gated Ca2+ channels 
(N, P, Q and L types and couple positively to stimulate the K+ channel (A and inward 
rectifying types) to hyperpolarise the cell membrane and stimulate mitogen-activated 
protein kinases (MAPK). With the exception of coupling to ion channels, the CB2 
receptor utilises similar signalling pathways as the CB1 receptor.  
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1.5. Other novel pharmacological targets 
 
The availability of both selective antagonists of the CB1 and CB2 receptor and 
transgenic CB1-/-, CB2-/-, and CB1-/-/ CB2-/- receptor gene knock out mice (Ledent et 
al., 1999; Zimmer et al., 1999) has provided an approach to characterise the 
biological role of these two receptors and to investigate whether additional 
cannabinoid receptor types exist.  
 
As discussed in detail elsewhere (Begg et al., 2005; Pertwee, 2004; 2005), since the 
discovery of the CB1 and CB2 receptors, a large body of evidence has emerged to 
suggest that additional cannabinoid receptor subtypes may exist. Some evidence also 
exists to suggest that a number of non-cannabinoid receptors possess binding sites for 
some established CB1 and CB2 receptor cannabinoids (Begg et al., 2005; Pertwee, 
2004). 
 
1.5.1. Transient receptor potential vanilloid type 1 receptor  
Originally cloned by Caterina et al. (1997) from a rat dorsal root ganglion sensory 
neurone cDNA library, the transient receptor potential vanilloid type 1 (TRPV1) 
receptor is non-selective ligand-gated ion channel which has been shown to be 
expressed along the entire length of sensory neurones in several peripheral tissues 
including the cardiovascular, respiratory, gastrointestinal and genitourinary systems 
(Szallasi & Blumberg, 1999). The receptor can be activated by capsaicin, protons and 
heat, and hence it has been suggested to transduce noxious chemical and physical 
stimuli (Szallasi & Blumberg, 1999). 
 
The existence of a possible cannabinoid-vanilloid receptor system cross-talk was 
proposed by Di Marzo et al. (1998) on observing close structural similarities between 
the AEA and the capsaicin analogue olvanil. This hypothesis was confirmed with the 
demonstration that AEA induced calcitonin gene-related peptide release from 
perivascular nerves and relaxation of rat and guinea-pig isolated arterial strips was 
blocked by the TRPV1 receptor antagonist capsazepine but not SR 141716 (Zygmunt 
et al., 1999). Furthermore, radio-ligand binding assays have confirmed that AEA 
displays affinity for the rat and human TRPV1 receptor (Zygmunt et al., 1999; Smart 
et al., 2000).  
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Further evidence has also been obtained from other in vitro functional assays for a 
role of the TRPV1 receptor in mediating a number of the pharmacological actions of 
AEA that are not blocked by antagonists of the CB1 and CB2 receptor. For example, 
the AEA-induced inhibition of electrically-evoked contractions of the mouse vas 
deferens has been shown to occur through both CB1 and TRPV1 receptor over the 
same concentration range (Ross et al., 2001). In the guinea-pig ileum MPLM 
preparation, Mang et al. (2001) have shown that AEA increased both basal ACh 
release from the myenteric plexus and resting tone of the longitudinal muscle through 
a stimulation of the TRPV1 receptor. In the same preparation AEA acting via the 
TRPV1 receptor potentiated the inhibitory effect of endogenously released GABA 
(Begg et al., 2002b). In the guinea-pig bronchus AEA was found to induce smooth 
muscle contraction via a capsazepine-sensitive, SR 141716 insensitive manner (Craib 
et al., 2001; Tucker et al., 2001). 
 
1.5.2. Putative CB2-like receptor 
Palmitoylelthanolamide, an endogenous structural analogue of AEA, has been 
reported to display cannabimimetic activity in several functional bioassays inspite of 
being known to lack affinity for both known cannabinoid receptor types (Felder et al., 
1993, Showalter et al., 1996, Lambert et al., 1999). Although palmitoylethanolamide 
has been reported to decrease locomotor activity (Adams et al., 1995) and intestinal 
transit (Capasso et al., 2001) in mice and relax rat isolated mesenteric arteries (White 
& Hiley, 1998) in similar manner to AEA, the antinociceptive and anti-inflammatory 
activity of the former fatty acid amide, unlike of the later, are attenuated by SR 
144528, albeit weakly, but not by SR 141716 or capsazepine (Calignano et al., 2001; 
Berdyshev et al., 1998). 
 
Whilst this putative receptor awaits to be cloned, some evidence for its existence has 
been obtained from studies on the mouse vas deferens. Griffin et al. (1997) have 
shown that the mouse vas deferens contains CB2-like mRNA, and that the putative 
receptor was capable of mediating the inhibitory action of palmitolyethanolamide on 
the electrically evoked contractions of this tissue in vitro.   
 
 
 
 22
1.5.3. Putative SR 141716 sensitive, non-CB1, non-CB2 receptor 
Studies have shown that AEA, its metabolically stable analogue methanandamide, and 
cannabidiol and its analogues such as abnormal cannabidiol and O-1602, can produce 
a concentration related relaxation of rat or mouse pre-contracted isolated mesenteric 
arteries from both wild type and CBB1-/- or CB1-/- / CB2-/- knock out mice (Jarai et al., 
1999; Wagner et al., 1999). This effect has been reported not to be reproduced by the 
other established cannabinoid receptor agonists (Wagner et al., 1999), nor is it 
antagonized by concentrations of SR 141716 which are sufficient to block the CB1B  
receptor.  
 
Recent reports suggest that the recently identified and cloned GPR 55 orphan receptor 
(Sawdargo et al., 1999) displays similar properties to the putative SR 141716 
sensitive, non-CB1, non-CB2 cannabinoid receptor (Brown et al., 2005; Sjögren et al., 
2005). The GPR 55 receptor, originally cloned from the human brain, has therefore 
been proposed to be the third G protein coupled cannabinoid receptor. 
 
1.5.4. Putative AEA and WIN 55,212-2 sensitive receptor 
The existence of a novel G protein-coupled receptor in the mouse brain which can be 
activated by both AEA and WIN 55,212-2, but not by members of the other classes of 
the cannabinoid receptor agonist has been proposed by both Di Marzo et al. (2000) 
and Breivogel et al. (2001). Both AEA and WIN 55,212-2 have been reported to 
induce [35S]GTPγS binding in brain membranes of CB1-/- receptor knock out mice in 
an SR 141716-SR 144528-and capsazepine-insensitive manner. Because maximal 
concentrations of AEA produced a submaximal level of stimulation of [35S]GTPγS 
binding relative to that induced by WIN 55,212-2, and that AEA was also capable of 
reducing the maximal stimulation produced by the later cannabinoid to its own 
maxima, these data suggested that both cannabinoids acted through a common 
mechanism. 
 
1.5.5. Allosteric sites on non-cannabinoid receptors 
Other than the established cannabinoid receptor subtypes, i.e. CB1 and CB2 receptors, 
and putative cannabinoid receptors (Section 1.5.1 to 1.5.4), a few recent studies have 
provided evidence for the presence of binding sites for cannabinoids on some 
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established non-cannabinoid receptors. Through these binding sites, cannabinoids 
have been demonstrated act in an allosteric manner to either enhance or reduce the 
affinity and/or stimulus-response coupling capacity of the non-cannabinoid receptors. 
Some examples of non-cannabinoid receptors that have been suggested to possess 
allosteric binding sites for cannabinoids include the serotonin 5-HT3 receptor, 
muscarinic acetylcholine (mACh) m1 and m4 and nicotinic acetylcholine (nACh) 
receptors and glutamate NMDA receptor.  
 
In both rat nodose ganglion cells naturally expressing the 5-HT3A receptor and 5-HT3A 
receptor-transfected human endothelial HEK-293 cells, AEA, CP 55,940, Δ9-THC 
and WIN 55,212-2 have been shown to non-competitively inhibit 5-HT-induced 
inward currents in a non-CB1-non-CB2 receptor-mediated manner without altering the 
affinity of the 5-HT3A receptor for 5-HT (Fan, 1995; Barann et al., 2002). These data 
have suggested that these cannabinoids receptor agonists can behave as allosteric 
antagonists of 5-HT3A receptor efficacy but not affinity. Because of the physiological 
role played by the 5-HT3A receptor in emesis, and since cannabinoids are useful 
clinically for alleviating emesis induced by chemotherapy drugs, a direct allosteric 
inhibitory effect of cannabinoids on the 5-HT3A receptor may account for the anti-
emetic effect of cannabinoids. 
 
Convincing evidence for a direct role of cannabinoids in modulating mACh receptor 
affinity through a mechanism that is unrelated to their actions on the cannabinoid 
receptor has been provided by Christopoulous & Wilson, (2001) using radioligand 
binding assays on Chinese hamster ovary cells expressing the m1 and m4 mACh 
receptors, but not the cannabinoid receptor. These authors showed that AEA, 
methanandamide and SR 141716 displaced the binding of the selective m1 and m4 
mACh subtype receptor ligands [3H]-N-methylscopolamine and [3H]-quinuclidinyl 
benzilate in a non-competitive manner. Although the biological significance of these 
data remain unknown, given the abundant expression of the m1 and m4 ACh receptor 
in the brain and their role in cognition, these findings may explain the well known 
inhibitory effects that cannabinoids have on learning and memory. 
 
Studies by Oz et al. (2003; 2004) have revealed the presence of an allosteric site for 
cannabinoids on the nACh receptor. In these studies, both AEA and CP 55,940 have 
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been found to inhibit nicotine-induced inward currents in Xenopus oocytes transfected 
with the nACh receptor in a non-competitive manner through a non-CB1-non-CB2 
receptor-mediated action.  
 
In contrast to the inhibitory effect of cannabinoids on the binding or stimulus response 
coupling capacity the receptors described above, AEA and methanandamide have 
been demonstrated to act allosterically on the NMDA receptor to potentiate NMDA 
induced currents in Xenopus oocytes transfected with NMDA receptors (Hampson et 
al., 1998). These data suggest that these cannabinoids can allosterically enhance the 
efficacy of the NMDA receptor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 25
1.6. Cannabinoid bioassays 
 
Because of the many diverse pharmacological actions of cannabinoids in man, several 
in vivo animal, and cell and tissue based in vitro, bioassays have been developed to 
elucidate the mechanism of action of the cannabinoids and for the study of their 
structure-activity relationships.  
 
1.6.1. In vivo bioassays 
1.6.1.1. Mouse tetrad model 
This model exploits the ability of cannabinoid agonists to simultaneously induce anti-
nociception, catalepsy, hypothermia and sedation in mice within the same dose range 
and time frame, such that all four effects can be determined in the same animal 
(Martin et al., 1995).  
 
Although individually these four behaviours are not unique to cannabinoids, their 
observation together has been regarded to be unique to cannabinoids. The rank order 
of potencies of cannabinoid receptor agonists determined using this model shows 
good correlation with the rank order of potencies for cannabinoids acting through the 
CB1 receptor. Because the tetrad effects are readily antagonised by CB1 receptor 
antagonists and are absent in CB1-/- transgenic mice, this model is a useful CB1 
receptor assay (Howlett et al., 2002). 
 
However, whilst cannabinoid agonist activity can be readily assessed with this assay, 
compounds with inverse agonist or partial agonist activity often provide inconsistent 
results due to their dual pharmacological activity (Howlett et al., 2002; Martin et al., 
1995).  
  
1.6.1.2. Drug discrimination model 
In this test, rats or monkeys are trained to press one of two levers to obtain a food 
reward and then after receiving injections of a cannabinoid such as Δ -THC or its 
vehicle. After the discrimination has been learned, the animal is monitored for its 
ability to press a specific lever for the food reward under the influence of a test drug 
or Δ -THC (
9
9 Howlett et al., 2002; Pertwee, 1997). On the test day, the lever chosen 
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tells the experimenter whether the test drug produces similar effects to those of Δ -
THC.  
9
 
Although drug discrimination studies are a reliable way of determining, with a high 
degree of accuracy, whether test substances are as like or unlike the drug used for 
training, they are very time consuming because of the extensive animal training 
required. Furthermore, this model is also prone to provide false positives when 
compounds exhibiting dual pharmacological activity are assayed.  
 
Structure-activity relationship studies have revealed that this model serves as a 
reliable CB1 receptor assay because of the excellent correlation between the rank 
orders of potencies of cannabinoid determined with other CB1 assays and also that SR 
141716 antagonises discriminative properties of the animals (Pertwee, 1997). 
 
1.6.1.3. Learning and memory models  
These models usually involve the use of the eight-arm radial or water maze to 
evaluate the ability of cannabinoids to impair working memory and spatial navigation.  
Rats or mice are trained to navigate to a particular hidden location or platform first 
before, and then under, the influence of cannabinoids.  
 
Although these models are not specific for cannabinoids, their blockade or reversal by 
CB1 receptor antagonists demonstrates their viability as a CB1 receptor assay (Howlett 
et al., 2002). 
 
1.6.2. In vitro bioassays 
1.6.2.1. Radio-ligand binding assay 
This assay allows a quantitative measurement of the affinity of a compound of interest 
for the cannabinoid receptor by determining the concentration of the test compound 
that is required to displace a radio-labelled cannabinoid ligand of known 
concentration from the cannabinoid receptor.  
A major disadvantage of this assay is that it cannot be used to distinguish between 
agonists and antagonists because it does not provide information about the efficacy of 
the compound (Howlett et al., 2002).  
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Commonly used radio-labelled cannabinoids include [3H]-SR 141716, [3H]-CP 
55,940 and [3H]-WIN 55,212-2. In order to yield useful information about the affinity 
of the unlabelled test compound, the binding assay must be performed with tissues or 
cells that contain either the CB1 receptor or CB2 receptor but not both.  
 
1.6.2.2. cyclic-AMP assay 
This enzyme-based functional assay exploits the ability of cannabinoids to either 
increase or decrease the basal or drug-induced synthesis of cAMP by stimulating or 
inhibiting the activity of adenylate cyclase respectively. This assay is based on the 
principle of competition between cAMP present in a biological sample with a fixed 
amount of alkaline phosphatase or peroxidase labelled cAMP for sites on a cAMP 
specific polyclonal antibody. The colour development of a substrate solution added to 
the reaction medium is used to determine the activity of the bound enzyme. The 
intensity of the colour is inversely proportional to the concentration of cAMP in the 
sample. This assay can be performed on whole tissues or cultured cells expressing the 
cannabinoid receptor naturally or cultured cell lines transfected with the cannabinoid 
receptor subtypes (Howlett et al., 2002; Pertwee, 1997) to provide information about 
the affinity, potency and efficacy of the compounds under study.  
 
1.6.2.3. Isolated nerve-smooth muscle preparations  
The mouse isolated vas deferens and guinea-pig ileum MPLM are two simple and 
reliable functional cannabinoid bioassays. These tissues exploit the ability of 
cannabinoid receptor agonists to inhibit the electrical field stimulation-(EFS-)-evoked 
contractions of the longitudinal muscle of these tissues in a concentration-dependent 
and stereo-specific manner. In both tissues, the observed effects are mediated 
predominantly through the activation of the CB1 receptor located on nerve terminals 
involved in neurotransmitter release. Although these bioassays are sensitive, they lack 
specificity as other classes of drugs also inhibit the EFS-evoked contractions. 
However, the lack of specificity can be overcome by the use of selective receptor 
antagonists. Cannabinoids with agonist, antagonists / inverse agonist or partial agonist 
activity can be easily studied with these assays (Howlett et al., 2002).  
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1.7. Endocannabinoid system 
 
To date, at least five endocannabinoids have been discovered; AEA (Devane et al., 
1992), 2-AG (Mechoulam et al., 1995; Sugiura et al., 1995), noladin ether (Hanus et 
al., 2001), N-arachidonoyl-dopamine, (Huang et al., 2002), palmitoylethanolamide 
(Kuehl et al., 1957) and virodhamine (Porter et al., 2002). Since their discovery, the 
major proteins and the molecular mechanisms for their biosynthesis, action and 
inactivation, as well as other pharmacological targets have been characterised (De 
Petrocellis et al., 2004). Collectively, this signalling system has been called the 
endocannabinoid system. 
 
Of all the endocannabinoids, the biosynthetic and degradative pathway of AEA is the 
best characterised. AEA is synthesised from the phospholipase D-catalysed hydrolysis 
of N-arachidonyl-phosphatidylethanolamides, which are in turn synthesised from 
membrane-derived phosphoglycerides and phosphatidylethanolamides by a Ca2+-
dependent N- acyltransferase (Di Marzo et al., 1994; Cadas et al., 1997) (Figure 1.4). 
An alternative pathway by which AEA is synthesised involves the condensation of 
ethanolamine and free fatty acid (Di Marzo et al., 1994).  
 
The termination of AEA signalling appears to be regulated by a two-step process via a 
putative membrane transporter followed by enzymatic hydrolysis by FAAH (Deutsch 
& Chin, 1993; De Petrocellis et al., 2004; Di Marzo et al., 1994; Freund al., 2003). 
Although the transporter has been characterised, it has not been cloned. There is 
evidence both for and against the existence of this protein, which remains an 
unresolved controversial subject. FAAH is a membrane bound hydrolase enzyme 
which shows broad specificity for a number of endocannabinoids (Freund al., 2003; 
Piomelli et al., 2005). FAAH-/- mice have also been developed and have confirmed 
the importance of FAAH for the inactivation of AEA in the brain (Piomelli et al., 
2005). 
 
A large number of studies have shown that AEA and 2-AG are not stored in vesicles, 
but are released on demand from various cells in response to a rise in intracellular 
Ca2+ and/or activation of cell surface receptors (see Freund al., 2003 for review). In 
the brain, AEA and 2-AG release have been demonstrated in several regions such as 
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the hippocampus, hypothalamus and cerebellum, where the somatodendritic region of 
the post-synaptic cells releases these transmitters retrogradely towards the pre-
synaptic neurones in response to nerve stimuli to modulate neuronal excitability 
(Alger, 2002; Freund al., 2003). AEA and 2-AG release has also been demonstrated 
to occur from non-neuronal sites such as endothelial cells of blood vessels (Deutsch et 
al., 1997; Sugiura et al., 1998). 
 
Several studies have also demonstrated that levels of a number of endocannabinoids 
are enhanced during pathophysiological conditions (Schmid, 2002). Because of their 
diverse actions, endocannabinoids can have both protective and toxic effects on 
cellular function. 
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Figure 1.4: Biosynthesis and metabolic pathway for the endocannabinoid anandamide.  
A rise in intracellular Ca2+ triggers N-acyl-transferase to transfer arachidonic acid 
from the phosphoglyceride to the phosphatidylethanolamine. Phospholipase D then 
cleaves N-arachidonoyl-phosphatidylethanolamine to synthesise AEA. The 
microsomal enzyme FAAH inactivates AEA into free arachidonic acid and 
ethanolamine. 
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1.8. Cannabinoids and the intestinal tract 
 
For centuries, various botanical preparations of Cannabis sativa have been used as 
herbal remedies for a variety of intestinal disorders such as diarrhoea, intestinal pain, 
ulcerative colitis etc. (Coutts & Izzo, 2004; Hornby & Prouty, 2004; Izzo & Coutts, 
2005). However, it has only been in the last two decades years that the mechanisms 
by which cannabinoids produce their therapeutic effect in the intestinal tract have 
begun to be elucidated, primarily because of the identification of a functional 
endocannabinoid system in the tract (for review see Coutts & Izzo, 2004; Duncan et 
al., 2005b; Hornby & Prouty, 2004; Izzo & Coutts, 2005; Izzo et al., 2001b, Massa et 
al., 2005; Pertwee, 2001; Pinto et al., 2002). 
 
1.8.1. Endocannabinoid system in the enteric nervous system 
The enteric nervous system (ENS) is the major site of action of cannabinoids in the 
intestinal tract. This system consists of nerve cell bodies and their processes which are 
capable of functioning independently but also under the extrinsic control of the CNS 
via the vagal, pelvic and splanchnic nerves (Furness et al., 2003).  
 
The ENS consists of two ganglionated nerve plexuses, the myenteric plexus and the 
submucosal plexus, which contain a variety of neurones to modulate the major 
physiological processes that occur in the intestinal tract i.e. motility, secretion, 
digestion, absorption and elimination. The myenteric plexus lies between the 
longitudinal and circular muscle layers to control the movements of the intestinal 
tract, whereas the submucosal plexus lies near the lumen between the circular muscle 
layer and submucosa to control water and electrolyte transport (Furness et al., 2003) 
(Figure 1.5).  
 
The neurones of the ENS have been classified into many groups based on their 
morphology, electrophysiology, key neurotransmitters and projections (Kunze & 
Furness, 1999). However, for an understanding of their role in modulating intestinal 
function, they have been divided into four classes as defined by their function. These 
are the motor neurones, secretomotor/vasomotor neurones, interneurones and intrinsic 
primary afferent neurones (IPANs) (Kunze & Furness, 1999). 
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Figure 1.5: The structure of the intestinal tract and type of enteric neurones as defined 
by their function and projections (Modified from Furness et al., 2004). ⊕, excitatory; 
Ө, inhibitory; LM, longitudinal muscle; MP, myenteric plexus; CM, circular muscle; 
SP, submucosal plexus; M, mucosa; L, lumen. 
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1.8.1.1. Motor neurones 
The enteric motor neurones transmit both excitatory and inhibitory stimuli from 
adjacent neurones to contract and relax the muscle layers respectively (Brookes et al., 
2001; Furness et al., 2003). They have been classified as either excitatory or 
inhibitory, as defined by the effect they have in the contractility of the smooth muscle 
layers (Figure 1.5). The primary transmitter of the excitatory neurones is ACh, which 
acts through the m3ACh receptor to induce muscle contraction. Other transmitters 
which can be released from the excitatory motor terminals include 5-HT and 
substance P which act predominantly through the 5HT2 and neurokinin NK1 receptors 
respectively (Brookes et al., 2001; Furness et al., 2003). 
 
In the human, guinea-pig, pig and rat ileal and colonic myenteric plexus, the CB1 
receptor has been shown to be completely co-localised with choline acetyltransferase 
(ChAT), a marker of ACh-containing neurones (Coutts et al., 2002; Hinds et al., 
2006; Kulkarni-Narla & Brown, 2000). A high degree of co-localisation of the CB1 
receptor with immunoreactivity for substance P-containing neurones has also been 
reported in the pig intestinal tract (Kulkarni-Narla & Brown, 2000). These 
immunohistochemical data strongly support functional evidence from in vitro organ 
bath studies that activation of the CB1 receptor inhibits the peristaltic reflex 
(Heinemann et al., 1999; Izzo et al, 2000) and EFS-evoked contractions of the guinea-
pig ileum by reducing the release of ACh and substance P from the myenteric plexus 
(Coutts & Pertwee, 1997; Izzo et al, 1998; Mang et al., 2001). Similar data have also 
been obtained from organ bath studies with the human ileum and colon (Croci et al., 
1998; Hinds et al., 2006; Manara et al., 2002) and mouse colon (Mancinelli et al., 
2001). These data are also consistent with results obtained from a plethora of in vivo 
studies demonstrating an enteric CB1 receptor-, but not CB2 receptor-, mediated delay 
in the transit of intra-gastrically or intra-duodenally administered non-absorbable 
markers along the small intestine in rats and mice (Calignano et al., 1997; Colombo et 
al., 1998; Izzo et al., 1999a, 2000, 2001a; Landi et al., 2002).   
 
However, it is noteworthy that despite the convincing immunohistochemical evidence 
that the CB1 receptor is completely co-localised with cholinergic neurones, data from 
two electrophysiological studies performed on the guinea-pig ileal MPLM have 
shown that not all neurally-(EFS-and nicotine-) evoked cholinergic responses of this 
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tissue were sensitive to the inhibitory actions of WIN 55,212-2 and CP 55,940, and 
those whose activity was attenuated by these cannabinoid agonists were not always 
mediated through the CB1 receptor (Lopez-Redondo et al.,  1997; Sones et al., 2004). 
These data suggest that there may be certain subclasses of excitatory cholinergic 
motor neurones which do not contain the CB1 receptor or that novel subtypes of the 
cannabinoid receptor are present in the ENS of the guinea-pig.  
 
A recent study has provided immunohistochemical evidence for the co-localisation of 
the CB2 receptor with nerves expressing calretinin, a marker for excitatory motor 
neurones in the rat ileal myenteric plexus (Duncan et al., 2005a). However, the co-
localisation of this receptor with specific markers of excitatory neurotransmitters was 
not reported. Thus, it clear that further studies are now required to investigate whether 
the CB2 receptor has a functional role in modulating intestinal transit. 
 
The inhibitory motor neurones involved in the relaxation of the smooth muscle layers 
are known to release a combination of transmitters such as nitric oxide (NO), 
noradrenaline (NAdr), adenosine triphosphate (ATP), vasoactive intestinal 
polypeptide (VIP) (Brookes et al., 2001; Furness et al., 2003; Kunze & Furness, 
1999). Immunohistochemical studies performed on the human, mouse and pig colonic 
myenteric plexus have shown that the immunoreactivity of the CB1 receptor does not 
overlap with markers of inhibitory neurones and transmitters (Hinds et al., 2006; 
Kulkarni-Narla & Brown, 2000; Pinto et al., 2002). Furthermore, cannabinoid 
receptor agonists have no effect on inhibitory junctional potentials of the mouse colon 
or relaxations of the human colon evoked by EFS of the inhibitory nerves (Hinds et 
al., 2006; Storr et al., 2004). These data suggest that activation of the CB1 receptor 
decreases intestinal transit by attenuating the release of contractile transmitters from 
excitatory motor neurones and not by facilitating of the release of inhibitory 
transmitters.  
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1.8.1.2. Secretomotor/vasomotor neurones 
The secretomotor/vasomotor neurones reside in the submucosal plexus but project to 
the mucosa and submucosal blood vessels to regulate water and electrolyte levels and 
blood flow through local reflex circuits respectively (Brookes et al., 2001; Costa et 
al., 2000). These neurones are also classified as either excitatory or inhibitory. ACh, 
substance P and VIP acting via the m3ACh, NK1 and VPAC1 receptors respectively, 
are the predominant excitatory transmitters which cause an increase in water and 
electrolyte secretion (Costa et al., 2000; Furness et al., 2003). NAdr is the principle  
neurotransmitter released upon activation of the inhibitory secretomotor neurones and 
acts through the α1 and α2 adrenoceptors to decrease submucosal blood flow and 
secretion of electrolytes and water respectively (Costa et al., 2000; Furness et al., 
2003)   
 
In the guinea-pig ileal submucosal plexus, the CB1 receptor has been associated with 
all VIP-containing neurones (MacNaughton et al., 2004). However, a similar 
immunoreactivity is absent in the pig submucosal plexus (Kulkarni-Narla & Brown, 
2000). These data suggest a species specific difference in the distribution of the CB1 
receptor.  In vitro functional studies using the Ussing chamber technique to measure 
electrogenic ion transport, have shown that activation of the CB1 receptor in the 
guinea-pig and rat ileal submucosal plexus-mucosal (SPM) preparations with WIN 
55,212-2 caused an inhibition of the capsaicin- and EFS-evoked increases in 
electrolyte secretion respectively. These inhibitory effects were not on the epithelial 
cells because the secretory responses to forskolin and carbachol, which act directly on 
the epithelium to elicit secretion, were not affected by WIN 55,212-2 treatment 
(MacNaughton et al., 2004; Tyler et al., 2000). Moreover, in extrinsically denervated 
segments of the guinea-pig ileum, the inhibitory effect of WIN 55,212-2 on the 
response to EFS was completely lost, suggesting that cannabinoids appear to act first 
through extrinsic primary afferent neurones to modulate submucosal secretomotor 
neurone function (MacNaughton et al., 2004). Far fewer studies have examined the 
role of the endocannabinoid system in the regulation of intestinal secretion in vivo. 
Oral administration of croton oil (Izzo et al., 2001b) or cholera toxin (Izzo et al., 
2003) to mice has been reported to cause diarrhoea and fluid accumulation in the 
small intestine through a disruption of the submucosa, activation of enteric neurones 
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and release of endogenous secretagogues. Treatment with CP 55,940 was shown to 
concentration-dependently inhibit the diarrhoea and fluid accumulation in a SR 
141716-sensitive and SR 144528-insensitive manner, suggesting the involvement of 
the CB1 receptor and not the CB2 receptor.  
 
1.8.1.3. Interneurones 
Interneurones behave as relay neurones to convey information between and within the 
myenteric and submucosal plexus. They are classified as either ascending (orally 
projecting) or descending (anally projecting), and are suggested to be involved in 
local neural circuits which control the propulsive function of the intestine (Brookes et 
al., 2001; Kunze & Furness, 1999) (Figure 1.5). Neurotransmission in the ascending 
pathways is cholinergic via the nACh receptor but non-cholinergic in the descending 
pathways, probably involving ATP, 5-HT, NO and VIP (Furness et al 2003). The 
ascending neurones which release ACh are excitatory and may contain the CB1 
receptor to modulate local motility.  
 
Some functional evidence for the presence of the CB1 receptor on ascending 
interneurones has been provided from studies demonstrating the CB1 receptor-
mediated inhibitory effect of WIN 55,212-2, CP 55,940 and methanandamide on the 
distension evoked peristaltic reflex of the guinea-pig isolated ileum. In this assay, all 
three cannabinoids inhibited the peristaltic reflex by increasing the threshold pressure 
and volume required for eliciting the reflex, whilst concomitantly decreasing the 
ejection pressure for the emptying phase (Heinemann et al., 1999; Izzo et al., 2000). 
This suggested that cannabinoid agonists inhibited the peristaltic activity by blockade 
of ascending excitatory motor pathways. These data have been shown to extend to the 
peristaltic reflex of the mouse isolated colon (Mancinelli et al., 2001).  
 
1.8.1.4. Intrinsic primary afferent neurones 
IPANs are sensory nerves that respond to chemical and mechanical stimuli (Furness et 
al., 2004). They connect to motor neurones, interneurones, secretomotor neurones and 
other IPANs to initiate reflex pathways involved in the control of gut movement, 
water and electrolyte secretion and blood flow (Brookes et al., 2001). IPANs also 
have efferent functions in that they release transmitters onto the mucosal epithelium 
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and the smooth muscle layers (Figure 1.5). Key transmitters released from these 
nerves are ACh, VIP, 5-HT and substance P (Furness et al., 2004).  
 
Co-localisation between the immunoreactivity of the CB1 receptor with ChAT, and 
calbindin, a marker for IPANS has been demonstrated in the rat and guinea-pig ileal 
myenteric plexus (Coutts et al., 2002). Additionally, IPANS containing 
immunoreactivity for ChAT, substance P and the CB1 receptor have been 
demonstrated in the pig ileal and colonic submucosal plexus (Kulkarni-Narla & 
Brown, 2000). These data indicate that cannabinoids can modulate the activity of 
motor neurones, interneurones and secretomotor neurones indirectly by acting on the 
IPANS. 
 
1.8.2. Other components of the endocannabinoid system in the intestinal tract 
In addition to the presence of the cannabinoid receptor in the ENS, levels of both 
AEA and 2-AG high enough to cause receptor activation have been reported in 
homogenates of the intestine of guinea-pig (Guagnini et al., 2006), human (Wright et 
al., 2005; Valenti et al., 2005), mouse (Izzo et al., 2001a), rat (Katayama et al., 1997; 
Valenti et al., 2005) and dog (Mechoulam et al., 1995). However, in addition to 
species-related differences in the levels of AEA and 2-AG in the intestinal tract, 
significant regional differences in the levels of these endocannabinoids have been 
noted, which may reflect a difference in the activity of these endocannabinoids.  
 
Unlike in the brain, neither the sources nor mechanisms by which endocannabinoids 
are released in the intestinal tract have been elucidated. However, the mechanisms for 
the inactivation of the endocannabinoids have been suggested to be present in the 
mouse small intestine because in vivo administration of VDM-11, an inhibitor of the 
putative endocannabinoid uptake transporter, into mice treated with cholera toxin 
caused a significant decrease in the diarrhoea in an SR 141716-sensitive manner (Izzo 
et al., 2001a). Additionally, VDM-11 has also been shown to worsen ileus in mice 
caused by an abdominal injection of acetic acid in an SR 141716-sensitive manner 
(Mascolo et al., 2002). These data indicate the presence of both the endocannabinoid 
uptake transporter and an active endocannabinoid agonist tone in the mouse small 
intestine.  
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To date, FAAH has only been isolated from the ileum of the rat and not of other 
species (Katayama et al., 1997). In the rat ileum, FAAH immunoreactivity has been 
detected on cell bodies and nerve fibres in both the myenteric and submucosal plexus 
(Duncan et al., 2005b). However, the classes of enteric neurones that express FAAH 
have not been identified.  In vivo administration of two FAAH inhibitors, AA-5-HT or 
palmitoylisopropylamide, into mice has been shown to delay small intestinal motility 
in an SR 141716-sensitive manner (Capasso et al., 2005). Moreover, the inhibitory 
effect of the FAAH inhibitors was absent in both CB1-/- mice and FAAH-/- mice 
suggesting that the decrease in intestinal transit caused by FAAH inhibitors was 
through a potentiation of the inhibitory effect of tonically released endocannabinoid 
agonists at the CB1 receptor. 
 
The presence of an active endocannabinoid tone in several in vivo and in vitro 
bioassays has been suggested because CB1 receptor antagonists alone produce effects 
which are opposite in direction to those produced cannabinoid receptor agonists. For 
example, while in vivo administration of cannabinoid receptor agonists into rodents 
delays intestinal transit, SR 141716 alone increases intestinal transit (Colombo et al., 
1998; Izzo et al., 1999a, b; 2001a). Similarly, while cannabinoid receptor agonists 
cause an inhibition of the EFS-evoked contractions of the guinea-pig ileum MPLM, 
the presence of SR 141716 alone augments the amplitude of the contractions. Whilst 
these effects of SR 141716 are suggestive of an ongoing endocannabinoid agonist 
activity, these data have to be interpreted with caution because SR 141716 is known 
to have inverse agonist activity (Pertwee, 2005). 
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1.9. Aim and objectives 
 
1.9.1. Aim 
The rat has long served as a common in vivo model for characterising the 
pharmacological actions of cannabinoids on intestinal motility and secretion. Given 
the lack of in vitro functional bioassays for evaluating cannabinoid effects on these 
intestinal functions of this species, the aim of this study was to investigate the 
viability of the contractile function of the isolated ileum myenteric plexus longitudinal 
muscle (MPLM) preparation and the secretory function of the isolated colonic 
submucosal plexus-mucosal (SPM) preparation as novel rat in vitro intestinal 
cannabinoid bioassays, and to pharmacologically characterise the cannabinoid 
receptor subtypes modulating the neurally evoked responses of these tissues. 
 
1.9.2. Objectives 
1.9.2.1. Contraction studies  
• To investigate whether representatives of the four main classes of structurally 
different cannabinoid receptor agonists i.e. AEA, CP 55,940, Δ9-THC and WIN 
55,212-2 inhibited the EFS evoked contractions of rat ileum MPLM. 
• To identify the cannabinoid receptor subtypes mediating the effect of the four 
cannabinoid receptor agonists under the EFS conditions using cannabinoid 
receptor subtype selective antagonists / inverse agonists in the rat isolated ileum 
MPLM. 
• To determine whether any non-cannabinoid receptor-mediated effects of the 
cannabinoid receptor agonists and antagonists / inverse agonists observed the 
under the EFS conditions in the rat ileal MPLM extended to the guinea-pig ileal 
MPLM. 
• To seek evidence for the presence of a functional endogenous cannabinoid tone in 
the rat MPLM and to determine whether the evidence extended to the guinea-pig 
ileum MPLM and rat vas deferens. 
 
1.9.2.2. Secretion studies  
• To investigate the role of the CB1 receptor in modulating the pharmacologically 
evoked secretory function of the rat colonic SPM preparation.  
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CHAPTER 2: 
GENERAL MATERIALS and METHODS 
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2.1. Animals 
 
Tissues were obtained from male Wistar rats (400 to 550 g) and Dunkin-Hartley or 
Heston-2 guinea-pigs of either sex (500 to 800 g). All animals were bred at the 
Biological Services Unit of the University of Hertfordshire, U.K. from stock 
originating at Charles River Laboratories, U.K. and Harlan, U.K. respectively.  
 
The animals were housed in rooms with a controlled temperature (22 ± 1 OC), relative 
humidity (55 ± 10 %) and 12 hour light-dark cycle with food and water available ad 
libitum. Rats were killed by carbon dioxide (CO2) asphyxiation, whilst guinea-pigs 
were killed by a blow to the head followed by exsanguination. All animal care and 
killing was conducted in accordance with requirements of the Animals (Scientific 
Procedures) Act 1986 and the University of Hertfordshire ethical review committee. 
 
2.2. Isolated nerve-smooth muscle preparation contraction studies 
 
2.2.1. Tissue dissection: Myenteric plexus longitudinal muscle preparation 
A 15 cm segment of the ileum was excised from the small intestine both rats and 
guinea-pigs and immersed in Krebs-Henseleit solution A of the composition (in mM): 
NaCl 118.3, KCl 4.7, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, D-glucose 11.1, CaCl2 
2.5, and gassed with 95 % O2 and 5 % CO2 at room temperature (21 ± 4 OC).  
 
A maximum of four 2 cm length MPLM strips were dissected from the ileum segment 
by the method of Paton & Zar (1968) after discarding the first 5 cm length closest to 
the ileo-caecal junction. Briefly, a 2 cm segment of the ileum was flushed of its 
contents with Krebs-Henseleit solution A and slipped over a glass rod of 5 mm 
diameter. After trimming the mesentery, the longitudinal muscle with the adhered 
myenteric plexus was separated from the rest of the ileum by gentle stroking with a 
cotton bud soaked with the Krebs-Henseleit solution A, starting at the mesenteric 
border and working along and around the length and circumference of whole ileum 
(Figure 2.0). Cotton sutures were tied at both ends of the strip, and the tissue was 
suspended between a pair of platinum wire electrodes, approximately 1 cm in length 
and 5 mm apart, and a Dynamometer UF1 isometric force transducer (Pioden 
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Controls, U.K.). The electrode with the tissue was then immersed in either 5, 10 or 30 
ml jacketed organ baths containing Krebs-Henseleit solution A at 33 or 37 OC and 
bubbled with a mixture of 95 % O2 and 5 % CO2 (Figure 2.1). The majority of the 
experiments were carried out at 33 OC in order to dampen the irregular spontaneous 
activity of the tissues, particularly of the rat ileum MPLM, to enable the evoked 
responses to be quantified easily. Pilot studies showed that running the experiments at 
33 O C had no significant effect on the ability of the tissues to respond to EFS or any 
drug. Therefore, data from experiments carried out at the different bath temperatures 
have been pooled.  
MPLM 
Ileum 
Cotton bud 
Glass rod 
 
Figure 2.0: Separation of the myenteric plexus-longitudinal muscle from an ileum 
segment. 
 
2.2.2. Tissue dissection: Vas deferens 
Both vasa deferentia were dissected from the rats and placed in Krebs-Henseleit 
solution B of the composition (in mM): NaCl 118.3, KCl 4.7, KH2PO4 1.2, NaHCO3 
25, D-glucose 11.1, CaCl2 2.5, and gassed with 95 % O2 and 5 % CO2 at room 
temperature (21 ± 4 OC). Krebs-Henseleit solution B differed from Krebs-Henseleit 
solution A (Section 2.2.1) in that Mg2+ was excluded. After expelling the contents 
from both vas deferentia by gentle squeezing, cotton sutures were tied at both ends 
and the tissue was suspended between a pair of platinum wire electrodes, 
approximately 1 cm in length and 5 mm apart, and a Dynamometer UF1 isometric 
force transducer (Pioden Controls, U.K). The electrodes with the tissues were then 
immersed in 30 ml organ baths containing Krebs-Henseleit solution B and bubbled 
with 95 % O2 and 5 % CO2 and maintained at 37 OC. 
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2.2.3. Apparatus set-up and maintenance 
The organ baths were connected by silicone tubing to reservoirs containing the Krebs-
Henseleit solutions via jacketed heating coils. The temperature of the organ baths and 
heating coils were controlled thermostatically with water circulated by 
thermocirculators (Harvard Apparatus, U.K.). 
 
Changes in tension of the tissues was recorded isometrically in units of grams (g) 
using the isometric force transducers connected to a MacLab Chart Version 3.5 data-
acquisition system on an Apple Macintosh computer (Apple Macintosh, U.K.), a 
PowerLab Chart Version 5.2 data-acquisition system (AD Instruments, U.K.) on a 
Personal computer (Dell, U.K.) or MX216 or MultiTrace-4 chart recorders 
(Lectromed, U.K.). 
 
For experiments involving EFS, the electrodes were connected to Grass S11 or S88 
stimulators (Grass Instruments, U.S.A) or a Multistim D330 (Digitimer, U.K.) 
stimulator via a variable cycle timer (Harvard Apparatus, U.K). 
 
Cannabinoids have been shown to stick to glassware due to their high lipophilicity. At 
the end of every experiment involving the use of cannabinoids, the organ baths and 
stimulation electrodes were washed thoroughly with 70 % ethanol followed by 2 M 
hydrochloric acid and copious amounts of distilled water. 
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Drain 
Transducer 
Water out 
33 / 37 OC            Drain 
 O2 / CO2
Electrode 
Water in  33 / 37 OC 
Amplifier          Chart recorder 
Cycle timer Stimulator 
MacLab/PowerLab 
OR 
Krebs in 
Tissue 
 
 
 
 
 
 
 
 
 
Figure 2.1: Schematic diagram of the apparatus for recording the motility of the 
isolated nerve-smooth muscle preparations (not to scale). 
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2.2.4. Electrical field stimulation parameters 
The EFS parameters employed for evoking contractions of rat and guinea-pig ileum 
MPLM and the rat vas deferens are summarised in Table 2.0. The parameters have 
been chosen from previous studies where some of the cannabinoid ligands used in the 
present study have been reported to produce an effect. Where these are not available, 
EFS parameters from studies on equivalent tissues were used. 
 
 
Table 2.0: Electrical field stimulation parameters and the contractile transmitters 
released by the isolated nerve-smooth muscle preparations 
 
Tissue Frequency Pulse width Voltage 
Contractile 
transmitter 
Reference 
0.05 Hz 0.5 ms 
110 % 
supramaximal 
ACh - 
Rat ileum 
MPLM 30 Hz for 2 
sec every min 
0.5 ms 
110 % 
supramaximal 
ACh 
Borelli et al., 
2004 
      
0.1 Hz 0.5 ms 
110 % 
supramaximal 
ACh 
Gill et al., 
1970 
Guinea-pig 
ileum 
MPLM 
30 Hz for 2 
sec every min 
0.5 ms 
110 % 
supramaximal 
ACh - 
      
Rat vas 
deferens 
0.1 Hz 0.5 ms 
110 % 
supramaximal 
ATP 
Pertwee et al., 
1993 
 
 
 
 
 
 
 
 
 
 
 
 46 
2.2.5. Experimental design 
2.2.5.1. Myenteric plexus-longitudinal muscle preparation 
2.2.5.1.1. Electrical field stimulation studies 
After 10 minutes since placing the tissues in the organ baths, each tissue was stretched 
by 0.5 g and allowed to equilibrate for a further 50 minutes until EFS was 
commenced. As summarised in Table 2.0, the rat and guinea-pig ileum MPLM strips 
were subjected to EFS over the entire duration of the experiment, either with single 
pulses repeated at a frequency of 0.05 Hz or 0.1 Hz respectively, or with trains of 
pulses for 2 seconds every minute at a frequency of 30 Hz.  
 
Each pulse at any given frequency was of 0.5 ms duration and at a voltage that was 10 
% greater than that required to elicit maximal contractions. 110 % supramaximal 
voltage was employed to ensure that the neurones sensitive to the respective 
frequency within the field of stimulus were stimulated and that the EFS conditions 
were comparable with previous studies (Coutts & Pertwee 1997; Mang et al., 2001; 
Pertwee et al., 1996).  
 
No drugs were added until the amplitude of EFS-evoked contractions had become 
consistent for a minimum of a 30 minute period. The time taken for the amplitude of 
the contractions to become uniform was about 3 to 4 hours. It was also noted that the 
amplitude of the EFS-evoked responses could remain stable for a further 4 hours 
without the need to renew the bathing Krebs-Henseleit solution. On each day, the 
drug treatments were randomised between the organ baths. Only one concentration-
response curve was constructed per tissue, as previous studies have shown that due to 
their lipophilicity, cannabinoids cannot be washed from the tissue by replenishing the 
organ bath with drug free Krebs-Henseleit solution (Pertwee et al., 1992).  
 
For tissues subjected to EFS with single pulses (0.05 Hz for rat ileum MPLM and 0.1 
Hz for guinea-pig ileum MPLM), concentration-response curves to the cannabinoid 
receptor agonists were constructed with a 20 minute dosing interval. When 
competition studies were performed, the cannabinoid receptor antagonists / inverse 
agonists were administered 20 minutes prior to the addition of the cannabinoid 
receptor agonists. 
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When both the rat and guinea-pig ileum MPLM were subjected to EFS with trains of 
pulses at 30 Hz, concentration-response curves to the cannabinoid receptor agonists 
were constructed with a 30 minute dosing interval. When competition studies were 
performed, the cannabinoid receptor antagonists / inverse agonists were administered 
30 minutes prior to the addition of the cannabinoid receptor agonists. 
 
For all other competition studies, such as with the FAAH inhibitors (see Chapter 4), 
the FAAH inhibitors or their vehicles were administered 20 minutes prior to the 
addition of a cannabinoid receptor agonists. The concentration-response curves to the 
cannabinoid receptor agonists were constructed with a 20 minute dosing interval in 
the presence of the FAAH inhibitors. 
 
All experiments were performed in parallel with relevant vehicle treated and time 
controls. 
 
2.2.5.1.2. Muscarinic acetylcholine receptor stimulation studies 
If a cannabinoid was found to alter the amplitude of EFS-evoked contractions, its 
ability to produce a similar effect on contractions elicited by exogenously applied 
ACh was investigated. Two experimental designs were used for carrying out this 
objective. The first involved administering the highest concentration of the 
cannabinoid, which maximally increased or decreased the amplitude of EFS-evoked 
contractions, between two semi-logarithmic ACh (10-10 to 10-5 M) cumulative 
concentration-response curves constructed 30 minutes apart. The second experimental 
design involved administering a single concentration of a cannabinoid in half-
logarithmic increments between single administrations of ACh (10-6 M) over 30 
minute intervals on a single piece of tissue. For both experimental designs, each tissue 
acted as its own control. All experiments were performed in parallel with relevant 
vehicle treated and time controls. 
 
2.2.5.2. Vas deferens 
After 10 min since placing the tissues in the organ baths, each tissue was stretched by 
0.5 g and allowed to equilibrate for a further 50 minutes until EFS was commenced. 
No drugs were added until the amplitude of EFS-evoked contractions had become 
consistent for a minimum of a 30 minute period. The time taken for the amplitude of 
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the contractions to become uniform was about 1 hour. It was also noted that the 
amplitude of the EFS-evoked responses could remain stable for a further 4 hours 
without the need to renew the bathing Krebs-Henseleit solution. On each day, the 
drug treatments were randomised between the organ baths. 
 
Cumulative concentration-response curves to the cannabinoids were constructed 
cumulatively with a dosing interval of 20 minutes. Only one concentration-response 
curve was constructed per tissue. Competition studies were only performed with WIN 
55,212-2 and SR 141716 for the purpose of comparison to the EFS experiments on 
the rat ileum MPLM. SR 141716 was added 20 minutes prior to the addition of WIN 
55,212-2. All experiments were performed in parallel with relevant vehicle-treated 
and time controls 
 
2.2.5.3. Data analysis 
This section describes the methods used for quantifying and analysing the effects of 
the cannabinoid receptor agonists in the presence and absence of the competing 
ligands on tissues stimulated with EFS (Section 2.2.5.3.1) and ACh (Section 
2.2.5.3.2).  
 
2.2.5.3.1. EFS studies 
2.2.5.3.1.1. Quantification of the agonist data in the absence and presence of a 
competing ligand 
The inhibition of the EFS-evoked contractions by a cannabinoid receptor agonist in 
the presence of a competing ligand or its vehicle was calculated in percentage terms 
using Equation 2.0: 
 
                       % Inhibition of contraction = 100 ⎟⎟⎠
⎞
⎜⎜⎝
⎛ −
y
xy                        (Equation 2.0) 
 
where x denotes the amplitude of the evoked contractions after each addition of the 
agonist and y the amplitude immediately before the first addition of the competing 
ligand or its vehicle.  
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2.2.5.3.1.2. Quantification of the inherent effect of the competing ligand 
During some competition experiments, depending on the tissue and/or frequency of 
EFS employed, the presence of certain competing ligands alone either enhanced or 
reduced the amplitude of the EFS-evoked contractions (see Results in Chapter 3). 
Therefore, the enhancement and (or) reduction of the amplitude of the EFS-evoked 
contractions was calculated using the methods describe in Section 2.2.5.3.1.2.1 and 
2.2.5.3.1.2.2 respectively. 
 
2.2.5.3.1.2.1. Quantification of the enhancement of the contractions 
The increase in the amplitude of the EFS-evoked contractions by a ligand was 
calculated in percentage terms using Equation 2.1: 
 
                          % Potentiation of contraction = 100 ⎟⎟⎠
⎞
⎜⎜⎝
⎛ −
y
yx          (Equation 2.1) 
 
where x denotes the amplitude of the evoked contractions after each addition of the 
ligand and y the amplitude immediately before the first addition of the same ligand. 
 
2.2.5.3.1.2.2. Quantification of the reduction of the contractions 
The reduction in the amplitude of the EFS-evoked contractions by a ligand was 
calculated in percentage terms using Equation 2.2: 
 
                       % Inhibition of contraction = ⎟⎟⎠
⎞⎜⎜⎝
⎛−
y
x100100                       (Equation 2.2) 
 
where x denotes the amplitude of the evoked contractions after each addition of the 
ligand and y the amplitude immediately before the first addition of the same ligand. 
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2.2.5.3.1.3. Graphical presentation of the data 
Individual agonist concentration-response curves in the absence and presence of a 
competing ligand were fitted via non-linear regression to the four-parameter Hill 
equation (Equation 2.3), using GraphPad PRISM 4.0 for Windows (GraphPad 
Software, CA., U.S.A); 
  (Equation 2.3) E =
Emax- Basal
1 + 10 (LogEC50-Log[A]) H
n Basal + 
 
where E denotes response, Log [A] the logarithm of the concentration of an agonist A, 
nH the midpoint slope of the curve, Log EC50 the logarithm of the midpoint location 
parameter along the concentration axis, and Emax and Basal the upper and lower 
asymptotes respectively.  
 
The concentration-response data were plotted as the mean ± standard error of the 
mean (mean ± s.e.m). Shifts in the agonist concentration concentration-response curve 
by the presence of a competing ligand was compared by a one-way ANOVA, 
followed by a Dunnett’s post hoc test. The probability P < 0.05 was taken to be 
statistically significant. 
 
2.2.5.3.1.4. Quantification of the augmentation and antagonism of the agonist 
action by the presence of a competing ligand  
The cannabinoid receptor agonist data quantified in the absence and presence of a 
competing ligand devoid of inherent activity yielded concentration-response curves 
with similar upper and lower curve asymptotes. Therefore, the EC50 for each agonist 
concentration-response curve in the absence and presence of a competing ligand was 
chosen for the measurement of the shift as a concentration ratio.  
 
In contrast, the cannabinoid receptor agonist data quantified in the presence of a 
competing ligand with inherent activity yielded concentration-response curves with 
similar upper asymptotes but different lower asymptotes. Because under these 
circumstances the EC50 value of each agonist concentration-response curve in the 
absence and presence of the competing ligand did not result in an equivalent level of 
response, the concentration ratios were measured from the agonist concentrations 
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corresponding to the 50 % equieffective response level in the absence and presence of 
the competing ligand. 
 
Equations 2.4 and 2.5 show the formulae used for measuring the concentration ratio 
for the leftward and rightward shift of an agonist concentration-response curve in the 
presence of a competing ligand respectively.  
 
(Equation 2.4) Concentration ratio = 
A
A'
 
 
 
(Equation 2.5) Concentration ratio = 
A
A'
 
 
In both Equation 2.4 and 2.5, A denotes the EC50 value of the cannabinoid receptor 
agonist in the absence of the competing ligand whereas A’ represents either the EC50 
value or the concentration corresponding to the 50 % effect of the agonist in the 
presence of a given concentration of a competing ligand respectively. Thus, for every 
concentration of the competing ligand, a corresponding value of the concentration 
ratio was calculated. 
 
2.2.5.3.1.4.1. Measurement of the antagonist affinity and /or potency 
When a series of concentration ratio values were available from experiments in which 
multiple concentrations of an antagonist were used, a Schild plot was constructed to 
estimate the pKB of the antagonist using the method of Arunlakshana & Schild, 1959. 
The Schild plot represented a linear regression of Log (Concentration ratio - 1) upon 
Log [B], for determining both the gradient and the 95% Confidence Intervals (C.I.) of 
the slope, and the pKB of the antagonist. Each plot was fitted via the linear regression 
function (Equation 2.6) using GraphPad PRISM 4.0. 
 
y = m x + pKB             (Equation 2.6) 
 
where y denotes the logarithm of the concentration ratio minus one i.e. Log 
(Concentration ratio - 1), x the logarithm of a given concentration of an antagonist B 
i.e. (Log [B]), m the gradient of the slope i.e. the ratio of the change in Log 
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(Concentration ratio - 1) for each unit change in Log [B], and pKB the negative 
logarithm of Log [B] when Log (Concentration ratio - 1) = 0. 
 
If the gradient of the Schild plot was not significantly different from unity, the 
antagonism was taken to be simple competitive. However, if the slope was 
significantly different from unity, but the 95 % C.I of the slope included unity, the 
plot was re-fitted by constraining the slope to unity. The intercept of the Log [B] axis 
where Log (Concentration ratio – 1) = 0 was read as the pKB of the antagonist. 
 
By definition, the pKB represented the equilibrium dissociation constant of the 
agonist-receptor complex, and the negative logarithm of the antagonist concentration 
that occupied 50 % of the receptors at equilibrium. Hence the pKB was a measure of 
the affinity of the antagonist for a specific receptor (Arunlakshana & Schild, 1959). 
 
When only a single value for the concentration ratio was available from experiments 
in which a single concentration of an antagonist B was used, the antagonist potency 
(pA2) was calculated using the Gaddum-Schild equation (Equation 2.7; Schild, 1947);  
 
             pA2 = Log (Concentration ratio – 1) – Log [B]             (Equation 2.7) 
 
The pA2 represented the negative logarithm of the concentration of the antagonist B 
that produced a rightward shift of the agonist concentration-response curve by two 
logarithmic units. Because the pA2 was derived from a single measurement, it 
represented an empirical measure of the potency of the antagonist and an estimate of 
the pKB. In contrast, the pKB value was taken to represent both the affinity and 
potency the antagonist.  
 
As the pKB and pA2 values of an antagonist were agonist-and system-independent 
measures of antagonism, they were used to classify the cannabinoid receptor subtypes 
mediating the inhibitory effect of the cannabinoid receptor agonists on the EFS-
evoked contractions of the various isolated nerve-smooth muscle preparations. 
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2.2.5.3.2. Muscarinic acetylcholine receptor stimulation studies 
The amplitude of the contractions to cumulative additions of ACh in the presence of 
the cannabinoid receptor ligands or their vehicle were expressed as a percentage mean 
± s.e.m of the amplitude of the maximal contraction to ACh (10-5 M). This 
concentration of ACh was determined from the initial ACh concentration-response 
curve constructed on each tissue in the absence of the cannabinoids or their vehicle. 
 
Shifts in the ACh concentration-response curves were compared by a one-way 
ANOVA, followed by a Dunnett’s post hoc test. The probability P < 0.05 was taken 
to be statistically significant. 
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2.3. Isolated nerve-epithelial preparation secretion studies 
 
2.3.1. Tissue dissection 
A 3 cm length segment of the proximal colon was excised from rats and immersed in 
Krebs-Henseleit solution A of the composition (in mM): NaCl 118.3, KCl 4.7, 
MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, D-glucose 11.1, CaCl2 2.5, and gassed with 95 
% O2 and 5 % CO2 at room temperature (21 ± 4 OC). 
 
The segment was opened longitudinally along the mesenteric border after trimming 
the mesentery and rinsing the faecal contents away with Krebs-Henseleit solution A. 
The tissue was then pinned as flat sheet with the basolateral (serosal) side up on a 
cork board lined with a piece of paper towel soaked with Krebs-Henseleit solution A. 
The smooth muscle layers with the attached myenteric plexus were then gently 
stripped away by blunt dissection leaving a submucosal plexus-mucosal (SPM) sheet 
(Figure 2.2). A maximum of two SPM sheets was prepared from the 3 cm segment.  
 
Serosal side 
Colon segment Mucosal surface Epithelial layer sheet 
 
 
Figure 2.2: Separation of the submucosal plexus-mucosal sheet from a segment of the 
colon. 
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2.3.2. Apparatus set-up and maintenance 
Each SPM sheet was lightly clamped between the halves of the Ussing chambers (WP 
Instruments, U.S.A.) with a circular window surface area of 0.63 cm2. Both apical and 
basolateral surfaces of the SPM sheet were bathed with 5 ml of Krebs-Henseleit 
solution A maintained at 37 OC and circulated with a stream of 95 % O2 and 5 % CO2 
(Figure 2.3).  
 
The chambers were connected through 3M KCl agar electrodes to a voltage clamp 
apparatus (DVC 1000, WP Instruments, U.S.A.) and the preparations automatically 
short-circuited by voltage clamping the tissue at a holding potential of 0 mV. The 
short circuit current (Isc, Section 2.3.4) was continuously recorded in units of μA.cm-2 
on a MacLab data-acquisition recording system running the Chart version 3.5 
software (AD Instruments, U.K.) on an Apple Macintosh computer (Apple Macintosh, 
U.K.).  
 
At the end of every experiment involving cannabinoids, the chambers were washed 
thoroughly with 70 % ethanol followed by 2 M hydrochloric acid and copious 
amounts of distilled water to ensure the complete removal of residual cannabinoids. 
The 3M KCl-agar electrolyte in the electrodes was also renewed regularly. 
 
Electrodes 
Voltage clamp apparatus MacLab recording system 
O2 / CO2O2 / CO2
Krebs-Henseleit 
solution 
Tissue 
Water jacket at 37 OC 
 
Figure 2.3: Schematic diagram of the Ussing chamber apparatus for recording ion 
transport in the isolated nerve-epithelial preparation (not to scale). 
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2.3.3. Experimental design 
A minimal 60 minute equilibration period was established before addition of any drug 
to the tissues. During this time the basal Isc and Rt had stabilised. Only one 
concentration of a nerve stimulant or a cannabinoid was used per tissue because the 
tissues developed tachyphylaxis to nerve stimulants and that the drugs could not be 
washed out because of the design of the chambers. 
 
Drugs were only added to the basolateral side of the stripped tissue, as Tyler et al, 
(2000) have demonstrated that cannabinoids do not produce an effect when added to 
the apical surface. Cannabinoid receptor agonists were added 30 minutes prior to the 
addition of a nerve stimulant. In competition studies, the CBB1 receptor antagonist SR 
141716 was administered 30 minutes prior to the addition of a cannabinoid receptor 
agonist. All experiments were performed in parallel with relevant vehicle treated and 
time controls. 
 
2.3.4. Data analysis 
By definition, the Isc was taken as a measure of active ion transport. A positive change 
in the Isc in response to stimulation of ion transport by a neurotransmitter or 
exogenous agonist indicated a net basolateral to apical anion flux or a cation flux in 
the opposite direction, and this increase was recorded as an upward deflection on the 
computer. The amplitude of the response was taken a measure of the intensity of the 
secretory response.  
 
Changes in the transmembrane tissue resistance (Rt) as an indicator of the 
integrity/leakiness of the tissue were monitored over the entire duration of the 
experiment by intermittently changing the membrane potential to from 0 to 2 mV for 
2 seconds every 30 seconds. The Rt was calculated using Ohm’s Law (Equation 2.8):  
 
                                                         Rt = 2 mV  / Δ Isc.          (Equation 2.8) 
 
The change in the Isc and Rt were measured as units of μA.cm-2 and Ω respectively as 
the mean ± s.e.m. Comparisons between the data were performed using a Student’s 
unpaired t-test and the probability P < 0.05 was taken to be statistically significant. 
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Table 2.1: Drugs used in the study 
NAME CELLULAR ACTION SOLVENT SUPPLIER 
Acetylcholine 
(ACh)  
Endogenous nACh 
/ mACh receptor 
agonist 
Distilled water Sigma-Aldrich (Poole, U.K.) 
AM 251 
Cannabinoid CB1 
receptor antagonist 
/ inverse agonist 
Ethanol Tocris-Cookson (Bristol, U.K.) 
Anandamide 
(AEA) 
Endogenous 
cannabinoid 
receptor and 
Vanilloid TRPV1 
receptor agonist 
Ethanol Tocris-Cookson (Bristol, U.K.) 
Arachidonyl 
serotonin 
(AA 5-HT) 
FAAH inhibitor Ethanol 
Axxora Life 
Sciences 
(Nottingham, U.K.)  
Atropine mACh receptor antagonist Distilled water 
Sigma-Aldrich 
(Poole, U.K.) 
(E)-Capsaicin Vanilloid TRPV1 receptor agonist Ethanol 
Tocris-Cookson 
(Bristol, U.K.) 
Capsazepine Vanilloid TRPV1  receptor antagonist Ethanol 
Tocris-Cookson 
(Bristol, U.K.) 
α-Chymotrypsin 
(Type I from 
bovine pancreas) 
Endopeptidase Krebs-Henseleit solution 
Sigma-Aldrich 
(Poole, U.K.) 
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CP 55,940 
 
Cannabinoid 
receptor agonist Ethanol Pfizer (Kent, U.K.) 
Hexamethonium  nACh receptor antagonist Distilled water 
Sigma-Aldrich 
(Poole, U.K.) 
L-NAME 
 
Nitric oxide 
synthase inhibitor Distilled water 
Sigma-Aldrich 
(Poole, U.K.) 
(-) Nicotine nACh receptor agonist Distilled water 
Sigma-Aldrich 
(Poole, U.K.) 
O-2050 Cannabinoid CB1 receptor antagonist Ethanol 
Tocris-Cookson 
(Bristol, U.K.) 
Phenylmethyl 
sulphonylfluoride 
(PMSF) 
FAAH inhibitor Ethanol Sigma-Aldrich (Poole, U.K.) 
PPADS P2X purinoceptor antagonist Distilled water 
Tocris-Cookson 
(Bristol, U.K.) 
Prazosin α1 Adrenoceptor antagonist 
Dimethyl 
sulphoxide 
Sigma-Aldrich 
(Poole, U.K.) 
SR 140333  Neurokinin NK1 receptor antagonist Ethanol 
Sanofi-Recherche 
(Montpellier, 
France) 
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SR 141716 
Cannabinoid CB1 
receptor antagonist 
/ inverse agonist 
Ethanol 
Sanofi-Recherche 
(Montpellier, 
France) 
SR 144528 
Cannabinoid CB2 
receptor antagonist 
/ inverse agonist 
Ethanol 
Sanofi-Recherche 
(Montpellier, 
France) 
Tetrodotoxin 
(TTX) 
Voltage dependent 
Na+ channel 
inhibitor 
Distilled water Tocris-Cookson (Bristol, U.K.) 
URB 597 FAAH inhibitor Ethanol 
Axxora Life 
Sciences 
(Nottingham, U.K.)  
Vasoactive 
Intestinal 
Polypeptide (VIP) 
VIP receptor 
agonist Distilled water 
Sigma-Aldrich 
(Poole, U.K.) 
[D-p-Cl-
Phe6,Leu117]-VIP 
(VIP 6-28) 
VPAC receptor 
antagonist Distilled water 
Sigma-Aldrich 
(Poole, U.K.) 
Veratridine 
Voltage dependent 
Na+ channel 
activator 
Ethanol Sigma-Aldrich (Poole, U.K.) 
WIN 55,212-2 Cannabinoid receptor agonist Ethanol 
Tocris-Cookson 
(Bristol, U.K.) 
WIN 55,212-3 Optical isomer of WIN 55,212-2 
Dimethyl 
sulphoxide 
Sigma-Aldrich 
(Poole, U.K.) 
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All chemicals used for preparing the Krebs-Henseleit solutions and the solvents for 
dissolving the drugs (Table 2.1), with the exception of distilled water, were purchased 
from Fisher Scientific (Loughborough, U.K.). The total volume of the drugs or 
solvent added to the organ baths or Ussing chambers did not exceed 1 % of the total 
bath volume. 
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CHAPTER 3: 
ISOLATED NERVE-SMOOTH MUSCLE 
PREPARATIONS 
  
Pharmacological Analysis of Cannabinoid Receptor 
Activity in the Rat Isolated Ileum Myenteric Plexus 
Longitudinal Muscle Preparation 
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3.1. Introduction 
 
A large body of evidence has emerged over the last two decades from a plethora of in 
vivo studies, which have been performed almost exclusively on the mouse and rat 
(Pertwee, 2001), that the predominant action of psychotropic cannabinoids on the 
intestinal tract is a reduction in the propulsive (Carai et al., 2006; Calignano et al., 
1997; Chesher et al., 1973; Colombo et al., 1998; Izzo et al., 1999a, 1999b, 2000, 
2001a; Landi et al., 2002; Mathison et al., 2004) and secretory (Izzo et al., 1999a, 
1999b, 2000, 2003; Shook & Burks, 1989) function of the small intestine. The former 
action has been invariably studied by evaluating either the distance travelled or the 
delay in the time taken for the transit of an orally or intra-duodenally administered 
non-absorbable marker from the pylorus to the caecum of the animal.  
 
Whilst in vivo bioassays have long played an important role in characterising the 
pharmacology of cannabinoids on intestinal motility under both physiological and 
pathophysiological states, the mechanism of the depressant action has been inferred 
from in vitro studies performed on segments or strips of the isolated ileum of the 
guinea-pig (Coutts & Pertwee, 1997; Gill et al., 1970; Mang et al., 2001; Pertwee et 
al., 1996; Izzo et al., 1998) and to a lesser extent of human (Croci et al., 1998; 
Guagnini et al., 2006; Manara et al., 2002). 
 
Therefore, to date the guinea-pig ileum has been the standard in vitro bioassay for 
screening cannabinoids for activity on the intestinal tract. The in vitro studies on this 
tissue have focussed on the ability of cannabinoids to inhibit either the peristaltic 
reflex in segments of whole ileum (Heinemann et al., 1999; Izzo et al., 2000), 
synaptic transmission (Lopez-Redondo et al., 1997), or the low frequency EFS-
evoked release of a variety of neurotransmitters (Begg et al., 2002a, 2002b; Coutts & 
Pertwee 1997; Mang et al., 2001) or subsequent contraction of the longitudinal 
(Coutts & Pertwee 1997; Mang et al., 2001; Pertwee et al., 1996) or circular (Izzo et 
al., 1998) smooth muscle layers.  
 
Results from these studies have suggested that psychotropic cannabinoids decrease 
intestinal motility by reducing the release of contractile neurotransmitters such as 
acetylcholine (ACh) from the myenteric plexus (Coutts & Pertwee 1997; Mang et al., 
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2001) through an activation of the CB1 receptor located on somatodendritic and 
terminal regions of the neurones (Coutts et al., 2002). 
  
Although the guinea-pig ileum has served as a useful bioassay for describing the 
inhibitory action of cannabinoids on intestinal transit observed in the mouse or rat in 
vivo, it is important that isolated ileal tissues from the latter species are used for 
studying cannabinoid effects. Firstly, because a large number of models of disturbed 
intestinal motility of man have been created using the rat and mouse (Izzo et al., 
1999a, 1999b, 2000, 2001a, 2003; Mascolo et al., 2002; Mathison et al., 2004) and 
secondly, to date, the guinea-pig has not been employed for investigating cannabinoid 
effects on ileal transit. 
 
The availability of an in vitro ileal bioassay from the rat and mouse would not only 
make it possible for a better comparison to be made between the data obtained from 
both types of studies, but may offer the opportunity to understand more about the 
mode of action of existing and future cannabinoid drugs on ileal motility under both 
physiological and pathophysiological conditions. Additionally, the existence of 
possible novel cannabinoid receptor subtypes or targets may be revealed. 
 
Previous studies have reported that the conservation between the rat and human 
mRNAs of the cannabinoid receptors is slightly higher compared to that between the 
mouse and human (Chakrabarti et al., 1995; Shire et al., 1996). Moreover, the 
mRNAs for both the cannabinoid receptors and their expression have been identified 
and mapped in the myenteric plexus of the rat ileum (Coutts et al., 2002; Duncan et 
al., 2005; Valenti et al., 2005). Furthermore, a number the endogenous cannabinoid 
ligands, exemplified by AEA and 2-AG, (Fegley et al., 2005; Gomez et al., 2002; 
Mascolo et al., 2002; Izzo et al., 2003; Valenti et al., 2005) along with the 
mechanisms for their enzymatic inactivation (Katayama et al., 1997) have been 
shown to be present in the rat ileum. Therefore, the purpose of the present study was 
to investigate whether the rat ileum MPLM served as a suitable and robust in vitro 
ileal cannabinoid receptor bioassay by assessing the interaction between 
representatives of the four main classes of cannabinoid receptor agonists i.e. AEA, CP 
55,940, Δ9-THC and WIN 55,212-2 and the CB1 and CB2 receptor selective 
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antagonists / inverse agonists SR 141716 and SR 144528 respectively. To aid in the 
interpretation of data obtained on the rat ileum MPLM, some experiments were 
performed on the guinea-pig ileum MPLM preparation. 
 
3.2. Methods 
 
MPLM strips were dissected from the ileum of both rats and guinea-pigs (Section 2.1) 
and set up in organ baths as described in Section 2.2.1. 
 
The experiments under EFS and muscarinic stimulation conditions were performed by 
the methods described in Section 2.2.5.1.1 and 2.2.5.1.2 respectively. 
 
The data obtained from the experiments with EFS and ACh stimulation were 
quantified and analysed by the methods described in Section 2.2.5.3.1 and 2.2.5.3.2 
respectively. 
 
The compounds used in this study were: ACh, AEA, atropine, capsazepine, CP 
55,940, hexamethonium, L-NAME, SR 141716, SR 144528, TTX, Δ9-THC, WIN 
55,212-2 and WIN 55,212-3. See Table 2.1 for the solvents and suppliers of the 
compounds used. 
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3.3. Results 
 
3.3.1. The EFS-evoked responses of the rat ileum MPLM  
Stimulation of the rat ileum MPLM strip with single pulses at a repetition frequency 
of 0.05 Hz elicited a transient twitch contraction every 20 seconds. Each twitch 
contraction occurred immediately in response to the electrical pulse (Figure 3.0a). In 
contrast, stimulation of the MPLM strip with 2 second trains of pulses at a frequency 
of 30 Hz every minute elicited a biphasic response. This response consisted of a 
transient relaxation during the train of pulses followed by a rapid transient rebound 
contraction on termination of the EFS (Figure 3.0b).  
 
The amplitude of the relaxations to EFS at 30 Hz were noted to diminish over the first 
20 minutes of stimulation as the basal tension of the tissues decreased from 0.5 g to 
about 0.2 g. By contrast, the amplitude of the rebound contractions gradually 
increased during this period and continued to increase for up to 3 to 4 hours without 
altering the basal tension of the tissue. The amplitudes of the twitch and rebound 
contractions after 3 to 4 hours of EFS were 0.45 ± 0.13 g (n = 100) and 1.42 ± 0.34 g 
(n = 100) respectively. As shown in Figure 3.1, the contractions evoked by both 
frequencies of EFS were significantly (P < 0.05, unpaired t test) attenuated by 
treatment with either atropine (10-6 M) or TTX (10-6 M) but not hexamethonium (10-4 
M).  
 
Preliminary experiments showed that the relaxations elicited by EFS at 30 Hz were 
abolished by treatment with TTX (10-6 M, data not shown) and L-NAME (10-4 M, 
data not shown). Additionally, the presence of L-NAME had no effect on the 
amplitude or timing of the rebound contractions. 
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 (a)  
 
 0.25 g 
10 sec 
  -                -                 -                 -                 -                - 
 
 
 
 
(b) 
 
 
  6 sec 
0.5g 
 
 
 
 
 
 
Figure 3.0: Representative traces of the EFS-evoked responses of the rat ileum 
MPLM. (a) Twitch contractions to EFS at 0.05 Hz frequency, 0.5 ms duration and 110 
% supramaximal voltage. Each upward deflection represents a contraction. The dots 
represent the time at which the EFS pulses were delivered. Upward deflections 
represent the contractions. (b) Biphasic responses to EFS at 30 Hz for 2 seconds every 
minute, 0.5 ms duration and 110 % supramaximal voltage. Note the transient 
relaxations during the 2 second stimulation periods and the subsequent the rebound 
contractions. The downward deflections denote relaxations whilst upward deflections 
represent contractions. The dots represent the time at which the EFS pulses were 
delivered 
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Figure 3.1: Bar graphs representing the amplitude of the EFS-evoked contractions of 
the rat ileum MPLM in the absence (control column, each n = 18) and presence of 
TTX (10-6 M, each n = 6), atropine (10-6 M, each n = 6) or hexamethonium (10-4 M, 
each n = 6). (a) Data for the twitch contractions to EFS at 0.05 Hz frequency, 0.5 ms 
duration and 110 % supramaximal voltage (b) Data for the rebound contractions to 
EFS at 30 Hz for 2 seconds every minute, 0.5 ms duration and 110 % supramaximal 
voltage. * represents a statistical difference (P < 0.05, unpaired t test) compared to the 
control column of each data set. Values are represented as the mean ± s.e.m. 
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3.3.2. Effect of the cannabinoid receptor agonists on the EFS-evoked 
contractions of the rat ileum MPLM 
  
AEA, CP 55,940, Δ9-THC and WIN 55,212-2 all caused a concentration-related 
inhibition of the contractions of the rat ileum MPLM elicited by EFS with single 
pulses at 0.05 Hz and trains of pulses at 30 Hz (Figures 3.3 and 3.5). Figure 3.2 shows 
representative traces of the contractions to both frequencies of EFS in the absence and 
presence of CP 55,940. 
 
All four agonists caused a similar maximal inhibition of the contractions evoked by 
both frequencies of EFS (Figures 3.3 and 3.5, Table 3.0). However, the twitch 
contractions evoked by EFS at 0.05 Hz were attenuated more readily by each agonist, 
at concentrations less than 10-6 M, than the rebound contractions elicited by EFS at 30 
Hz. A comparison between the pEC50 values of each agonist under the two EFS 
conditions indicated that all four agonists were significantly (P < 0.05, unpaired t test) 
more potent inhibitors of the twitch contractions than of the rebound contractions 
(Table 3.0).  
 
A comparison between the rank orders of the pEC50 values of the four agonists on 
tissues subjected to the two EFS conditions showed no correlation. The rank order of 
the pEC50 values of the agonists on tissues subjected to EFS at 0.05 Hz was CP 
55,940 = WIN 55,212-2 > AEA > Δ9-THC, whereas that for tissues subjected to EFS 
at 30 Hz was AEA > CP 55,940 = Δ9-THC = WIN 55,212-2. The lack of correlation 
between the rank orders of the pEC50 values of the agonists was attributed to 
differences in the degree of reduction in the pEC50 value of each agonist with the 
increase in the frequency of EFS. These differences are revealed by a comparison 
between ratios of the EC50 value of each agonist under the two EFS conditions. Table 
3.0 shows that the pEC50 value of CP 55,940 and WIN 55,212-2 was reduced by 
around one logarithmic unit greater than the pEC50 value of AEA and Δ9-THC as a 
result of the increase in the frequency of EFS. 
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The rate of onset of the inhibition of the contractions by each agonist was both slow 
and dependent on the frequency of EFS employed. The maximal inhibition of the 
contractions at each concentration of an agonist was achieved within 20 and 30 
minutes of administration on tissues stimulated at 0.05 Hz and 30 Hz respectively. 
Figure 3.6 shows the time courses for the maximal inhibition of the twitch and 
rebound contractions by all four agonists at 10-6 M and 10-4 M respectively.  
 
Despite the differences in the rank orders of the pEC50 values of the four agonists 
under the two EFS conditions, the rank orders of rate of onset of the inhibition of the 
contractions were similar under both EFS conditions i.e. WIN 55,212-2 > CP 55,940 
> Δ9-THC > AEA. The time taken for WIN 55,212-2, CP 55,940, Δ9-THC and AEA 
to produce a 50 % inhibition of the contractions evoked by EFS at 0.05 Hz was 4, 5, 7 
and 9 minutes respectively, whereas that at 30 Hz was 7, 9, 11 and 12 minutes 
respectively.  
 
Unlike WIN 55,212-2, its stereoisomer WIN 55,212-3 was a significantly (P < 0.05 
unpaired t test) less efficacious inhibitor of the EFS-evoked contractions over the 
same concentration range under both EFS conditions (Table 3.0). 
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(a)  
[CP 55,940]   10-10 M           10-9 M         10-8 M     10-7 M            10-6 M          10-5M 
10 min 
0.25g  
 
 
 
 
 
 
(b)  
 
 
[CP 55,940]   10-8 M                  10-7 M         10-6 M     10-5 M               10-4 M 
10 min 
1g 
 
 
 
 
 
Figure 3.2: Representative traces of the EFS-evoked contractions of the rat ileum 
MPLM in the absence and presence of CP 55,940 added in half-logarithmic unit 
increments. Unlabelled arrows represent intermediate concentrations. (a) Trace 
illustrating the twitch contractions to EFS at 0.05 Hz frequency, 0.5 ms duration and 
110 % supramaximal voltage in the absence and presence CP 55,940 (10-10 to 10-5 M) 
(b) Trace illustrating the rebound contractions to EFS at 30 Hz for 2 seconds every 
minute, 0.5 ms duration and 110 % supramaximal voltage in the absence and presence 
of CP 55,940 (10-8 to 10-4 M). 
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Figure 3.3: Concentration-response curves for the inhibition of the EFS (0.05 Hz 
frequency, 0.5 ms duration, 110 % supramaximal voltage) evoked twitch contractions 
of the rat ileum MPLM by (a) AEA, (b) CP 55,940, (c) Δ9-THC and (d) WIN 55,212-
2 constructed in the presence of ethanol () or SR 141716 (10-8 M (Δ), 10-7 M ({) or 
10-6 M ()). Each curve was fitted by non-linear regression analysis. Each symbol 
represents the mean value of inhibition of the contractions expressed as a percentage 
reduction of the amplitude of the twitch response measured immediately before the 
addition of any drug to the organ bath. Vertical lines indicate s.e.m, n = 6 for each 
curve. SR 141716 or ethanol was added 20 minutes before the first addition of an 
agonist. 
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Figure 3.4: Schild plot for SR 141716 for the antagonism of the inhibition of the EFS- 
(0.05 Hz frequency, 0.5 ms duration, 110 % supramaximal voltage) evoked twitch 
contractions of the rat ileum MPLM by AEA ({), CP 55,940 (), Δ9-THC () and 
WIN 55,212-2 (Δ). The concentration ratios were calculated using the agonist 
concentrations corresponding to the 50 % equieffective inhibition level in the absence 
and presence of SR 141716 (10-8 to 10-6 M). The intersection of the slope with the 
abscissa where Log (Concentration ratio – 1) = 0 represents the pKB value of SR 
141716 against each of the four agonists.  
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Figure 3.5: Concentration-response curves for the inhibition of the EFS- (30 Hz 
frequency, 2 seconds every minute, 0.5 ms duration, 110 % supramaximal voltage) 
evoked rebound contractions of the rat ileum MPLM by (a) AEA, (b) CP 55,940, (c) 
Δ9-THC and (d) WIN 55,212-2 constructed in the presence of ethanol () or SR 
141716 (10-6 M ()). Each curve was fitted by non-linear regression analysis. Each 
symbol represents the mean value of inhibition of the contractions expressed as a 
percentage reduction of the amplitude of the twitch response measured immediately 
before the addition of any drug to the organ bath. Vertical lines indicate s.e.m, n ≥ 6 
for each curve. SR 141716 or ethanol was added 30 minutes before the first addition 
of an agonist. 
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Figure 3.6: Comparison of the time-response curves for the inhibition of the EFS-
evoked contractions of the rat ileum MPLM by AEA ({), CP 55,940 (), Δ9-THC 
() and WIN 55,212-2 (Δ). (a) Data for the twitch contractions to EFS at 0.05 Hz 
frequency, 0.5 ms duration and 110 % supramaximal voltage in the presence of 10-6 
M of each agonist. (b) Data for the rebound contractions to EFS at 30 Hz for 2 
seconds every minute, 0.5 ms duration and 110 % supramaximal voltage in the 
presence of 10-4 M of each agonist. Each symbol represents the mean value of the 
inhibition of the contractions expressed as a percentage reduction of the amplitude of 
the contractile response measured immediately before the first addition of the agonist. 
Vertical lines indicate s.e.m, n = 4 for each curve. 
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Table 3.0: A comparison of the potency (pEC50), tissue maximal response (Emax) and potency ratios of the various cannabinoid receptor agonists 
for the inhibition of the EFS-evoked contractions of the rat ileum MPLM.  
 
 
Cannabinoid agonist pEC50 (0.05 Hz) Emax (0.05 Hz) (%) pEC50 (30 Hz) Emax (30 Hz) (%) Log ⎥⎥⎦
⎤
⎢⎢⎣
⎡
Hz) (0.05  50
Hz) (30  50
EC
 EC
 
AEA 7.91 ± 0.02 87.28 ± 3.45 5.90 ± 0.03 * 91.59 ± 3.48 2.0 
CP 55,940 8.42 ± 0.02 96.64 ± 3.32 5.37 ± 0.04 * 90.77 ± 1.63 3.0 
WIN 55,212-2 8.31 ± 0.04 97.25 ± 1.12 5.49 ± 0.01 * 92.10 ± 1.36 2.8 
Δ9-THC 7.56 ± 0.02 95.78 ± 7.88 5.47 ± 0.01 * 88.24 ± 7.84 2.1 
WIN 55,212-3 7.45 ±  0.04 4.02 ± 2.12 # 6.03 ± 0.12 8.65 ± 3.53 # 1.4 
 
 
Agonist pEC50, Emax values were derived by non-linear regression analysis for tissues stimulated electrically with either single pulses of 0.5 ms 
duration, 110 % supramaximal voltage at 0.05 Hz frequency or 2 second trains of pulses of 0.5 ms duration and 110 % supramaximal voltage at 
a frequency of 30 Hz every minute. * represents a significantly (P < 0.05, unpaired t test) lower pEC50 compared to pEC50 of the same agonist in 
tissues stimulated at 0.05 Hz. # represents a significantly (P < 0.05, unpaired t test) lower Emax compared to the Emax of WIN 55,212-2 on tissues 
under similar EFS conditions. Values are represented as mean ± s.e.m, n ≥ 6.  
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3.3.3. Effect of the cannabinoid receptor agonists on the EFS-evoked 
contractions of the rat ileum MPLM in the presence of SR 141716 
 
In tissues stimulated with single pulses at 0.05 Hz, the presence of increasing 
concentrations of SR 141716 (10-8 to 10-6 M) caused significant (P < 0.05, ANOVA 
and Dunnett’s test) progressive degrees of dextral shifts of the AEA, CP 55,940, Δ9-
THC and WIN 55,212-2 concentration-response curves with no significant (P < 0.05, 
paired t test) effect on the Emax of each agonist (Figure 3.3).  
 
An sum-of-squares F test on the Hill slope parameters of each family of agonist 
concentration-response curves in the absence and presence of SR 141716 indicated 
that the slope of each curve was not significantly (P > 0.05) different from unity. 
Hence, the dextral shifts of the agonist concentration-response curves caused by SR 
141716 were considered parallel. 
 
In contrast, a sum-of-squares F test on the Emax parameter of the agonist 
concentration-response curves in the absence and presence of SR 141716 revealed 
that a significant (P < 0.05) improvement in the sum-of-squares could be achieved by 
constraining the Emax to be shared between each data set. Therefore, each family of 
curves was re-fitted to Equation 2.3 (Chapter 2) with the Emax shared between each 
data set. Figure 3.3 represents the agonist concentration-response curves in the 
absence and presence of SR 141716 after constraining the Emax to be shared between 
each family of curves for all four agonists. 
 
Schild analysis (Figure 3.4) of the rightward displacements of the concentration-
response curves of each agonist by SR 141716 (Figure 3.3) yielded the estimates of 
the pKB value and slope shown in Table 3.1. In all instances, the slope of the Schild 
plots were significantly (P < 0.05, unpaired t test) less than unity. But, the estimates 
of the pKB value obtained from these slopes were similar irrespective of the agonist 
that was used.  
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Because the experimentally determined dose ratios represented a sample from the 
complete population of the infinite dose ratios that could be determined using infinite 
concentrations of SR 141716, the 95 % C.I. of the slope of each Schild analyses was 
calculated to investigate whether random sample variation may have produced the 
non-unit slopes, and if the sample data came from the population describing simple 
competitive antagonism i.e. unit slope.  
 
As shown in Table 3.1, the 95 % a C.I. value of the slopes of each Schild analysis 
contained unity. Therefore, each Schild plot was re-plotted by constraining the slope 
to unity to estimate the pKB value of SR 141716, with the assumption that the 
interaction between SR 141716 and each of the agonists was simple competitive and 
that random variation caused the deviation from unit slope.   
 
The estimates of the pKB value of SR 141716 obtained before and after constraining 
the slopes of the Schild plots to unity are listed in Table 3.1. It can be seen that the 
estimates of the pKB value of SR 141716 yielded from the Schild plots with the unit 
slopes were slightly higher than those obtained from the non-unit slopes. Nonetheless, 
the pKB values of SR 141716 obtained were similar irrespective of the agonist that 
was used. 
 
As mentioned above, the concentrations of each agonist required to inhibit the 
rebound contractions elicited by EFS at 30 Hz were significantly higher than those 
necessary for inhibiting the twitch contractions to EFS at 0.05 Hz. Additionally, it was 
impossible to prepare very highly concentrated stock solutions of each cannabinoid 
agonist. Therefore, the pA2 values of SR 141716 were calculated using the Gaddum 
Schild equation following incubation of a single concentration of 10-6 M. 
 
SR 141716 (10-6 M) caused small but significant (P < 0.05, ANOVA and Dunnett’s 
test) rightward displacements of the concentration-response curves of AEA, Δ9-THC 
and WIN 55,212-2 but not CP 55,940 (Figure 3.5). As shown in Table 3.1, the 
estimates of the pA2 values of SR 141716 for the antagonism of WIN 55,212-2, AEA 
and Δ9-THC were similar against these three agonists, but significantly lower than the 
pKB value obtained in the twitch contraction experiments.  
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In addition to its antagonist activity, the presence of SR 141716 alone caused a 
significant (P < 0.05, paired t test) concentration dependent augmentation of the 
amplitude of the twitch contractions to EFS at 0.05 Hz. The augmentation of the 
twitch contractions can be easily seen in Figure 3.3 as the progressive concentration 
dependent downward shift of the bottom asymptote of each agonist concentration-
response curve in the presence of SR 141716. Figure 3.7 shows a concentration 
response curve for the augmentation of the twitch contractions by SR 141716 (10-8 to 
10-5 M). The amplitude of the contractions in the presence of SR 141716 at 10-6 and 
10-5 M were significantly (P < 0.05, paired t test) larger than those in the presence of 
ethanol. The maximum potentiation of the contractions at 10-5 M corresponded to an 
increase of 12.45 ± 4.12 % (n = 6). The pEC50 value of SR 141716 from this data was 
7.52 ± 0.02. 
 
In contrast to the augmentation of the twitch contractions, SR 141716 alone 
significantly (P < 0.05, paired t test) inhibited the rebound contractions elicited by 
EFS at 30 Hz. The inhibition of the rebound contractions can be easily seen in Figure 
3.5 as the elevation of the bottom asymptote of the agonist concentration-response 
curves in the presence of SR 141716 (10-6 M). Higher concentrations of SR 141716 
were not used for antagonism studies because this cannabinoid produced a further 
concentration related inhibition of the rebound contractions (Figure 3.7). The 
inhibition of the contractions caused by SR 141716 at 10-6 M was 28.3 ± 4.4 % (n = 9) 
whereas that at the maximal concentration used i.e. 10-5 M was 76.1 ± 3.7 % (n = 9). 
The pEC50 value of SR 141716 from Figure 3.7 was 5.70 ± 0.01. 
 
The rate of onset of the action of SR 141716 was slower on tissues subjected to EFS 
at 30 Hz than those stimulated with 0.05 Hz. The maximal effect at each 
concentration of SR 141716 was achieved within 20 and 30 minutes of administration 
on tissues stimulated at 0.05 Hz and 30 Hz respectively. Figure 3.8 shows the time 
courses for the maximal inhibition of the twitch and rebound contractions by SR 
141716 at 10-5 M. The time taken for SR 141716 to produce a 50 % enhancement and 
inhibition of the twitch and rebound contractions to EFS at 0.05 Hz and 30 Hz was 4 
and 6 minutes respectively.  
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Table 3.1: A comparison of the estimates of the pKB and pA2 values of SR 141716 against AEA, CP 55,940, Δ9-THC and WIN 55,212-2 for the 
inhibition of the EFS-evoked contractions of the rat ileum MPLM. 
 
Cannabinoid receptor  
agonist 
Experimentally 
fitted slope Constrained slope 
pKB from the 
experimentally 
fitted slope 
pKB from  the 
constrained slope pA2
AEA 0.88 ± 0.03* (0.55 to 1.21) 1.00 
7.78 ± 0.18 
(5.45 to 10.1) 
8.65 ± 0.07 
(8.33 to 8.97) 6.91 
CP 55,940 0.91 ± 0.02* (0.65 to 1.16) 1.00 
7.96 ± 0.14 
(6.15 to 9.77) 
8.63 ± 0.06 
(8.39 to 8.87) – 
Δ9-THC 0.90 ± 0.03* (0.53 to 1.27) 1.00 
7.91 ± 0.20 
(5.32 to 10.5) 
8.60 ± 0.06 
(8.35 to 8.87) 6.83 
WIN 55,212-2 0.88 ± 0.03* (0.60 to 1.18) 1.00 
7.78 ± 0.16 
(5.77 to 9.90) 
8.61 ± 0.06 
(8.33 to 8.89) 6.62 
 
The experimentally fitted slope column represents the slopes of the Schild plots of SR 141716 obtained from a line of best fit, for the antagonism 
of the four cannabinoid receptor agonists in tissues subjected to EFS at 0.05 Hz frequency, 0.5 ms duration, 110 % supramaximal voltage. The 
constrained slope column represents the unit slopes of the Schild plots of SR 141716 for the same experiments. Where appropriate, the 95 % C.I. 
values are shown in parenthesis. * represents significantly (P < 0.05, unpaired t test) lower than unity. The pKB values of SR 141716 represent 
the negative logarithmic concentrations of SR 141716 on the Schild plot where the experimentally fitted and constrained slopes of the Schild 
plot intersected with the abscissa. The pA2 values represent the negative logarithmic concentrations of SR 141716 calculated using the Gaddum-
Schild equation for the antagonism of the cannabinoid receptor agonists by SR 141716 (10-6 M) on tissues stimulated with 30 Hz frequency, 2 
seconds every minute, 0.5 ms duration, 110 % supramaximal voltage. – represents no antagonism. Where appropriate values represent mean ± 
s.e.m.  
 82
 
 
 
 
 
 
 
(a)      (b)  
-9 -8 -7 -6 -5
0
5
10
15
20 * *
Log [SR 141716] (M)
Po
te
nt
ia
tio
n 
of
 co
nt
ra
ct
io
n
(%
 o
f m
ax
im
al
 re
sp
on
se
)
-8 -7 -6 -5
0
20
40
60
80
100
*
*
*
Log [SR 141716] (M)
In
hi
bi
tio
n 
of
 co
nt
ra
ct
io
n
(%
 o
f m
ax
im
al
 re
sp
on
se
)
 
 
Figure 3.7: Concentration-response curves for the effect of SR 141716 on the EFS-
evoked contractions of the rat ileum MPLM (a) Data for the enhancement of the 
twitch contractions evoked by EFS at 0.05 Hz frequency, 0.5 ms duration, 110 % 
supramaximal voltage. Each symbol represents the mean value of increase in the 
contractions expressed as a percentage of the amplitude of the twitch response 
measured immediately before the addition of SR 141716 to the organ bath (n = 6). 
Increasing concentrations of SR 141716 were added every 20 minutes. (b) Data for 
the inhibition of the rebound contractions evoked by EFS at 30 Hz frequency, 2 
seconds every minute, 0.5 ms duration, 110 % supramaximal voltage. Each symbol 
represents the mean value of inhibition of the contractions expressed as a percentage 
of the amplitude of the contraction measured immediately before the addition of SR 
141716 to the organ bath (n = 9). Increasing concentrations of SR 141716 were added 
every 30 minutes. Vertical lines indicate s.e.m. . Both curves were fitted by non-linear 
regression analysis. * represents a statistical difference (P < 0.05, paired t test) 
compared to amplitude in the absence of SR 141716 i.e. 0 % 
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Figure 3.8: Time-response curves for the change in the amplitude of the EFS-evoked 
contractions of the rat ileum MPLM by SR 141716 (10-5 M). (a) Data for the 
enhancement of the twitch contractions to EFS at 0.05 Hz frequency, 0.5 ms duration 
and 110 % supramaximal voltage. Each symbol represents the mean value of increase 
of the contractions expressed as a percentage of the amplitude of the twitch response 
measured immediately before the addition of SR 141716 to the organ bath (n = 6). (b) 
Data for the inhibition of the rebound contractions to EFS at 30 Hz for 2 seconds 
every minute, 0.5 ms duration and 110 % supramaximal voltage. Each symbol 
represents the mean value of inhibition of the contractions expressed as a percentage 
of the amplitude of the contraction measured immediately before the addition of SR 
141716 to the organ bath (n = 9). Vertical lines indicate s.e.m.  
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3.3.4. Effect of the cannabinoid receptor agonists on the EFS-evoked 
contractions of the rat ileum MPLM in the presence of SR 144528 
 
Pre-treatment of the rat ileum MPLM with SR 144528 (10-6 M) did not cause a 
displacement of the AEA, CP 55,940 Δ9-THC or WIN 55,212-2 concentration-
response curves under either of the EFS conditions (Figures 3.9 and 3.10).  
 
SR 144528 alone had no effect on the amplitude of the EFS-evoked contractions 
evoked by either frequency of EFS.  
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Figure 3.9: Concentration-response curves for the inhibition of the EFS- (0.05 Hz 
frequency, 0.5 ms duration, 110 % supramaximal voltage) evoked twitch contractions 
of the rat ileum MPLM by (a) AEA, (b) CP 55,940, (c) Δ9-THC  and (d) WIN 55,212-
2 constructed in the presence of ethanol () or SR 144528 (10-6 M ()). Each curve 
was fitted by non-linear regression analysis. Each symbol represents the mean value 
of inhibition of the contractions expressed as a percentage reduction of the amplitude 
of the twitch response measured immediately before the addition of any drug to the 
organ bath. Vertical lines indicate s.e.m. n = 6 for each curve. SR 144528 or ethanol 
was added 30 minutes before the first addition of an agonist. 
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Figure 3.10: Concentration-response curves for the inhibition of the EFS (30 Hz 
frequency, 2 seconds every minute, 0.5 ms duration, 110 % supramaximal voltage) 
evoked rebound contractions of the rat ileum MPLM by (a) AEA, (b) CP 55,940, (c) 
Δ9-THC and (d) WIN 55,212-2 constructed in the presence of ethanol () or SR 
144528 (10-6 M ()). Each curve was fitted by non-linear regression analysis. Each 
symbol represents the mean value of inhibition of the contractions expressed as a 
percentage reduction of the amplitude of the twitch response measured immediately 
before the addition of any drug to the organ bath. Vertical lines indicate s.e.m, n = 6 
for each curve. SR 144528 or ethanol was added 30 minutes before the first addition 
of an agonist. 
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3.3.5. Effect of the AEA on the EFS-evoked contractions of the rat ileum MPLM 
in the presence of capsazepine 
 
Figure 3.11 shows that the presence of capsazepine (10-5 M) did not alter the ability of 
AEA to attenuate the twitch and rebound contractions of the rat ileum MPLM evoked 
by EFS at 0.05 Hz and 30 Hz respectively.  
 
Capsazepine alone at this concentration significantly (P < 0.05, paired t test) inhibited 
both types of the EFS-evoked contractions to a similar degree by 22.3 ± 5.5 % (n = 6) 
and 15.35 ± 6.14 % (n = 6) respectively (Figure 3.11). 
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Figure 3.11: Concentration-response curves for the inhibition of the EFS-evoked 
contractions of the rat ileum MPLM by AEA constructed in the presence of ethanol 
() or capsazepine (10-5 M ()). (a) Data for the twitch contractions to EFS at 0.05 
Hz frequency, 0.5 ms duration and 110 % supramaximal voltage (b) Data for the 
inhibition of the rebound contractions to EFS at 30 Hz for 2 seconds every minute, 0.5 
ms duration and 110 % supramaximal voltage. Each curve was fitted by non-linear 
regression analysis. Each symbol represents the mean value of inhibition of the 
contractions expressed as a percentage reduction of the amplitude of the contractions 
measured immediately before the addition of capsazepine to the organ bath (n = 6). 
Vertical lines indicate s.e.m. Capsazepine or ethanol was added 30 minutes before the 
first addition of AEA.* represents a statistical difference (P < 0.05, paired t test) in 
the inhibition of contractions caused by the presence of capsazepine. 
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3.3.6. The EFS-evoked responses of the guinea-pig ileum MPLM  
 
Stimulation of the guinea-pig ileum MPLM strip with single pulses at a repetition 
frequency of 0.1 Hz elicited a transient twitch contraction of 1.62 ± 0.75 g (n = 60) 
during the duration of the electrical pulse. In contrast, stimulation with 2 second trains 
of pulses every minute at a frequency of 30 Hz elicited a rebound contraction of 3.31 
± 0.48 g (n = 60) at the end of the 2 second train of pulses. Figure 3.12 shows that 
both types of contractions were abolished by treatment with either TTX (10-6 M) or 
atropine (10-6 M) but not hexamethonium (10-4 M). 
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Figure 3.12: Bar graphs representing the amplitude of the EFS-evoked contractions of 
the guinea-pig ileum MPLM in the absence (control column, each n = 18) and 
presence of TTX (10-6 M, each n = 6), atropine (10-6 M, each n = 6) or 
hexamethonium (10-4 M, each n = 6). (a) Data for the twitch contractions to EFS at 
0.1 Hz frequency, 0.5 ms duration and 110 % supramaximal voltage  (b) Data for the 
rebound contractions to EFS at 30 Hz for 2 seconds every minute, 0.5 ms duration and 
110 % supramaximal voltage. * represents a statistical difference (P < 0.05, unpaired t 
test) compared to the control column of each data set. Values are represented as the 
mean ± s.e.m. 
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3.3.7. Effect of WIN 55,212-2 on the EFS-evoked contractions of the guinea-pig 
ileum MPLM in the absence and presence of SR 141716 
 
WIN 55,212-2 caused a concentration-dependent inhibition of the contractions of the 
guinea-pig ileum MPLM elicited by EFS with single pulses at 0.1 Hz and trains of 
pulses at 30 Hz with a similar Emax (Figure 3.13). The pEC50 values for the inhibition 
of twitch and rebound contractions were 8.62 ± 0.04 (n = 6) and 6.25 ± 0.03 (n = 6) 
respectively. This cannabinoid receptor agonist was chosen for this experiment 
because previous studies (Pertwee et al., 1996; Coutts & Pertwee, 1997) have 
demonstrated its stereospecific effects in this tissue.  
 
In similar manner to the rat ileum MPLM (Section 3.3.2), the twitch contractions of 
the guinea-pig ileum MPLM evoked by EFS at 0.1 Hz were attenuated by 
significantly (P < 0.05, unpaired t test) lower concentrations of WIN 55,212-2 than 
the rebound contractions elicited by EFS at 30 Hz . The pEC50 values of WIN 55,212-
2 for the inhibition of the twitch contractions of the guinea-pig ileum MPLM and rat 
ileum MPLM were very similar. In contrast, WIN 55,212-2 was a 0.75 logarithmic 
unit more potent in the guinea-pig ileum MPLM than in the rat ileum MPLM for the 
inhibition of the rebound contractions elicited by EFS at 30 Hz. 
 
The onset and duration of action of WIN 55,212-2 at each concentration was similar 
to that on rat ileum MPLM under both EFS conditions (data not shown). Pre-exposure 
to SR 141716 (10-6 M) resulted in a significant (P < 0.05, ANOVA and Dunnett’s 
test) parallel dextral shift of the mean WIN 55,212-2 concentration-response curve 
without a reduction in the mean Emax under either EFS conditions (Figure 3.13). The 
pA2 values of SR 141716 for the rightward displacement of the WIN 55,212-2 
concentration-response curve on tissues subjected to EFS at 0.1 Hz and 30 Hz were 
7.97 and 6.71 respectively.  
 
SR 141716 (10-6 M) alone caused a significant (P < 0.05, paired t test) 55.34 ± 5.53 % 
(n = 6) increase in the amplitude of the twitch contractions. By contrast, SR 141716 
alone at this concentration had no effect on the amplitude of the rebound contractions 
of this tissue. 
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Figure 3.13: Concentration-response curves for the inhibition of the EFS-evoked 
contractions of the guinea-pig ileum MPLM by WIN 55,212-2 in the absence and 
presence of ethanol () or SR 141716 (10-6 M, ). (a) Data for the twitch 
contractions to EFS at 0.1 Hz frequency, 0.5 ms duration and 110 % supramaximal 
voltage  (b) Data for the rebound contractions to EFS at 30 Hz for 2 seconds every 
minute, 0.5 ms duration and 110 % supramaximal voltage. Each curve was fitted by 
non-linear regression analysis. Each symbol represents the mean value of inhibition of 
EFS-evoked contractions expressed as a percentage reduction of the amplitude of 
contractions measured immediately before the addition of any drug to the organ bath 
(n = 6). SR 141716 or ethanol was added 20 and 30 minutes before the first addition 
of WIN 55,212-2 on tissues subjected to EFS at 0.1 Hz and 30 Hz respectively. * 
represents a statistical difference (P < 0.05, paired t test) compared to amplitude in the 
absence of SR 141716 i.e. 0 %.  
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3.3.8. Effect of the cannabinoids on the ACh-evoked contractions of the rat ileum 
MPLM 
 
AEA (10-4 M), CP 55,940 (10-4 M), Δ9-THC (10-4 M) and WIN 55,212-2 (10-4 M) 
which represented the concentrations that produced a marked inhibition of the EFS-
evoked contractions of the rat ileum MPLM (Sections 3.3.2 and 3.3.3), had no effect 
on basal tension of this tissue nor did their presence alter the amplitude of the 
contractions elicited by single (Figure 3.14, for CP 55,940) or cumulative (Figure 
3.15) additions of exogenously applied ACh (10-6 M).  
 
Similarly, SR 141716 (10-5 M) also had no effect on the basal tension of this tissue or 
the contractions elicited by exogenously applied ACh (Figure 3.15). 
 
 
 
[CP 55,940] (M) 
10 min 1 g 
     10-7 M                  10-6 M          10-5 M                         10-4 M 
 
 
Figure 3.14: Trace illustrating the contraction of the rat ileum MPLM to single 
administrations of ACh (10-6 M) in the presence of CP 55,940 added in half-
logarithmic unit increments. Unlabelled arrows represent intermediate concentrations 
of CP 55,940. → represents the peak of the ACh-evoked contraction. 
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Figure 3.15: Concentration-response curves to exogenously applied ACh constructed 
in the presence of ethanol (X), AEA ({, 10-4 M), CP 55,940 (, 10-4 M), Δ9-THC (, 
10-4 M), WIN 55,212-2 (Δ, 10-4 M) or SR 141716 (+, 10-5 M) on the rat ileum MPLM. 
Each curve was fitted by non-linear regression analysis. The amplitude of the 
contractions to cumulative additions of ACh in the presence of ethanol or a 
cannabinoid were expressed as a percentage of the maximal contraction to ACh 
obtained at 10-5 M from an initial ACh concentration-response curve constructed on 
each tissue. Ethanol or a cannabinoid was added 30 minutes before constructing the 
second ACh concentration-response curve. n = 6 for all curves. All values represent 
mean ± s.e.m. 
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3.3.9. Effect of the cannabinoids on the ACh evoked contractions of the guinea-
pig ileum MPLM  
 
The presence of WIN 55,212-2 (10-4 M) or SR 141716 (10-4 M) which represented the 
concentrations that markedly altered the amplitude of the EFS-evoked contractions of 
the guinea-pig ileum MPLM (Section 3.3.7) had no effect on basal tension of this 
tissue nor did their presence alter the amplitude of the contractions elicited by 
cumulative additions of exogenously applied ACh (Figure 3.16).  
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Figure 3.16: Concentration-response curves to exogenously applied ACh constructed 
in the presence of ethanol (X), WIN 55,212-2 (Δ, 10-4 M) or SR 141716 (+, 10-5 M) 
on the guinea-pig ileum MPLM. The amplitude of the contractions to cumulative 
additions of ACh in the presence of ethanol or a cannabinoid were expressed as a 
percentage of the maximal contraction to ACh obtained at 10-5 M from an initial ACh 
concentration-response curve constructed on each tissue. Ethanol or a cannabinoid 
was added 30 minutes before constructing the second ACh concentration-response 
curve. n = 6 for all curves. All values represent mean ± s.e.m. 
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3.4. Discussion 
 
The results obtained show that the ability of representatives of the four established 
classes of structurally different cannabinoid receptor agonists to inhibit the EFS-
evoked contractions of the guinea-pig and human ileal MPLM extends to the rat ileal 
MPLM. More importantly, they have revealed that the ability of each of the four 
agonists to act selectively through the CB1 receptor was dependent on the frequency 
of EFS employed because clear differences in their rank order of potencies and the 
estimates of the pKB and pA2 values of SR 141716 were identified against the 
agonists between the two EFS conditions. Moreover, as demonstrated using WIN 
55,212-2 and SR 141716, these observations appeared to extend to the guinea-pig 
ileum MPLM under similar EFS conditions.  
 
In the rat MPLM, the potencies estimated for all four agonists to inhibit of the EFS-
evoked twitch contractions of this tissue and their rank order of potencies i.e. CP 
55,940 = WIN 55,212-2 > AEA > Δ9-THC were consistent with those previously 
reported at the guinea-pig, human, mouse and rat CB1 receptor (Martin et al., 2000; 
Pertwee & Fernando, 1996; Pertwee et al., 1996; Rinaldi-Carmona et al., 1998; 
Showalter et al., 1996). These findings together with the observation that the presence 
of increasing concentrations of SR 141716 caused similar agonist independent, 
progressive parallel and surmountable dextral shifts of the concentration response 
curves of each agonist suggested that the inhibitory effect each agonist was mediated 
by the activation of the CBB1 receptor.  
 
Schild analysis of the interaction between each of the four agonists and SR 141716 
yielded Schild plots with slopes of less than unity, but pKB values of SR 141716 
which were in line with its pKB value previously reported at the CB1 receptor 
(Rinaldi-Carmona et al., 1994) and irrespective of the agonist that was used. This 
result suggested that the interaction between SR 141716 and each of the four agonists 
was not strictly simple competition at the CB1 receptor.  However, because the 95 % 
C.I. values of the experimentally fitted slopes of each Schild analysis included unity, 
it was possible that the experimentally fitted slopes were not equal to unity because of 
random variation in the sample of the dose ratios. A re-fit of each Schild plot with a 
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unit slope yielded estimates of the pKB value of SR 141716 which were again both 
consistent with its pKB value reported at the CB1 receptor (7.93-8.74; Rinaldi-
Carmona et al., 1994) and independent of the agonist that was used. These data 
suggested that the inhibition of the EFS-evoked twitch contractions of the rat ileum 
MPLM caused by all four agonists was through full agonism at the CB1 receptor and 
that the interaction between each agonist and SR 141716 at this receptor was simple 
competitive. These results supported previous immunohistochemical (Coutts et al., 
2002) and in vivo (Izzo et al.,  1999a, 199b) data demonstrating the presence of the 
CB1 receptor in this tissue and its functional role in delaying small intestinal transit in 
vivo respectively. 
 
There are two reasons for believing that the antagonism produced by SR 141716 was 
not through functional antagonism, i.e. the agonists and SR 141716 were not 
counteracting each other’s effect by producing opposing responses through separate 
receptors. Firstly, the maximal enhancement of twitch contractions produced by the 
highest concentration of SR 141716 was not large enough to completely offset the 
maximal inhibitory effect of each agonist. Secondly, the estimates of the pKB values 
of SR 141716 obtained were similar irrespective of the agonist that was used.  
 
In contrast to the CB1 receptor pharmacology of all four agonists for the inhibition of 
the EFS-evoked twitch contractions of the rat ileum MPLM, the agonist potencies and 
their corresponding rank of order for the inhibition of the EFS-evoked rebound 
contractions of this tissue, i.e. AEA > CP 55,940 = Δ9-THC = WIN 55,212-2, were 
not consistent with activity at either the CB1 or CB2 receptor (Rinaldi-Carmona et al., 
1998; Showalter et al., 1996). This observation suggested that the inhibition of the 
rebound contractions of the rat ileum MPLM was not mediated through the activation 
of either the CB1 or CB2 receptor. 
 
An unexpected but consistent finding was that the SR 141716 only antagonised the 
ability of AEA, Δ9-THC and WIN 55,212-2, but not CP 55,940 to inhibit the EFS-
evoked rebound contractions of the rat MPLM. Moreover, the pA2 values of SR 
141716 calculated against the former three agonists, albeit being similar, were around 
2 logarithmic units lower than its pKB value reported at the CBB1 receptor. This finding 
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suggested that AEA, Δ -THC and WIN 55,212-2 interacted with SR 141716 through a 
receptor distinct from the CB
9
1 receptor. The failure of SR 141716 to antagonise the 
inhibition of the rebound contractions caused by CP 55,940 indicated that this agonist 
did not interact with either the CB1 receptor or the receptor mediating the inhibitory 
effect of AEA, Δ -THC and WIN 55,212-2.  9
 
The inhibition of the rebound contractions caused by AEA, Δ9-THC and WIN 55,212-
2 was unlikely to be mediated through a part activation of CB1 receptor because, if the 
inhibition occurred through this receptor, the inhibitory effect of CP 55,940 should 
have also been susceptible to antagonism by SR 141716. These observations 
suggested that the CB1 receptor did not mediate the inhibition of the rebound 
contractions of the rat ileum MPLM caused by all four agonists.  
 
Relative to the inhibitory effects of WIN 55,212-2, its enantiomer WIN 55,212-3 was 
a significantly poor inhibitor of both types of the EFS-evoked contractions of the rat 
ileal MPLM. This observation suggested that the inhibitory effects of at least WIN 
55,212-2 on this tissue was stereo-specific and supportive of a receptor-mediated 
action of this agonist under both EFS conditions. Indeed, at least at the cannabinoid 
receptor, WIN 55,212-2 demonstrates far greater affinity and intrinsic efficacy than its 
enantiomer in several in vivo and in vitro assays (Compton et al., 1992; Izzo et al., 
1999; Pacheco et al., 1993).  
 
It is well established that all four agonists used in the present study do not 
demonstrate marked selectivity for either the CB1 or CB2 receptor. Moreover, AEA is 
also known to activate the TRPV1 receptor (Zygmunt et al., 1999; Smart et al., 2000).  
The failure of SR 144528 to antagonise the inhibitory effects of each of the four 
agonists under both EFS conditions suggested that none of the four agonists acted 
through the CB2 receptor to attenuate the EFS-evoked contractions. This finding was 
consistent with previous data from similar in vitro contraction studies on the guinea-
pig and human ileal MPLM (Croci et al., 1998; Manara et al.,  2005; Mang et al., 
2001) and in vivo studies evaluating the inhibitory effect of these cannabinoids on 
small intestinal transit in the rat and mouse (Izzo et al., 1999a, 1999b, 2000a, 2003). 
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Recent reports have shown the presence of the mRNA of the CB2 receptor and the 
receptor protein in rat ileal myenteric plexus (Duncan et al., 2005a, 2006; Storr et al., 
2002). However, the ability of cannabinoid receptor agonists to delay small intestinal 
transit of the rat in vivo through acting at this receptor has been reported to occur only 
after inflammation of the small intestine, specifically that induced with the bacterial 
endotoxin lipopolysaccharide (Mathison et al., 2004) and not other inflammatory 
agents (Izzo et al., 1999a; 1999b). Because the MPLM strips used in the present study 
were prepared from healthy rats, it is unlikely that the CBB2 receptor mediated the 
inhibitory effects of all four agonists under both EFS conditions. These data are also 
supported by the failure of SR 144528 to antagonise the inhibitory of the agonists  
 
The failure of capsazepine to antagonise the inhibitory effects of AEA under both 
EFS conditions suggested that the TRPV1 receptor was either absent or not activated 
by this agonist in this tissue. It was unlikely that the TRPV1 receptor was absent in 
tissue because the mRNA and immunoreactivity for this receptor has been identified 
in the rat ileum MPLM (Anavi-Goffer et al., 2002). Moreover, in the present study, 
capsazepine alone caused an inhibition of the both types of EFS-evoked contractions 
of this tissue, possibly through a TRPV1 receptor mediated direct relaxation of the 
longitudinal muscle as reported previously by Nocerino et al., (2002).  
 
This study also demonstrated an inhibitory effect of WIN 55,212-2 on both the twitch 
and rebound contractions of the guinea-pig ileum MPLM elicited by EFS. The 
potency of this agonist for inhibiting the twitch contractions was similar to that 
reported previously at the CB1 receptor in this tissue (Coutts & Pertwee, 1997; 
Pertwee et al., 1996) and to that obtained in the rat ileum MPLM when subjected to 
similar EFS conditions. This inhibitory effect was likely to be mediated through the 
activation of the CB1 receptor because it was antagonised by SR 141716 with a pA2 
value in agreement with its pKB value at the CB1 receptor. However, as was observed 
in the rat ileum MPLM, the potency of WIN 55,212-2 to inhibit the rebound 
contractions of the guinea-pig ileum MPLM was also significantly lower than its 
potency measured for the inhibition of the twitch contractions. Moreover, the potency 
obtained was inconsistent with that reported previously at both the CB1 and CB2 
receptor (Rinaldi-Carmona et al., 1998; Showalter et al., 1996). Because the pA2 
value of SR 141716 calculated for this antagonism was over a logarithmic unit less 
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than its pKB value at the CB1 receptor, the inhibition of the rebound contraction 
caused by WIN 55,212-2 was unlikely to be mediated through the CB1 receptor.  
 
The similarity between the pA2 value of SR 141716 obtained against WIN 55,212-2 in 
the guinea-pig ileum MPLM and those obtained against the same agonist, AEA and 
Δ9-THC in the rat MPLM, for the inhibition of the rebound contractions of both 
tissues suggested that the MPLM of both species contained the same putative non-
CB1-non-CB2 receptor, in addition to the CB1 receptor. Moreover, in addition to the 
presence of these two receptors in the rat ileum MPLM, this tissue also appeared to 
contain an additional non-CB1-non-CB2 receptor that mediated the inhibitory effect of 
CP 55,940.  
 
The twitch and rebound contractions of both MPLM tissues to EFS were abolished by 
TTX or atropine but not hexamethonium. This suggested that the electrical stimulus 
indirectly provoked contractions of the longitudinal smooth muscle layer, through the 
mACh receptor, by stimulating the release of ACh from post-ganglionic nerve 
terminals of the myenteric plexus. Because the relaxations of the rat ileum MPLM 
observed during the first 20 minutes of EFS at 30 Hz were abolished by TTX and L-
NAME, it was likely that these responses were mediated by the release of NO from 
the myenteric plexus. The failure of EFS to induce relaxations of the guinea-pig ileum 
MPLM preceding the rebound contractions suggests that either an inhibitory 
transmitter was not released from this tissue or the amount released was not sufficient 
to produce a relaxation of the muscle.  
 
None of the four agonists, nor SR 141716 at the highest concentrations used had, any 
effect on the resting tone or contractions of the rat ileum MPLM evoked by 
exogenously applied ACh. Similar observations were on the made on guinea-pig 
ileum MPLM in the presence of WIN 55,212-2 and SR 141716. Therefore, in 
agreement with previous studies (Coutts & Pertwee, 1997; Mang et al., 2001), the 
effects of the cannabinoids on the EFS-evoked contractions of both tissues may be 
ascribed to a pre-synaptic modulation of the release of ACh from the myenteric 
plexus and not a post-junctional interaction with the mACh receptor on the smooth 
muscle or an interference with the hydrolysis of ACh by ACh esterase.  
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All cannabinoids assayed displayed a slow onset of action on the EFS-evoked 
contractions of both MPLM tissues. The slow kinetics may be attributed to the 
relative low aqueous solubility and high lipophilicity of the compounds, which would 
cause them to be sequestered by the solubilising agent and delay the equilibration 
between the cannabinoids molecules in free solution and those present in the tissue. 
The low solubility of these drugs in water would be expected to delay their onset of 
action by limiting their rate of diffusion across the aqueous phase from the 
solubilising agent to the tissue. In the rat ileum MPLM, the good correlation between 
the rank order of the onset of action of the four agonists i.e. WIN 55,212-2 > CP 
55,940 > Δ9-THC > AEA and their rank order of logarithmic octanol-water partition 
coefficients i.e. 3.4, 4.6, 5.5 and 6.3 respectively (Valvetti et al., 2004) suggests that 
the rate of onset of action of each agonist was slow because of their low aqueous 
solubility, high lipophilicity and slow receptor kinetics.  Because the rank orders of 
onset of the inhibition of contractions by all four agonists in the rat ileum MPLM 
correlated well between the two EFS conditions, it is conceivable that the differences 
in the rates of onset of inhibition between the two EFS conditions were not attributed 
to differences in the diffusion of the agonists through the tissue to the receptor. The 
differences between the rates of onset of action between the two EFS conditions 
supports the notion that the inhibitory effects under the two EFS conditions were not 
mediated through a common receptor. 
 
In the absence of other drugs, SR 141716 alone produced a small but significant 
concentration dependent increase in the amplitude of the EFS-evoked twitch 
contractions of the rat ileum MPLM. Consistent with results from previous studies, 
SR 141716 at the single concentration used caused a marked increase in the amplitude 
of the EFS-evoked twitch contractions of the guinea-pig ileum MPLM (Coutts & 
Pertwee, 1997; Pertwee et al., 1996). This augmentation of the twitch contractions 
may be through an SR 141716-induced antagonism of the tonic activation of the CB1 
receptor by endogenously released CB1 receptor agonists. Indeed, recent reports have 
shown that levels of both AEA and 2-AG high enough to cause the activation CB1 
receptor have been detected in the rat and guinea-pig ileum MPLM (Katayama et al., 
1997; Valenti et al., 2005; Guagnini et al., 2006). Alternatively, the augmentation of 
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the twitch contractions may be through an unmasking of the constitutive activity of 
the CB1 receptor via inverse agonism. 
 
Whilst SR 141716 increased the amplitude of the EFS-evoked twitch contractions of 
both ileal MPLM tissues, it did not do the same to the EFS-evoked rebound 
contractions. This might be because there are different subtypes of the cannabinoid 
receptor in these tissues as suggested by the difference between the pKB and pA2 
values of SR 141716 between the two EFS conditions.  
 
Taken together, the data in this study have provided evidence that the rat ileum 
MPLM served as a viable in vitro ileal cannabinoid receptor bioassay as the guinea-
pig ileum MPLM. Representatives of the four main classes of structurally different 
cannabinoid receptor agonists were shown to attenuate the EFS-evoked contractions 
of this tissue in a concentration dependent, presynaptic and stereospecific manner. 
Evidence was provided for a functional role of the CB1 receptor and a putative non-
CB1-non-CB2 but SR 141716-sensitive and agonist dependent receptor in selectively 
mediating the inhibitory effects of the cannabinoid receptor agonists on the twitch and 
rebound contractions of the rat ileum MPLM respectively. These observations were 
shown to extend to the guinea-pig ileum subjected to similar EFS conditions. Neither 
the CB2 receptor nor the TRPV1 receptor were involved in mediated the inhibitory 
effects of the cannabinoid receptor agonists or AEA under either EFS conditions 
respectively. The ability of SR 141716 to cause an augmentation of the EFS-evoked 
twitch contractions suggests either the presence of an endocannabinoid tone or a 
constitutively active CB1 receptor. 
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CHAPTER 4: 
ISOLATED NERVE-SMOOTH MUSCLE 
PREPARATIONS 
 
Studies into the Mechanism of the SR 141716-Mediated 
Increase in the Amplitude of the Twitch Contractions of 
the Rat Myenteric Plexus Longitudinal Muscle 
Preparation 
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4.1. Introduction 
 
In the previous chapter, it was shown that in addition to its antagonist activity at the 
CB1 receptor, SR 141716 alone caused an augmentation of the EFS-evoked twitch 
contractions of both the rat and guinea-pig ileal MPLM. Two common explanations 
that have been offered to describe such antagonist mediated changes in responses are 
the unmasking of a constitutive activity of the receptor via inverse agonism, or the 
antagonism of tonically released endogenous agonists from the receptor. To date, SR 
141716 has only been conclusively shown to behave as an inverse agonist in 
recombinant cell-based assays monitoring cAMP accumulation or [35S]-GTPγS 
incorporation (Bouaboula et al.,  1997; Landsman et al., 1997; MacLennnan et al.,  
1997) in which the CBB1 receptor was over-expressed. Whilst inverse agonism and 
constitutive activity of the CB1 receptor have been easily demonstrated and 
characterised in receptor over-expression systems, it has appeared unlikely that such 
activity could occur in intact tissues in which receptor expression was likely to be at a 
natural physiological level. 
 
Over the last decade, a large body of evidence has emerged to indicate that a 
functional endocannabinoid tone may be present in the intestinal tract, primarily 
because of the identification of AEA and 2-AG (Fegley et al., 2005; Gomez et al., 
2002; Guagnini et al., 2006; Mechoulam et al., 1995; Mascolo et al., 2002; Izzo et al., 
2003) and the mechanisms for their inactivation, via facilitated uptake by a putative 
transporter protein (Mascolo et al., 2002) followed by enzymatic hydrolysis such as 
by FAAH (Katayama et al., 1997). Furthermore, the demonstration that in vivo 
administration of inhibitors of FAAH or the putative uptake transporter into rodents 
mimics the inhibitory effects of exogenously administered cannabinoid receptor 
agonists has added weight to a possible physiological inhibitory role of an 
endocannabinoid agonist tone on intestinal motility (Capasso et al., 2005; Pinto et al., 
2002). However, the stimulatory effect of SR 141716 on the intestinal tract may not 
be attributed unequivocally to the presence of ongoing local enteric endocannabinoid 
agonist activity because the existence of a possible constitutive activity of the CB1 
receptor in the small intestine has not been investigated.  
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The purpose of this study to make an attempt to elucidate the mechanism by which SR 
141716 alone augmented the EFS-evoked twitch contractions of the rat ileum MPLM. 
Parallel experiments were also performed on the guinea-pig ileum MPLM because of 
the common use of this tissue as a cannabinoid bioassay. Additionally, some 
experiments were also performed on the rat vas deferens, because despite it 
possessing a functional pre-synaptic CB1 receptor, in this tissue SR 141716 does not 
alter the amplitude of the EFS-evoked contractions (Lay et al., 2000).  
 
Recently, a number of ligands have been developed and suggested to behave as potent 
“silent” CB1 receptor antagonists (Pertwee, 2005b). Among these is O-2050, a 
commercially available sulphonamide analogue of Δ9-tetrahydrocannabinol, which 
has been reported to be devoid of agonist or inverse agonist activity on the EFS-
evoked contractions of the mouse vas deferens (Martin et al., 2002). Therefore, the 
availability of O-2050 offered the opportunity to elucidate the mechanism by which 
SR 141716 alone produced its inherent effects. For example, if O-2050 was found not 
to augment the EFS-evoked contractions of the rat and guinea-pig ileum MPLM, 
evidence would be obtained to suggest that SR 141716 behaved as an inverse agonist 
and that an endocannabinoid tone was absent. 
 
In this study, the effect of three inhibitors of FAAH; AA-5HT (arachidonoyl-
serotonin), PMSF (phenylmethylsulphonyl fluoride) and URB-597 and of VDM-11, 
an inhibitor of the putative endocannabinoid uptake transporter were also evaluated on 
the MPLM tissues, as an approach to unmask an inhibitory endocannabinoid tone by 
limiting the inactivation of tonically released endocannabinoid agonists.  
 
Additionally, the effects of AA-5HT, PMSF, URB-597 and VDM-11 were examined 
on the potency of exogenously applied AEA and WIN 55212-2 as inhibitors of the 
EFS-evoked contractions of the MPLM tissues. The latter cannabinoid receptor 
agonist was used because it is not a substrate of FAAH as lacks an amide linkage, and 
in addition to its common use as an agonist, it has been shown to have stereospecific 
activity at the CB1 receptor in these tissues (Coutts & Pertwee, 1997; see Chapter 2).  
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4.2. Methods 
 
MPLM strips were dissected from the ileum of both rats and guinea-pigs (Section 2.1) 
and set up in organ baths as described in Section 2.2.1. The experiments under EFS 
and muscarinic stimulation conditions were performed by the methods described in 
Section 2.2.5.1.1 and 2.2.5.1.2 respectively. 
 
The data obtained from the experiments with EFS and ACh stimulation were 
quantified and analysed by the methods described in Section 2.2.5.3.1 and 2.2.5.3.2 
respectively.  
 
The vas deferens was dissected from the rats (Section 2.1) by the method described in 
Section 2.2.2. The experiments on the rat vas deferens under EFS stimulation 
conditions were performed by the methods described in Section 2.2.5.2. The data 
obtained from the experiments with EFS were quantified and analysed by the methods 
described in Section 2.2.5.3.1. 
 
The compounds used in this study were: AA-5HT, ACh, AEA, AM 251, atropine, O-
2050, PPADS, Prazosin, PMSF, SR 141716, TTX, WIN 55,212-2, URB-597 See 
Table 2.1 for the solvents and suppliers of the compounds used. 
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4.3. Results 
 
4.3.1. Effect of SR 141716, AM 251 and O-2050 on EFS-evoked twitch 
contractions of the rat and guinea-pig ileum MPLM 
SR 141716, AM 251 and O-2050 all caused a concentration-dependent enhancement 
of the EFS-evoked twitch contractions of both the rat and guinea-pig ileum MPLM 
(Figure 4.1). The twitch contractions in the presence of these cannabinoids were 
abolished by application of either TTX (10-6 M) or atropine (10-6 M). Figure 4.0 
shows representative traces of the augmentation of the twitch contractions of both 
tissues by SR 141716.  
 
All three cannabinoid antagonists produced different degrees of maximal 
enhancement of the twitch contractions in both tissues. The Emax values of all three 
antagonists were over 20 times (P < 0.05, unpaired t test) greater in the guinea-pig 
ileum MPLM than in the rat ileum MPLM (Table 4.0). Nevertheless, the rank order of 
the Emax values were similar in both tissues i.e. AM 251 > SR 141716 > O-2050. 
  
Because each set of curves in Figure 4.1 had different maxima and that the slopes 
were not parallel, a direct comparison between the pEC50 values of the three 
cannabinoids was not possible. A comparison between the concentrations 
corresponding to the 5 % and 150 % level of enhancement of the contractions of the 
rat and guinea-pig ileum MPLM curves, respectively, indicated that the rank order of 
potency of the three cannabinoids on both tissues was similar i.e. AM 251 > SR 
141716 > O-2050. 
 
The rate of onset of the potentiation of the contractions by each cannabinoid was slow 
on both tissues, with the maximal enhancement at each concentration being achieved 
within 20 minutes of administration. Figure 4.2 shows the time courses for the 
maximal enhancement of the twitch contractions of the rat and guinea-pig ileum 
MPLM by all three cannabinoids at a concentration of 10-6 M. 
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  (a) 
[SR 141716]   10-9 M         10-8 M        10-7 M           10-6 M          10-5M 
10 min 
0.25g 
[Atropine] 10-6 M 
 
 
 
 
(b) 
  10-9 M  10-8 M         10-7 M                      10-6 M  [SR 141716] 
[Atropine] 10-6 M 
1 g 
10 min 
Figure 4.0: Representative traces of the EFS-evoked twitch contractions of the rat and 
guinea-pig ileum MPLM in the absence and presence of SR 141716 added in half-
logarithmic unit increments. Unlabelled arrows represent intermediate concentrations. 
(a) Trace illustrating the twitch contractions of the rat ileum MPLM to single pulses 
of 0.5 ms duration and 110 % supramaximal voltage repeated at a frequency of 0.05 
Hz in the absence and presence SR 141716 (b) Trace illustrating the twitch 
contractions of the guinea-pig ileum MPLM to single pulses of 0.5 ms duration and 
110 % supramaximal voltage repeated at a frequency of 0.1 Hz in the absence and 
presence SR 141716. 
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Figure 4.1: Concentration-response curves for the enhancement of the EFS-evoked 
twitch contractions of the rat and guinea-pig ileum MPLM by SR 141716 (), AM 
251 ({) and O-2050 (). Each curve was fitted by non-linear regression analysis. (a) 
Data for the twitch contractions of the rat ileum MPLM to single pulses of 0.5 ms 
duration and 110 % supramaximal voltage repeated at a frequency of 0.05 Hz (b) Data 
for the twitch contractions of the guinea-pig ileum MPLM to single pulses of 0.5 ms 
duration and 110 % supramaximal voltage repeated at a frequency of 0.1 Hz. Each 
symbol represents the mean value of potentiation of the twitch contractions expressed 
as a percentage of the amplitude of the twitch response measured immediately before 
the addition of the same cannabinoid to the organ bath (n = 6). Vertical lines indicate 
the s.e.m.  
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Table 4.0: A comparison of the potency (pEC50) and tissue maximal response (Emax) and the ratio of the Emax values of the enhancement 
of the EFS-evoked contractions of the rat and guinea-pig ileum MPLM by the CB1 receptor antagonist / inverse agonists SR 141716, AM 
251 and O-2050. 
 
 
 
 Rat ileum MPLM Guinea-pig ileum MPLM  
Cannabinoid pEC50 Emax (%) pEC50 Emax (%) 
 
(%)
(%)
)(max
)(max
rat
pigguinea
Ε
Ε −  
SR 141716 7.46 ± 0.04 12.45 ± 4.12 6.97 ± 0.01 287.8 ± 43.9 * 23.1 
AM 251 7.60 ± 0.02 14.55 ± 2.34 7.07 ± 0.01 343.0 ±37.5 * 23.5 
O-2050 7.19 ± 0.01 8.15 ± 2.21 6.96 ± 0.03 215.5 ± 50.2 * 26.4 
pEC50 and Emax values were derived by non-linear regression analysis for the rat and guinea-pig ileum MPLM strips stimulated 
electrically with single pulses of 0.5 ms duration, 110 % supramaximal voltage at 0.05 Hz and 0.1 Hz frequency respectively. * represents 
a significantly (P < 0.05, unpaired t test) greater Emax value than the Emax value for the same cannabinoid obtained on the rat ileum 
MPLM. Where appropriate, values are represented as mean ± s.e.m of n ≥ 6 experiments. 
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Figure 4.2: Comparison of the time-response curves for the enhancement of the 
amplitude of the EFS-evoked twitch contractions of the rat and guinea-pig ileum 
MPLM by SR 141716 (), AM 251 ({) and O-2050 () at 10-6 M. (a) Data for the 
twitch contractions of the rat ileum MPLM elicited by single pulses of 0.5 ms 
duration and 110 % supramaximal voltage repeated at a frequency of 0.05 Hz. (b) 
Data for the twitch contractions of the guinea-pig ileum MPLM to single pulses of 0.5 
ms duration and 110 % supramaximal voltage repeated at a frequency of 0.1 Hz. Each 
symbol represents the mean value of potentiation of the twitch contractions expressed 
as a percentage of the amplitude of the twitch  response measured immediately before 
the addition of the same cannabinoid to the organ bath (n = 4). Vertical lines indicate 
the s.e.m. 
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4.3.2. Effect of SR 141716, AM 251 and O-2050 on EFS-evoked twitch 
contractions of the rat vas deferens 
 
Stimulation of the rat vas deferens with single pulses at a repetition frequency of 0.1 
Hz elicited a transient twitch contraction of 1.27 ± 0.23 g (n = 60) every 10 seconds 
during the duration of the electrical pulse (Figure 4.3). Figure 4.4 shows that the 
twitch contractions were abolished by treatment with either TTX (10-6 M) or PPADS 
(10-6 M) but not prazosin (10-6 M). 
 
Cumulative additions of SR 141716, AM 251 and O-2050 from 10-9 M to 10-5 M 
every 20 minutes had no effect on the basal tension or the EFS-evoked twitch 
contractions of this tissue (data not shown). 
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                                          [Prazosin] [PPADS] 
                                             10-5 M        3 x 10-6 M 
20 min 
1 g 
           10-7 M          10-6 M     10-5 M   10-4 M   [SR 141716]
Figure 4.3: Representative trace of the EFS-evoked twitch contraction of the rat vas 
deferens to single pulses of 0.5 ms duration and 110 % supramaximal voltage 
repeated at a frequency of 0.1 Hz in the absence and presence of prazosin (10-6 M) 
and PPADS (10-6 M). SR 141716 was added in half-logarithmic unit increments. 
Unlabelled arrows represent intermediate concentrations. Solid line indicates the 
monophasic contraction of the rat vas deferens to EFS on a fast time base. Subsequent 
contractions are recorded on a slow time base. 
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Figure 4.4: Bar graphs representing the amplitude of the EFS-evoked twitch 
contractions of the rat vas deferens evoked by single pulses of 0.5 ms duration and 
110 % supramaximal voltage repeated at a frequency of 0.1 Hz in the absence (control 
column, n = 18) and presence of TTX (10-6 M, n = 6), PPADS (10-6 M, n = 6) or 
prazosin (10-6 M, n = 6). * represents a statistical difference (P < 0.05, unpaired t test) 
compared to the control column. Values are represented as the mean ± s.e.m. 
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4.3.3. Effect of AA-5HT, PMSF and URB-597 alone and on the potency of AEA 
and WIN 55,212-2 as inhibitors of the EFS-evoked twitch contractions of 
the rat and guinea-pig ileum MPLM 
 
Cumulative additions of AA-5HT (10-9 to 10-5 M), PMSF (10-6 to 10-4 M) or URB-
597 (10-9 to 10-5 M) every 15 minutes had no effect on basal tension or the EFS-
evoked twitch contractions of both the rat and guinea-pig ileum MPLM (data not 
shown).  
 
The effect of AA-5HT and URB-597 at concentrations higher than 10-5 M could not 
be investigated because of difficulties in preparing sufficiently concentrated stock 
solutions of these compounds.  
 
Pre-incubation of the tissues for 20 minutes with AA-5HT (10-6 M), PMSF (10-4 M) 
or URB-597 (3 x 10-8 M) resulted in a significant (P < 0.05, ANOVA and Dunnett’s 
test) parallel leftward displacement of the AEA concentration-response curve on both 
the rat and guinea-pig ileum MPLM without a change in Emax (Figure 4.5) or slope. 
The presence of these concentrations of AA-5HT, PMSF and URB-597 increased the 
potency of AEA by 2.0, 22.1 and 20.2 times on the rat ileum MPLM respectively, and 
by 3.2, 32.4 and 48.8 times on the guinea-pig ileum MPLM respectively.  
 
By contrast, pre-treatment of the rat and guinea-pig ileum MPLM for 20 minutes with 
AA-5HT (10-6 M), PMSF (10-4 M) or URB-597 (3 x 10-8 M) had no effect on the 
location and Emax of the WIN 55,212-2 concentration-response curve (Figure 4.6). 
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Figure 4.5: Concentration-response curves for the inhibition of the EFS-evoked 
contractions of the rat and guinea-pig ileum MPLM by AEA in the presence of 
ethanol (), AA-5HT (, 10-6 M), PMSF (z, 10-4 M) or URB-597 ({, 3 x 10-8 M). 
Each curve was fitted by non-linear regression analysis with the upper asymptote 
constrained to a common value. (a) Data for the twitch contractions of the rat ileum 
MPLM to single pulses of 0.5 ms duration and 110 % supramaximal voltage repeated 
at a frequency of 0.05 Hz (b) Data for the twitch contractions of the guinea-pig ileum 
MPLM to single pulses of 0.5 ms duration and 110 % supramaximal voltage repeated 
at a frequency of 0.1 Hz. Each symbol represents the mean value of inhibition of 
twitch contractions expressed as a percentage of the amplitude of the contraction 
measured immediately before the addition of any drug to the organ bath (n = 6). 
Vertical lines indicate the s.e.m. AA-5HT, PMSF or URB-597 or ethanol was added 
20 minutes before the first addition of AEA. 
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Figure 4.6: Concentration-response curves for the inhibition of the EFS-evoked 
contractions of the rat and guinea-pig ileum MPLM by WIN 55,212-2 in the presence 
of ethanol (), AA-5HT (, 10-6 M), PMSF (z, 10-4 M) or URB-597 ({, 3 x 10-8 M). 
Each curve was fitted by non-linear regression analysis with the upper asymptote 
constrained to a common value. (a) Data for the twitch contractions of the rat ileum 
MPLM to single pulses of 0.5 ms duration and 110 % supramaximal voltage repeated 
at a frequency of 0.05 Hz (b) Data for the twitch contractions of the guinea-pig ileum 
MPLM to single pulses of 0.5 ms duration and 110 % supramaximal voltage repeated 
at a frequency of 0.1 Hz. Each symbol represents the mean value of inhibition of 
twitch contractions expressed as a percentage of the amplitude of the contraction 
measured immediately before the addition of any drug to the organ bath (n = 6). 
Vertical lines indicate the s.e.m. AA-5HT, PMSF or URB-597 or ethanol was added 
20 minutes before the first addition of WIN 55,212-2. 
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4.3.4. Effect of VDM-11 alone and on the potency of AEA as an inhibitor of the 
EFS-evoked twitch contractions of the rat and guinea-pig ileum MPLM 
 
Cumulative additions of VDM-11 (10-9 to 10-5 M) every 15 minutes had no effect on 
basal tension or EFS-induced contractions of rat and guinea-pig ileum MPLM (data 
not shown). Concentrations of VDM-11 higher than 10-5 M were not investigated. 
Pre-incubation of the tissues for 20 minutes with VDM-11 (10-5 M) did not shift the 
AEA concentration-response curve on either tissues (Figure 4.7). 
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Figure 4.7: Concentration-response curves for the inhibition of the EFS-evoked 
contractions of the rat and guinea-pig ileum MPLM by AEA in the presence of 
ethanol () or VDM-11 ({, 10-5 M). Each curve was fitted by non-linear regression 
analysis with the upper asymptote constrained to a common value. (a) Data for the 
twitch contractions of the rat ileum MPLM to single pulses of 0.5 ms duration and 
110 % supramaximal voltage repeated at a frequency of 0.05 Hz (b) Data for the 
twitch contractions of the guinea-pig ileum MPLM to single pulses of 0.5 ms duration 
and 110 % supramaximal voltage repeated at a frequency of 0.1 Hz. Each symbol 
represents the mean value of inhibition of twitch contractions expressed as a 
percentage of the amplitude of the contraction measured immediately before the 
addition of any drug to the organ bath (n = 6). Vertical lines indicate the s.e.m. VDM-
11 or ethanol was added 20 minutes before the first addition of AEA. 
 119
4.3.5. Effect of AEA on the EFS-evoked contractions of the guinea-pig ileum 
MPLM in the absence and presence of SR 141716 
 
The ability of both AEA and WIN 55,212-2 to attenuate the twitch contractions of the 
rat ileum MPLM, and of the latter agonist to inhibit the twitch contractions of the 
guinea-pig ileum MPLM were shown to be mediated through the activation of the 
CB1 receptor (Chapter 3, Sections 3.3.3 and 3.3.7). Because of the use of AEA in 
Section 4.3.3 and 4.3.4, the effect of this agonist was investigated on the twitch 
contractions of the guinea-pig ileum MPLM in the presence and absence of SR 
141716 to characterise the receptor mediating the inhibitory effect of this agonist.  
 
AEA caused a concentration-dependent inhibition of the twitch contractions of the 
guinea-pig ileum MPLM with a pEC50 value of 6.81 ± 0.02 (n = 6, Figure 4.8). This 
value was significantly (P < 0.05, unpaired t test) lower than the pEC50 value obtained 
on the rat ileum MPLM (Section 3.3.3), but similar to that obtained previously on this 
tissue (Mang et al., 2001). 
 
The onset and duration of action of AEA at each concentration was similar to that 
observed on the rat ileum MPLM (data not shown). Pre-treatment of the tissue with 
SR 141716 (10-7 M) caused a significant (P < 0.05, ANOVA and Dunnett’s test) 
parallel dextral shift of the AEA concentration-response curve without a reduction in 
the Emax value (Figure 4.8). The pA2 value of SR 141716 for this antagonism was 
7.90. 
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Figure 4.8: Concentration-response curves for the inhibition of the EFS (0.1 Hz, 0.5 
ms duration, 110 % supramaximal voltage) evoked twitch contractions of the guinea-
pig ileum MPLM by AEA in the presence of ethanol () or SR 141716 (10-7 M, {). 
Each curve was fitted by non-linear regression analysis with the upper asymptote 
constrained to a common value. Each symbol represents the mean value of inhibition 
of EFS-evoked contractions expressed as a percentage reduction of the amplitude of 
contractions measured immediately before the addition of any drug to the organ bath 
(n = 6). Vertical lines represent the s.e.m. SR 141716 or ethanol was added 20 
minutes before the first addition of AEA. * represents a statistical difference (P < 
0.05, paired t test) compared to amplitude in the absence of SR 141716 i.e. 0 %.  
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4.3.6. Effect of WIN 55,212-2 on the EFS-evoked contractions of the rat vas 
deferens in the absence and presence of SR 141716 
 
To rule out the possibility that the failure of SR 141716, AM 251 and O-2050 to 
augment the EFS-evoked contractions of the this tissue (Section 4.3.2) may have been 
a consequence of the absence of the CB1  receptor, the effect of WIN 55,212-2 was 
investigated in the absence and presence of SR 141716.  
 
WIN 55,212-2 caused a concentration related inhibition of the twitch contractions of 
this tissue with a pEC50 value of 7.76 ± 0.02 (n = 5). The onset of the inhibition of the 
contractions by WIN 55,212-2 was slow, with the maximal inhibition at each 
concentration being achieved within 30 minutes of administration (data not shown).  
 
The presence of SR 141716 (10-6 M) caused a significant (P < 0.05, ANOVA and 
Dunnett’s test) parallel dextral shift of the WIN 55,212-2 concentration-response 
curve without a reduction in the Emax value (Figure 4.9). The pA2 value of SR 141716 
for the antagonism of WIN 55,212-2 was 7.81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 122
  
 
 
-10 -9 -8 -7 -6 -5
0
20
40
60
80
100
Log [WIN 55,212-2] (M)
%
 In
hi
bi
tio
n 
of
 co
nt
ra
ct
io
n
 
Figure 4.9: Concentration-response curves for the inhibition of the EFS-evoked twitch 
contractions (0.1 Hz, 0.5 ms duration, 110 % supramaximal voltage) of the rat vas 
deferens by WIN 55,212-2 in the presence of ethanol () or SR 141716 (10-6 M, {). 
Each curve was fitted by non-linear regression analysis with the upper asymptote 
constrained to a common value. Each symbol represents the mean value of inhibition 
of EFS-evoked contractions expressed as a percentage reduction of the amplitude of 
contractions measured immediately before the addition of any drug to the organ bath 
(n = 5). Vertical lines indicate the s.e.m. SR 141716 or ethanol was added 20 minutes 
before the first addition of WIN 55,212-2. 
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4.3.7. Effect of SR 141716, AM 251 and O-2050 on ACh-evoked contractions of 
the rat and guinea-pig ileum MPLM 
 
AM251 (10-5 M), SR 141716 (10-5 M) and O-2050 (10-5 M) used at the concentrations 
that produced a marked augmentation of the EFS-evoked twitch contractions of the rat 
and guinea-pig ileum MPLM (Section 4.3.1), had no effect on basal tension of this 
tissue nor did their presence alter the amplitude of the contractions elicited by 
cumulative additions of exogenously applied ACh (Figure 4.10).  
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Figure 4.10: Concentration-response curves of exogenously applied ACh constructed 
in the presence of ethanol (X), AM251 ({, 10-5 M), SR 141716 (, 10-5 M) or O-
2050 (z, 10-5 M). Each curve was fitted by non-linear regression analysis. (a) Data for 
the rat ileum MPLM. (b) Data for the guinea-pig ileum MPLM. The amplitude of the 
contractions to cumulative additions of ACh in the presence of ethanol or a 
cannabinoid were expressed as a percentage of the maximal contraction to ACh 
obtained at 10-5 M from an initial ACh concentration-response curve constructed on 
each tissue. Ethanol or the cannabinoid was added 30 minutes before constructing the 
second ACh concentration-response curve. n = 6 for all curves. All values represent 
mean ± s.e.m. 
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4.3.8. Effect of AEA and WIN 55,212-2 on ACh-evoked contractions of the 
guinea-pig ileum MPLM 
 
Both AEA (10-5 M; Section 4.3.5) and WIN 55,212-2 (10-4 M; Section 3.3.7) at the 
concentrations that produced a marked inhibition of the EFS-evoked twitch and 
rebound contractions of the guinea-pig ileum MPLM respectively, had no effect on 
basal tension of this tissue nor did their presence alter the amplitude of the 
contractions elicited by cumulative additions of exogenously applied ACh (Figure 
4.11).  
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Figure 4.11: Concentration-response curves of exogenously applied ACh constructed 
in the presence of ethanol (X), AEA (, 10-5 M) or WIN 55,212-2 (z, 10-4 M) on the 
guinea-pig ileum MPLM. Each curve was fitted by non-linear regression analysis. 
The amplitude of the contractions to cumulative additions of ACh in the presence of 
ethanol or a cannabinoid were expressed as a percentage of the maximal contraction 
to ACh obtained at 10-5 M from an initial ACh concentration-response curve 
constructed on each tissue. Ethanol or the cannabinoid was added 30 minutes before 
constructing the second ACh concentration-response curve. n = 6 for all curves. All 
values represent mean ± s.e.m. 
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4.4. Discussion 
 
The purpose of this study was to investigate whether the mechanism by which SR 
141716 increased the EFS-evoked twitch contractions of the rat and guinea-pig 
MPLM was through inverse agonism or the antagonism of an inhibitory effect of 
tonically released endocannabinoid agonists at the CB1 receptor.  
 
There are two main reasons for believing that the enhancement of the twitch 
contractions caused by SR 141716 was mediated through the CB1 receptor and not 
another pharmacological target. Firstly, as was shown in the experiments with the rat 
MPLM in Chapter 3, the estimates of the pKB value of SR 141716 obtained for the 
antagonism of the inhibitory effect of AEA, CP 55,940, Δ9-THC and WIN 55,212-2 
were both independent of the agonist that was used and similar to its pKB value 
previously reported at the CB1 receptor. Secondly, as was shown in the present study, 
the ability of SR 141716 to cause a concentration-dependent augmentation of the 
twitch contractions of both the rat and guinea-pig MPLM was shared by AM251 and 
O-2050 at concentrations which are known to act selectively through the CB1 
receptor.  
 
The sensitivity of the EFS-evoked twitch contractions of both tissues to TTX and 
atropine but not hexamethonium, both before and after the augmentation of the twitch 
contractions by SR 141716, AM 251 or O-2050, together with the lack of effect of 
these cannabinoid receptor blockers on contractions elicited by exogenously applied 
ACh suggested that the enhancement of the twitch contractions was because of an 
increase in the release of ACh from the myenteric post-ganglionic nerve terminals and 
not a sensitisation of the post-junctional mACh receptor on the smooth muscle or an 
elevation of neurally released ACh through an inhibition of ACh esterase. 
 
The observation that all three cannabinoid antagonists were more efficacious on the 
guinea-pig MPLM than on the rat MPLM could be ascribed to differences in the 
stimulus-response coupling capacity of the tissues, or the lower quanta of ACh output 
from the rat MPLM.  
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The data also demonstrated that the log concentration-response curves for all three 
antagonists had different Emax values with respect to each other, with AM 251 being 
the most efficacious followed by SR 141716 and O-2050. This observation provided 
strong evidence for a constitutive activity of the CB1 receptor and possibly that these 
cannabinoid antagonists were behaving as inverse agonists in these tissues, because if 
the potentiation of contraction produced by each ligand was due to a displacement of 
endocannabinoid agonists from the CB1 receptor, the maxima of all three 
concentration-response curves should have been equal, assuming that the amount of 
such displacement was equal.  
 
Given that the concentrations of all three antagonists used were about 3 logarithmic 
units higher than their respective pKB values at the CB1 receptor, but within the 
selectivity range for the CB1 receptor, it was unlikely that tonically released 
endocannabinoid agonists may have been capable of binding to a receptor that was 
already saturated with the antagonist. 
 
It is noteworthy that O-2050 also potentiated the twitch contractions of both MPLM 
tissues at concentrations previously shown to be devoid of activity on the EFS-evoked 
contractions of the mouse vas deferens (Martin et al., 2002). Although the reason for 
this discrepancy is not clear, this finding could be ascribed to differences in the tissue, 
animal species, neurotransmitter released or the stimulus-response coupling 
mechanisms.  
 
Previous studies have shown that differences in the pharmacological actions of a 
number cannabinoids have been known to occur in different bioassays. For example, 
AM 630, an analogue of WIN 55,212-2, has been shown to behave as a competitive 
antagonist in the mouse vas deferens (Pertwee et al., 1995), an agonist in the guinea-
pig MPLM (Pertwee et al., 1996), but possess no cannabinoid activity in the mouse 
urinary bladder (Pertwee & Fernando, 1996). Moreover, in Chinese hamster ovarian 
cells transfected with the human CB1 receptor, the same compound has been shown to 
behave as an inverse agonist (Landsman et al., 1998). 
 
The observation that the twitch contractions of the rat vas deferens were not altered by 
SR 141716, AM 251 or O-2050 at concentrations which would be expected to 
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completely occupy the CB1 receptor, suggested that this the tissue either did not 
contain the CB1 receptor, or that the receptor was not constitutively activite or was not 
subjected to tonic activation by endogenously released cannabinoid agonists. 
However, the presence of the CB1 receptor was shown by the demonstration that the 
inhibitory effect of WIN 55,212-2 was antagonised by SR 141716 with a pA2 value in 
line with its pKB value at the CB1 receptor.  
 
It is known that the EFS of the rat vas deferens elicits a twitch contraction to single 
pulses and a biphasic contraction to trains of pulses. The twitch contraction and the 
first contraction of the biphasic response have been attributed to the release of ATP 
whilst the second contraction of the biphasic response is because of the release of 
NAdr (Ventura, 1998). In the present study, EFS-evoked twitch contractions of the rat 
vas deferens were attenuated by PPADS and TTX but not prazosin. This result 
suggested that the contractions of the vas deferens were caused an action of neurally 
released ATP on the P2X purinoceptors. The failure of SR 141716, AM 251 and O-
2050 to augment the EFS-evoked contractions of the rat vas deferens suggests that 
CB1 receptor in this tissue was neither subjected to a tonic activation by 
endocannabinoid agonists or constitutively active. In comparison with the data from 
MPLM tissues, these data suggest that the expression of inverse agonist activity or the 
presence of an endocannabinoid tone was dependent on the tissue used and / or 
neurotransmitter released.  
 
Data from studies on cell-based assays have indicated that the termination of 
endocannabinoid signalling is regulated by a two-step process, involving a 
translocation of released endocannabinoids from the extracellular space into cells via 
a putative uptake transporter, followed by enzymatic hydrolysis, predominantly by 
FAAH to form arachidonic acid and ethanolamine from AEA, or glycerol from 2-AG 
(Deutsch & Chin, 1993; Cravatt et al., 1996).  
 
Given that high levels of a large number of endocannabinoids including AEA and 2-
AG have been detected in both the rat and guinea-pig ileum (see references in the 
Introduction) and that their protection from inactivation by cellular uptake or 
enzymatic degradation by FAAH inhibits intestinal motility in vivo in mice (Capasso 
et al., 2005; Pinto et al., 2002), an attempt was made to unmask the presence of a 
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possible functional inhibitory endocannabinoid agonist tone in the MPLM by 
evaluating the effects of VDM-11, AA-5HT, PMSF and URB-597.  
 
It was shown that cumulative additions of VDM-11 up to 10-5 M, a concentration 
which was almost equal to its EC50 determined in the rat RBL-2H3 basophilic 
leukaemia and C6 glioma cells (De Petrocellis et al., 2000) did not attenuate the EFS-
evoked contractions. Similarly, application of all three FAAH inhibitors by 
themselves up to concentrations which have been previously shown to completely 
inactivate FAAH and lack affinity for the CB1 receptor in vitro (Bisogno et al., 1998; 
Deutsch et al., 1997; Kathuria et al., 2003) also failed to attenuate the EFS-evoked 
contractions of either MPLM strips. 
 
Whilst these results confirmed that VDM-11, AA-5HT, PMSF and URB-597 did not 
possess cannabinoid activity, they suggested that pharmacologically active 
endocannabinoids or substrates of the putative uptake transporter and FAAH were not 
released from the MPLM in response to EFS. These data supported the notion that the 
CB1 receptor was likely to be constitutively active and that the three CB1 antagonists 
behaved as inverse agonists.  
 
To investigate whether the failure of VDM-11 and the three FAAH inhibitors to 
inhibit the EFS-evoked contractions may have been attributable to an absence of a 
functional endocannabinoid uptake transporter or FAAH in these tissues, or that the 
tissues were not incubated with the inhibitors for a sufficient period of time, the 
inhibitory effect of exogenously applied AEA in the absence and presence of these 
inhibitors was compared. The data from these experiments showed that the presence 
of any one of the three FAAH inhibitors, but not VDM-11, resulted in a significant 
increase in the potency of exogenously applied AEA to inhibit the EFS-evoked 
contractions of the MPLM from both species. These findings suggested that unlike the 
putative endocannabinoid uptake transporter, FAAH was likely to be both present and 
functional in the MPLM. Furthermore, because the concentration ratio for the 
potentiation of the inhibitory effect of AEA was reasonably similar in both the rat and 
guinea-pig ileum MPLM, it was likely that both tissues contained the same isoform of 
FAAH.  
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The lack of an effect of all three FAAH inhibitors on the potency of WIN 55,212-2 as 
an inhibitor of the EFS-evoked contractions of both tissues not only confirmed that 
this agonist was not a substrate of FAAH, but it added weight to the evidence that 
FAAH was present in the MPLM of both animal species and that the potentiation of 
the inhibitory effect of AEA by all three FAAH inhibitors was specific. Moreover, 
this observation also indicated that the FAAH inhibitors did not simply augment the 
sensitivity of the CB1 receptor to AEA.  
 
It has been recognised that unlike classical neurotransmitters such as ACh, 
endocannabinoid agonists including AEA and 2-AG are not stored in synaptic 
vesicles in nerves following synthesis, instead they are synthesised and released on 
demand in response to nerve stimuli (Di Marzo et al., 2004). Considering that the 
MPLM tissues in the present study were being stimulated, and therefore, that the 
release of these endocannabinoids was probably being induced, the levels of these 
endocannabinoids would be anticipated to be high. However, given that an inhibitory 
effect of the FAAH inhibitors alone was not observed, it appears that a functional 
endocannabinoid tone was absent in the MPLM, as suggested by the data with the 
three CB1 receptor antagonists. Alternatively, it could be possible that the levels of the 
endocannabinoid agonists were not sufficient to maintain a tonic activation of the CB1 
receptor. 
 
Previous investigators have shown that in vivo administration of PMSF (McVey et al., 
2003) or AA-5HT (Capasso et al., 2005) produced a concentration related inhibition 
of small intestinal transit in rats and mice respectively. This effect was ascribed to a 
potentiation of the inhibitory action of tonically released endocannabinoid agonists at 
the CB1 receptor, because high levels of AEA and 2-AG were detected in 
homogenates of biopsies of the small intestine. Although the effects of FAAH 
inhibitors have not been evaluated on intestinal transit of the guinea-pig in vivo, 
similar levels of AEA and 2-AG have been measured in the MPLM of the ileum of 
this species (Guagnini et al., 2006). However, as suggested above, it is unlikely that 
these levels would be sufficient to maintain a tonic activation of the CB1 receptor, and 
explain the potentiation of the EFS-evoked contractions by the CB1 antagonists. 
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Whilst the effect of URB-597 has not been investigated on small intestinal transit of 
rodents in vivo, this FAAH inhibitor has been shown to selectively elevate the levels 
of AEA in the brain without affecting the levels of this endocannabinoid in the rat 
duodenum at concentrations that abolished the activity of FAAH (Fegley et al., 2005). 
This finding indicates that the hydrolysis of AEA in the rat may occur via at least two 
enzymes, and that in this species other endocannabinoids may modulate small 
intestinal transit. Apart from FAAH, several enzymes including monoacylglycerol 
lipase and N-palmitoylethanolamine hydrolase have been implicated to be involved in 
inactivating endocannabinoids in the small intestine (van der Stelt & Di Marzo, 2004; 
Ueda et al., 2000). However, given that FAAH is capable of hydrolysing a broad 
spectrum of established and putative endocannabinoids including 2-AG and 
palmitolyethanolamide, which are substrates of monoacylglycerol lipase and N-
palmitoylethanolamine hydrolase respectively, it appears unlikely that these ligands 
were released in the rat and guinea-pig MPLM to inhibit the EFS-evoked contractions 
of these tissues. 
 
In the present study, it was unlikely that the removal of the mucosa-submucosal 
plexus during the preparation of the MPLM resulted in the loss of the source of the 
endocannabinoid agonists, hence was responsible for the lack of an inhibitory effect 
of the FAAH inhibitors on the EFS-evoked contractions of the MPLM, because all 
three CB1 receptor antagonists still were capable of augmenting the EFS-evoked 
contractions of the MPLM 
 
While the data obtained suggests that SR 141716 augments intestinal transit via 
inverse agonism and not because of an antagonism of an endocannabinoid agonist 
tone, it may be possible that, by using an isolated preparation, the endocannabinoid 
agonist activity was not detected because the endocannabinoids may behave as 
hormones in vivo, in addition to their role as neurotransmitters in the brain. For 
instance, it has been demonstrated that the AEA can be synthesised by endothelial 
cells of the mesenteric vasculature (Randall et al., 1996). Considering that these 
vessels are known to supply blood to the small intestine, it could be possible that in 
vivo endocannabinoid agonists are synthesised in the mesenteric vasculature but 
produce an inhibitory effect on the enteric transmission via a endocrine hormonal 
effect. However, while these speculations may be valid in vivo, they do not appear to 
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apply to the MPLM in vitro. Assuming that SR 141716 was an inverse agonist, 
because the CB1 receptor was constitutively active in the MPLM, its ability to 
augment the EFS-evoked contractions may be explained using the theoretical “two 
state” receptor model (Leff, 1995). According to this model, the CB1 receptor would 
exist in at least two interchangeable states, an active state, in which the receptor was 
coupled to the effector pathways to suppress the release of ACh, and an inactive sate, 
in which the receptor was not coupled to the effector pathways and thereby would 
increase the release of ACh. In the absence of any ligands, both conformations would 
exist at equilibrium; therefore, the CB1 receptor would be inhibiting the release of 
ACh. However, as an inverse agonist, SR 141716 having preferential affinity for the 
inactive state would bind to the inactive state of the CBB1 receptor and shift the 
equilibrium to reduce the number of receptors in the active conformation, thereby 
reversing the suppression of the release of ACh.  
 
In conclusion, this study showed that under the experimental conditions employed, 
the ability of SR 141716 to potentiate the EFS-evoked contraction of both the rat and 
guinea-pig ileum was attributed to an inverse agonist action at the CB1 receptor and 
not because of an antagonism of tonically released endocannabinoid agonists.  
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CHAPTER 5: 
ISOLATED NERVE-EPITHELIAL 
PREPARATION 
 
Investigation into the Role of the  
Cannabinoid CBB1 Receptor In Modulating 
Pharmacologically Evoked Secretory Function of the Rat 
Colonic Submucosal Plexus-Epithelial Preparation. 
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5.1. Introduction 
 
A number of studies (Izzo et al., 1999a, 1999b, 2000, 2003; Shook & Burks, 1989) 
have reported that in vivo administration of cannabinoid receptor agonists into rats 
and mice causes a dose-dependent suppression of basal and evoked small intestinal 
motility and secretion over the same range of doses (Izzo et al., 1999a, 1999b, 2000, 
2003). Because cannabinoids are known to potently inhibit the peristaltic reflex 
(Heinemann et al., 2000; Mancinelli et al., 2001; Izzo et al., 2000) and the EFS-
evoked contractions of both the longitudinal (Croci et al., 1999; Guagnini et al., 2006; 
Manara et al., 1998; Pertwee et al., 1996;) and circular (Hinds et al., 2006; Manara et 
al.,  1998) smooth muscle layer of segments of the both the small and large intestine 
of a number of mammals in vitro, it is possible that the anti-diarrhoeal action of 
cannabinoids observed in vivo is through the inhibition of intestinal propulsion, which 
results in a slower elimination of intestinal contents, and indirectly, to more efficient 
absorption of water and electrolytes due to the longer contact time with the mucosa. 
Alternatively, the possibility also exists that the cannabinoids themselves stimulate 
absorption of the luminal water and electrolytes.  
 
To date, only two studies have investigated the effect of cannabinoids on intestinal 
secretion in vitro (MacNaughton et al., 2004; Tyler et al., 2000). These studies, 
performed on submucosal plexus-mucosal (SPM) preparations of the guinea-pig and 
rat ileum have shown that WIN 55,212-2 attenuated the EFS- and capsaicin- evoked 
secretory responses of these tissues through a CB1 receptor-mediated reduction in the 
neuronal release of ACh and VIP respectively (MacNaughton et al., 2004; Tyler et 
al., 2000). Although these bioassays have provided good evidence for a specific anti-
diarrhoeal action of cannabinoids, it is surprising that the effect of cannabinoids has 
not been investigated on secretory responses of the colonic tissues, considering that 
the colon is the region of the gut which plays an important role maintaining the 
homeostatic balance of water and electrolytes in the body (Rao, 2004).  
 
Therefore, the aim of this study was to explore the viability of the rat colonic SPM 
preparation as an in vitro cannabinoid bioassay for colonic ion transport. A previous 
in vivo study (Izzo et al., 1999a) has shown that while WIN 55,212-2 and CP 55,940 
both equipotently decreased upper gastrointestinal transit, the later unlike the former, 
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did not modify castor-oil-induced diarrhoea. Therefore, this study examined the 
effects of both CP 55,940 and WIN 55,212-2 on the secretory responses of the rat 
isolated colonic epithelial sheet evoked by pharmacological stimulation of the nerves 
with capsaicin, nicotine and veratridine. This method of neural stimulation was 
chosen because the Ussing set-up employed was not customised for EFS studies. 
 
5.2. Methods 
 
SPM sheets were prepared from the colon dissected from rats (Section 2.1) by the 
method described in Section 2.3.1 and mounted in Ussing chambers as described in 
Section 2.3.2.  
 
The experiments on the SPM preparation were carried out as described in Section 
2.3.3. 
 
The compounds used in this study were: α-chymotrypsin, atropine, capsaicin, CP 
55,940, nicotine, SR 141716, SR 144528, SR 140333, TTX, WIN 55,212-2, 
veratridine, VIP 6-28. See Table 2.1 for the solvents and suppliers of the compounds 
used. 
 
The data obtained from the experiments were quantified by the methods described in 
Section 2.3.4. 
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5.3. Results 
 
5.3.1. The basal ISC and Rt of the rat colonic SPM preparation 
The SPM sheets exhibited a basal ISC of 21.7 ± 2.4 μA.cm-2 (n = 45) and a Rt of 96.2 
± 15.4 Ω (n = 45) when voltage clamped at 0 mV. These parameters were not altered 
by the presence of atropine (10-6 M, 15 minutes, n = 6), α-chymotrypsin (4 units ml-1, 
30 minutes, n = 4), SR 140333 (10-6 M, 15 minutes, n = 6), TTX (10-6 M, 10 minutes, 
n = 6), VIP 6-28 (10-6 M, 15 minutes, n = 5) or the solvents of these drugs.  
CP 55,940 (10-6 M, 30 minutes, n = 6), WIN 55,212-2 (10-6 M, 30 min, n = 6), SR 
141716 (10-6 M, 30 min, n = 6) were also without effect. Figures 5.0 and 5.1 show the 
lack of effect of these drugs on the basal ISC and Rt respectively. 
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Figure 5.0: Bar graphs showing the lack of effect of a range of drugs on the basal ISC 
of the rat colonic SPM preparation voltage clamped at 0 mV in Ussing chambers.  
Each bar represents the mean ± s.e.m. value of the basal ISC in the absence (n = 45, 
closed column) and presence (open columns) of TTX (10-6 M, n = 6), atropine (10-6 
M, n = 6), SR 140333 (10-6 M, n = 6), VIP 6-28 (10-6 M, n = 5), α-Chymotrypsin (4 
units ml-1, n = 4), CP 55,940 (10-6 M, n = 6), WIN 55,212-2 (10-6 M, n = 6) or SR 
141716 (10-6 M, n = 6). 
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Figure 5.1: Bar graphs showing the lack of effect of a range of drugs on the basal Rt of 
the rat SPM preparation calculated using Ohm’s law from the change in basal ISC in 
response to an intermittent change in voltage clamped from 0 mV to 2 mV. Each bar 
represents the mean ± s.e.m. value of the basal Rt in the absence (n = 45, closed 
column) and presence (open columns) of TTX (10-6 M, n = 6), atropine (10-6 M, n = 
6), SR 140333 (10-6 M, n = 6), VIP 6-28 (10-6 M, n = 5), α-Chymotrypsin (4 units ml-
1
, n = 4), CP 55,940 (10-6 M, n = 6), WIN 55,212-2 (10-6 M, n = 6) or SR 141716 (10-6 
M, n = 6). 
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5.3.2. Effect of CP 55,940 and WIN 55,212-2 on the capsaicin-evoked change in 
ISC and Rt of the rat colonic SPM preparation in the absence and presence 
of SR 141716.  
 
Capsaicin (10-6 M) evoked a significant (P < 0.05, unpaired t-test) transient increase 
in ISC of 19.6 ± 2.7 μA.cm-2 (n = 15, Figures 5.2 and 5.3). The evoked ISC peaked 
within a minute of application of capsaicin and returned to the original basal value 
within 3 minutes. As shown in Figure 5.2, the presence of capsaicin had no effect on 
the Rt of the preparation.  
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Figure 5.2: Trace illustrating the capsaicin- (10-6 M) evoked increase in the ISC of the 
rat SPM preparation observed as a transient upward deflection from a basal ISC of 20 
μA.cm-2. The small spikes represent the change in ISC in response to the automatic 
change in the holding potential from 0 mV to 2 mV by the voltage clamp apparatus, 
intermittently for 2 seconds every 30 seconds. The Rt was calculated using Ohm’s 
Law i.e. Rt = 2 mV  / Δ Isc. 
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As shown in Figure 5.3, the capsaicin-evoked ISC was abolished (P < 0.05, unpaired t-
test) by the presence of TTX (10-6 M, 10 minutes, n = 3) or SR 140333 (10-6 M, 15 
minutes, n = 6) but not atropine (10-6 M, 15 minutes, n = 6).  
 
C
ap
sa
ic
in
+ 
TT
X
+ 
A
tr
op
in
e
+ 
SR
 1
40
33
3
0
5
10
15
20
25
* *
µA
.cm
-2
 
 
 
Figure 5.3: Bar graph representing the amplitude of the capsaicin- (10-6 M) evoked ISC 
by the rat SPM preparation in the absence (closed column, n = 15) and presence (open 
column) of TTX (10-6 M, n = 3), SR 140333 (10-6 M, n = 6) or atropine (10-6 M, n = 
6). * indicates a statistical difference (P < 0.05, unpaired t-test) compared to the 
capsaicin column. 
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Pre-treatment for 30 minutes with either CP 55,940 (10-6 M, n = 12, Figure 5.4) or 
WIN 55,212-2 (10-6 M, n = 6, Figure 5.5) caused a significant (P < 0.05, unpaired t-
test) 72.18 % and 71.17 % inhibition of the capsaicin evoked ISC respectively.  
 
The inhibitory effects of both CP 55,940 and WIN 55,212-2 were completely (P < 
0.05, unpaired t-test) antagonised by a 30 minute pre-exposure to SR 141716 (10-6 M, 
n = 6 against each agonist). At this concentration, SR 141716 alone (n = 6 for both 
Figure 5.4 and 5.5, 6 minutes) had no effect on the capsaicin response.  
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Figure 5.4: Bar graph representing the amplitude of the capsaicin- (10-6 M) evoked ISC 
by the rat SPM preparation in the presence of ethanol (closed column, n = 26), CP 
55,940 (10-6 M, n = 12) or SR 141716 (10-6 M, n = 6), or both CP 55,940 (10-6 M) and 
SR 141716 (10-6 M, n = 6). * indicates a significant difference (P < 0.05) compared to 
the capsaicin control response. # indicates a significant (P < 0.05, unpaired t-test)  
difference  compared to the capsaicin response in the presence of CP 55,940.  
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Figure 5.5: Bar graph representing the amplitude of the capsaicin- (10-6 M) evoked ISC 
by the rat SPM preparation in the presence of ethanol (closed column, n = 20), WIN 
55,212-2 (10-6 M, n = 6) or SR 141716 (10-6 M, n = 6), or both WIN 55,212-2 (10-6 
M) and SR 141716 (10-6 M, n = 8). * indicates a significant difference (P < 0.05, 
unpaired t-test) compared to the capsaicin control response. # indicates a significant 
difference (P < 0.05, unpaired t-test) compared to the capsaicin response in the 
presence of WIN 55,212-2. 
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5.3.3. Effect of CP 55,940 and WIN 55,212-2 on the nicotine-evoked ISC and Rt of 
the rat colonic SPM preparation in the absence and presence of SR 
141716.  
 
Application of nicotine (10-4 M) to the SPM preparation resulted in a significant (P < 
0.05, unpaired t-test) transient increase in ISC of 56.6 ± 6.4 μA.cm-2 (n = 13, Figure 
5.6 and 5.7). The evoked ISC peaked within a minute of application of nicotine and 
returned to the original basal value within 5 minutes. Figure 5.5 also shows that 
nicotine had no effect on the basal Rt of the tissues.  
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Figure 5.6: Trace illustrating the nicotine (10-4 M) evoked increase in the ISC of the rat 
SPM preparation observed as a transient upward deflection from a basal ISC of 18.8 
μA.cm-2.  
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As shown in Figure 5.7, the nicotine evoked ISC was abolished (P < 0.05, unpaired t-
test) by the presence of TTX (10-6 M, 10 minutes, n = 3) or SR 140333 (10-6 M, 15 
minutes, n = 6) but not atropine (10-6 M, 15 minutes, n = 6).  
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Figure 5.7: Bar graph representing the amplitude of the nicotine- (10-4 M) evoked 
change in ISC by the rat SPM preparation in the absence (closed column, n = 15) and 
presence (open column) of TTX (10-6 M, n = 3), SR 140333 (10-6 M, n = 6) or 
atropine (10-6 M, n = 6). * indicates a statistical difference (P < 0.05, unpaired t-test) 
compared to the nicotine column. 
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Pre-treatment for 30 minutes with either CP 55,940 (10-6 M, n = 12, Figure 5.8) or 
WIN 55,212-2 (10-6 M, n = 6, Figure 5.9) caused a significant (P < 0.05, unpaired t-
test) 72.2 % and 71.2 % inhibition of the capsaicin evoked  ISC respectively.  
 
The inhibitory effect of both CP 55,940 and WIN 55,212-2 was completely (P < 0.05, 
unpaired t-test) antagonised by a 30 minute pre-exposure to SR 141716 (10-6 M, n = 6 
against each agonist). At this concentration, SR 141716 alone (n = 6 for both Figure 
5.8 and 5.9, 6 minutes) had no effect on the nicotine response.  
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Figure 5.8: Bar graph representing the amplitude of the nicotine- (10-4 M) evoked ISC 
by the rat SPM preparation in the presence of ethanol (closed column, n = 21), CP 
55,940 (10-6 M, n = 7) or SR 141716 (10-6 M, n = 7), or both CP 55,940 (10-6 M) and 
SR 141716 (10-6 M, n = 7). * indicates a significant difference (P < 0.05, unpaired t-
test) compared to the nicotine control response. # indicates a significant difference (P 
< 0.05, unpaired t-test) compared to the nicotine response in the presence of CP 
55,940. 
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Figure 5.9: Bar graph representing the amplitude of the nicotine- (10-4 M) evoked 
change in ISC by the rat SPM preparation in the presence of ethanol (closed column, n 
= 19), WIN 55,212-2 (10-6 M, n = 6) or SR 141716 (10-6 M, n = 6), or both WIN 
55,212-2 (10-6 M) and SR 141716 (10-6 M, n = 7). * indicates a significant difference 
(P < 0.05, unpaired t-test) compared to the nicotine control response. # indicates a 
significant difference (P < 0.05, unpaired t-test) compared to the nicotine response in 
the presence of WIN 55,212-2. 
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5.3.4. Effect of CP 55,940 and WIN 55,212-2 on the veratridine-evoked change 
in ISC and Rt of the rat colonic SPM preparation in the absence and 
presence of SR 141716.  
 
Veratridine (3 x 10-5 M) evoked a sustained increase in ISC of 52.83 ± 6.54 μA.cm-2 (n 
= 26) above the basal ISC, without altering the Rt (Figure 5.10 and 5.11). The evoked 
ISC peaked within 3 minutes of application of this stimulant and the response could 
remain sustained for up to 1 hour before gradually returning to the basal value within 
another hour.  
 100 
80 
60 
40 
20 
0 
2 min 
μA
.c
m
-2
Veratridine 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: Trace illustrating the veratridine- (3 x 10-5 M) evoked increase in the ISC 
of the rat SPM preparation.  
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As shown in Figure 5.11, the veratridine-evoked response was abolished by treatment 
with either TTX (10-6 M, 10 minutes, n = 3) or α-chymotrypsin (4 units ml-1, 20 
minutes, n = 6) but not atropine (10-6 M, 15 minutes, n = 6), SR 140333 (10-6 M, 15 
minutes, n = 6) or VIP 6-28 (10-6 M, 15 minutes,  n = 5).  
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Figure 5.11: Bar graph representing the amplitude of the veratridine- (3 x 10-5 M) 
evoked increase in ISC by the rat SPM preparation in the absence (closed column, n = 
26) and presence (open column) of TTX (10-6 M, n = 3), atropine (10-6 M, n = 6), SR 
140333 (10-6 M, n = 6), VIP 6-28 (10-6 M, n = 5) or α-chymotrypsin (4 units ml-1, n = 
6). * indicates a statistical difference (P < 0.05, unpaired t-test) compared to the 
veratridine column. 
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Pre-treatment of the tissues for 30 minutes with either CP 55,940 (10-6 M, n = 8) or 
WIN 55,212-2 (10-6 M, n = 6) had no significant (P > 0.05, unpaired t-test) effect on 
the veratridine- (3 x 10-5 M, n = 12) evoked response (Figure 5.12). 
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Figure 5.12: Bar graph representing the amplitude of the veratridine (3 x 10-5 M) 
evoked increase in ISC by the rat SPM preparation in the presence of ethanol (closed 
column, n = 12), CP 55,940 (10-6 M, n = 8) or WIN 55,212-2 (10-6 M, n = 6). 
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5.4. Discussion 
 
In the present study, it was demonstrated that basolateral application of capsaicin or 
nicotine evoked a transient secretory response in the rat colonic SPM preparation as 
measured as an increase in the ISC. Because the secretory responses to both stimulants 
were abolished by TTX or SR 140333 but not atropine, it was likely that both 
capsaicin and nicotine stimulated the same population of secretomotor neurones of the 
submucosal plexus to release substance P or neurokinin A, but not ACh. Indeed, 
activation of the TRPV1 or nACh receptor by capsaicin or nicotine, respectively, has 
been shown to elicit similar transient increases in ISC in other intestinal tissues such as 
rat distal colon (Cox et al., 1993; Yarrow et al., 1988) guinea-pig ileum 
(MacNaughton et al., 2003) and mouse jejunum (Sheldon et al., 1989).  
 
The finding that the veratridine-evoked sustained secretory response was only blocked 
by TTX and α-chymotrypsin, but not atropine, SR 140333 or VIP 6-28 indicated that 
this stimulant activated the submucosal plexus to induce the release of a neuropeptide 
that was distinct from substance P and VIP.  To date, the secretory neurotransmitter 
released by veratridine in intestinal tissues has proven difficult to identify primarily 
because this stimulant is known to cause a sustained stimulation of neurones through 
persistent activation of the voltage gate Na+ channels which are involved in the 
generation and propagation of action potentials.  
 
It was shown that the presence of either CP 55,940 or WIN 55,212-2 at concentrations 
which act selectively through the CB1 receptor in intestinal tissues caused a 
significant attenuation of the ISC evoked by capsaicin and nicotine. These results 
support and extend earlier findings for the inhibitory effect of WIN 55,212-2 on the 
EFS-evoked secretory response of the rat ileum (Tyler et al., 2000) and the capsaicin-
stimulated secretory response of the guinea-pig ileum (MacNaughton et al., 2003). 
The presence of SR 141716, at a concentration which would be predicted to occupy 
all of the CB1 receptor population, blocked the inhibitory effects of both CP 55,940 
and WIN 55,212-2 on the capsaicin- or nicotine- evoked secretory responses. This 
result suggested that both cannabinoid receptor agonists inhibited the secretory 
response to capsaicin and nicotine through a CBB1 receptor-mediated inhibition of the 
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release of substance P and/or neurokinin A. Indeed previous studies have shown that 
the CB1 receptor and TRPV1 receptor are colocalised in the submucosal plexus of at 
least the guinea-pig ileum (MacNaughton et al., 2003). Furthermore, similar 
presynaptic CB1 receptor activation has been shown to inhibit the release of substance 
P from the airways (Nemeth et al., 2003; de Vries et al., 2001), dorsal root ganglion 
neurons (Tognetto et al., 2001) and spinal cord (Lever & Malcangio, 2002).  
 
Although CP 55,940 and WIN 55,212-2 have been shown to demonstrate affinity for 
the CB2 receptor, it was unlikely that this receptor was involved in modulating the 
secretory responses to capsaicin and nicotine in the rat SPM sheet because, SR 
141716 completely antagonised the inhibitory effect of the cannabinoid agonists, and 
data from in vivo studies have shown that the administration of the CB2 receptor 
antagonist SR 144528 does not attenuate the inhibitory effect of these agonists (Izzo 
et al., 1999a, 1999b, 2000, 2003).  
 
It is well known that the CB1 receptor is coupled through Gi/o proteins, positively to 
A-type and inwardly rectifying K+ channels and negatively to Na+ and N- and P/Q-
type Ca2+ channels (Caufield and Brown, 1992; Mackie et al., 1993; Howlett et al., 
2002). Thus, in the present study, the inhibition of the capsaicin- and nicotine- evoked 
secretory responses of the colonic SPM preparations via of a reduction in the release 
of substance P and/or neurokinin A could be attributed to the suppression of the 
excitability of the neurones of the submucosal plexus via the modulation of these ion 
channels upon activation of the CB1 receptor.  
 
The lack of effect of CP 55,940 and WIN 55,212-2 on the veratridine- evoked 
secretory response suggested that the CB1 receptor was absent on the neurones 
activated by veratridine. These data suggest that the cannabinoid agonist were not 
inhibiting the Na+ channel directly. It was demonstrated that the SPM preparation 
displayed a resting basal ISC in the absence of exogenously applied drugs. It is well 
known that the basal ISC is due to the leakage of ions from the tight junctions between 
the epithelial cells (Baird, 1994). Thus, the finding that the treatment with TTX, 
atropine, SR 140333, VIP-628, CP 55,940, WIN 55,212-2 or SR 141716 failed to 
alter the basal ISC of the SPM preparation suggested that these compounds were not 
directly acting post-synaptically on the epithelial cells. The observation that both CP 
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55,940 and WIN 55,212-2 failed to attenuate the secretory response to veratridine 
supported the lack of a non-specific effects of these cannabinoids. Furthermore, the 
lack of effect of these cannabinoids on the Rt added weight to the notion that the 
effects of the cannabinoids were not non-specific. 
 
In addition to its antagonist activity, SR 141716 alone has been shown to increase 
intestinal fluid secretion when administered into rodents (Izzo, et al., 1999a, 199b, 
2000, 2003). Furthermore, diarrhoea is among the adverse effects associated with the 
intake of SR 141716 for the management of body weight by obese patients (Van Gaal 
et al., 2005). Two common explanations that have been offered to explain such 
antagonist-mediated changes in basal or evoked responses have been a possible: 
inverse agonist activity of SR 141716, or a confounding presence of an 
endocannabinoid tone. In the present study it was demonstrated that SR 141716 alone 
failed to alter the basal ISC and the ISC evoked by capsaicin and nicotine. Thus, it was 
likely that in the rat colonic SPM preparation either endocannabinoid agonists were 
not released tonically or that SR 141716 appeared to behave as a neutral antagonist 
because the CB1 receptor was not constitutively active. Although this finding was in 
agreement with studies on SPM sheets of the rat (Tyler et al., 2000) and guinea-pig 
(MacNaughton et al., 2003) ileum, endocannabinoid agonists such as AEA and 2-AG 
have been detected in the rat colonic submucosa. Moreover, the levels measured have 
been suggested to be sufficient to cause the activation of the CB1 receptor (D’Argenio 
et al., 2006). The failure of SR 141716 to augment the secretory response to capsaicin 
and nicotine suggest that the endocannabinoid agonists levels were either insufficient 
to activate the CB1 receptor because of their lower rate of synthesis or rapid 
hydrolysis.  
 
In conclusion, the results from the present study extend the role of the CB1 receptor in 
selectively modulating neurally-evoked secretory responses of the rat colon. 
Additionally, the results indicate that the anti-diarrhoeal action of cannabinoids 
observed in vivo may not be attributed exclusively to the blockade of intestinal 
propulsion, which may result in slower elimination of the intestinal contents and, 
indirectly, to a more efficient absorption of water and electrolytes due to the longer 
contact time with the mucosa. 
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6.1. General discussion 
 
The experimental work described in this thesis was directed at addressing two primary 
aims. Firstly, to explore the viability of the electrically-evoked contractions of the rat 
isolated ileum MPLM preparation and of the pharmacologically evoked secretory 
responses of the isolated colonic SPM preparation as novel in vitro intestinal nerve 
smooth muscle and epithelial cannabinoid bioassays respectively. Secondly, to 
characterise the cannabinoid receptors mediating the effects produced in these 
preparations. 
 
Data obtained in Chapter 3 provided evidence for the suitability of the rat isolated 
ileum MPLM preparation as a cannabinoid bioassay. In this tissue, representatives of 
the four established classes of cannabinoid receptor agonists caused a concentration-
dependent inhibition of both the EFS-evoked twitch and rebound contractions in a 
pre-synaptic and stereo-specific manner. The inhibition of both types of contractions 
was attributed to an inhibition of the excitation of the smooth muscle indirectly by a 
reduction in the release of ACh from post-ganglionic neurones of the myenteric 
plexus.  
 
That the cannabinoid agonists inhibited the twitch and rebound contractions in the 
nanomolar and micromolar concentration ranges, respectively, and that the rank of 
order of the pEC50 values of the agonists did not correlate between the two EFS 
conditions suggested that the inhibition of both types of the contractions was not 
mediated through a common receptor. This interpretation was supported by the 
demonstration that SR 141716 antagonised the inhibition of the twitch contractions 
caused by each agonist with pKB values consistent with its antagonist activity at the 
CB1 receptor, whereas it only blocked the inhibition of the rebound contractions 
produced by AEA, Δ9-THC and WIN 55,212-2, but not CP 55,940, with pA2 values 
lower than its reported antagonistic activity at both the CB1 and CB2 receptors. Using 
similar EFS conditions, and WIN 55,212-2 as the cannabinoid receptor agonist, these 
findings were shown to extend to the guinea-pig ileum MPLM preparation. In this 
tissue, the pEC50 values of WIN 55,212-2 and the pA2 values of SR 141716 were in 
line with those obtained in the rat ileum MPLM under comparable EFS conditions. 
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Because the inhibition of both types of contractions of the rat ileum MPLM by each 
agonist was not antagonised by SR 144528 and neither was the inhibitory effect of 
AEA blocked by capsazepine, strong evidence was obtained for the lack of a 
functional role of the CB2 and TRPV1 receptors in modulating the EFS-evoked 
contractions of this tissue. Taken together, these data suggested that the inhibition of 
the twitch contractions of both the rat and guinea-pig ileum MPLM were mediated by 
activation of the pre-synaptically located CB1 receptor whereas the inhibition of the 
rebound contractions, of at least the former tissue, was mediated through the 
activation of two pre-synaptically located putative non-CB1-non-CB2-non-TRPV1 
receptors.  
 
Data obtained in Chapter 3 also showed that in addition to its antagonist activity SR 
141716 alone caused an augmentation of the twitch contractions of both the rat and 
guinea-pig ileum MPLM, but an attenuation of the rebound contractions of only the 
former tissue. The ability of SR 141716 to enhance the amplitude of the twitch 
contractions was suggestive of an increase in the release of ACh by either an 
antagonism of the inhibitory effect of tonically released endocannabinoid agonists or 
inverse agonism at the CB1 receptor. The inhibition of the rebound contractions and 
antagonist activity SR 141716 was attributed to an uncharacterised partial agonist 
activity at the putative SR 141716 sensitive non-CB1-non-CB2-non-TRPV1 receptor.  
 
The presence of a functional CB1 receptor in the rat ileum MPLM was consistent with 
previous immunohistochemical and in vivo data showing the presence of the CB1 
receptor protein in this tissue and its functional role in delaying small intestinal transit 
in the rat in vivo respectively. In contrast, from the data available, neither of the 
putative non-CB1-non-CB2-non-TRPV1 receptors appeared to fit the pharmacological 
profile of the novel pharmacological targets for cannabinoids summarised in Chapter 
1 (Section 1.5). For instance, as mentioned above, the refractoriness of the AEA 
induced inhibition of the rebound contractions to antagonism by capsazepine 
demonstrated the lack of involvement of the TRPV1 receptor. The inability of AEA to 
stimulate the TRPV1 receptor could be ascribed to the poor affinity and lack of 
efficacy of AEA at this receptor in the MPLM.  
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The inhibition of the rebound contractions caused by each of the four cannabinoids 
was unlikely to be mediated by the activation of the putative CB2-like receptor for two 
reasons. Firstly, because this putative receptor has been characterised to be only 
stimulated by palmitoylelthanolamide, an eicosanoid structurally related to AEA, and 
not by any of the four cannabinoids used in the present study (Pertwee, 2004; 2005). 
Secondly, although the putative CB2-like receptor has been suggested to be weakly 
antagonised by SR 144528 (Calignano et al., 2001; Berdyshev et al., 1998; Pertwee, 
2005), the inability of this antagonist to block the inhibitory effect each of the four 
cannabinoid agonists on the MPLM suggested the absence of this receptor in this 
tissue. An investigation into the effect of palmitoylelthanolamide on EFS-evoked 
contractions of the MPLM could be examined to determine whether the putative CB2-
like receptor is present in the MPLM and if it can modulate EFS-evoked contractions 
of this tissue.  
 
The putative SR 141716-sensitive, non-CB1-non-CB2 receptor which has been 
reported to mediate the vasodilator actions of AEA, methanandamide, cannabidiol and 
its analogues is known not to be activated by CP 55,940, WIN 55,212-2 and Δ9-THC. 
Therefore, it is unlikely that the putative cannabinoid receptors identified in the 
MPLM are identical to the putative cannabinoid receptor found in vascular tissues. O-
1918, a cannabidiol analogue, has been reported to behave as a selective antagonist of 
the putative vascular cannabinoid receptor (Begg et al., 2005). An investigation into 
the inhibitory effects of the four cannabinoid receptor agonists in the presence O-1918 
could be examined to determine whether the putative cannabinoid receptors in the 
MPLM are similar to or different from the putative cannabinoid receptor in the 
vasculature. 
 
The putative cannabinoid receptors in the MPLM do not appear to be similar to the 
putative AEA and WIN 55,212-2 receptor described in the brain by both Di Marzo et 
al. (2000) and Breivogel et al. (2001). This is because the putative cannabinoid 
receptors in the MPLM were activated not only by AEA and WIN 55,212-2 but also 
by Δ9-THC and CP 55,940.  
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Taken together, the identification of the two putative non-CB1-non-CB2-non-TRPV1 
receptors in the MPLM adds to the list of novel pharmacological targets for 
cannabinoids. Whether the putative non-CB1-non-CB2-non-TRPV1 receptors 
identified in the MPLM serves a physiological role in modulating intestinal motility in 
vivo remains to be established. 
 
Experiments described in Chapter 4 were an attempt to elucidate whether the 
mechanism by which SR 141716 augmented the twitch contractions of the rat and 
guinea-pig ileum MPLM was caused by an antagonism of an endocannabinoid agonist 
tone or inverse agonism at the CB1 receptor. The evidence collected showed that an 
endocannabinoid tone was absent in these tissues and that SR 141716 behaved as an 
inverse agonist. The absence of a tonic inhibitory effect of endocannabinoid agonists 
was demonstrated by the lack of an attenuation of the twitch contractions in response 
to administration of inhibitors of FAAH, i.e. AA-5HT, PMSF and URB-597, and 
VDM-11, an inhibitor of the putative endocannabinoid uptake transporter protein. If 
endocannabinoid agonists were tonically released by EFS, the inhibitors of FAAH or 
the putative uptake transporter should have inhibited the twitch contractions by 
limiting the hydrolysis, the putative uptake of tonically released endocannabinoid 
agonists, or both. Because the presence of AA-5HT, PMSF or URB-597 selectively 
enhanced the inhibitory effect of exogenously applied AEA but not WIN 55,212-2 by 
a similar degree in both tissues, it was likely that both tissues contained FAAH. The 
lack of effect of VDM-11 on the potency of exogenously applied AEA suggested that 
the putative uptake transporter was absent in both tissues, that the uptake of AEA by 
the myenteric plexus was most likely by passive diffusion and that SR 141716 was an 
inverse agonist and not a simple competitive antagonist at the CB1 receptor. 
 
Convincing evidence for the inverse agonist activity of SR 141716 was obtained from 
a comparison between the augmentation of the twitch contractions produced by this 
cannabinoid and that produced by two other CB1 receptor antagonists i.e. AM 251 and 
O-2050. These experiments showed that the maximal enhancement produced by SR 
141716 was lower than that produced by AM 251 but greater than that by O-2050. 
These data suggested that SR 141716 enhanced the EFS-evoked twitch contractions 
of both tissues by inverse agonism, because, if the potentiation of contraction 
produced by each ligand was due to a displacement of endocannabinoid agonists from 
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the CB1 receptor, the maxima of SR 141716, AM 251 and O-2050 should have been 
equal. 
 
Experiments performed on the rat isolated vas deferens in Chapter 4 showed that 
neither SR 141716, AM 251 nor O-2050 increased the EFS-evoked ATP-mediated 
twitch contractions of this tissue. Additionally, the pA2 value of SR 141716 obtained 
against WIN 55,212-2 was in agreement with its pKB and pA2 values estimated in the 
twitch contraction experiments of the rat and guinea-pig ileum MPLM. These data 
suggested that SR 141716 behaved as a neutral CB1 antagonist in the rat vas deferens 
and that the constitutive activity of the CB1 receptor was dependent on the tissue 
employed, neurotransmitter released or stimulus response coupling capacity of the 
drug-receptor complex. 
  
Experiments described in Chapter 5 aimed to investigate the role of the CB1 receptor 
in modulating the basal and capsaicin-, nicotine- and veratridine-evoked electrogenic 
secretory function of the rat isolated colonic SPM preparation. These experiments 
showed that the basal ISC and Rt of the SPM preparation were not maintained by 
neuronal cholinergic or peptidergic tone, but most likely by the epithelial cells 
themselves. The lack of effect of CP 55,940, WIN 55,212-2 and SR 141716 on the 
basal ISC and Rt was most likely because of an absence of the cannabinoid receptor on 
the epithelial cells. The presence of either CP 55,940 or WIN 55,212-2 selectively 
attenuated the transient increase in the ISC evoked by capsaicin and nicotine but not 
the sustained increase in the ISC elicited by veratridine. Moreover, the inhibition of the 
capsaicin and nicotine responses by CP 55,940 and WIN 55,212-2 was antagonised by 
the presence of SR 141716. Because the transient increase in the ISC elicited by both 
capsaicin and nicotine was both neurogenic and sensitive to the blockade of the NK1 
receptor, it was likely that both CP 55,940 and WIN 55,212-2 inhibited the neuronal 
release of substance P and neurokinin A by activation of the CB1 receptors. The 
sustained increase in the ISC elicited by veratridine was shown to be mediated by the 
release of a neuropeptide distinct from substance P, neurokinin A and VIP. The lack 
of an effect of CP 55,940 and WIN 55,212-2 on the veratridine response suggested 
that the CB1 receptor was not involved in the release of all neuropeptides. The lack of 
effect of SR 141716 to alter the capsaicin- and nicotine- evoked increase in the ISC 
suggested that the CB1 receptors modulating the release of substance P and neurokinin 
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A from the submucosal plexus was not constitutively active and that this cannabinoid 
behaved as a neutral CB1 receptor antagonist. These data added weight to the notion 
that the constitutive activity of the CB1 receptor was dependent on the tissue 
employed, neurotransmitter released or stimulus response coupling capacity of the 
drug-receptor complex.  
 
In conclusion, this project has shown that the rat ileum MPLM and colonic SPM 
preparations serve as suitable in vitro intestinal nerve smooth muscle and epithelial 
cannabinoid bioassays respectively. 
 
6.2 Future work 
 
Experiments described in Chapter 3 were restricted to investigating the effect of the 
cannabinoids on contractions of the rat ileum MPLM to two frequencies of EFS. An 
examination of the effect of the cannabinoids on contractions to a range of 
frequencies of EFS would help characterise the EFS frequency range over which the 
cannabinoids act separately on one or both of the CB1 and non-CB1-non-CB2-non-
TRPV1 receptors. These experiments may also uncover the presence of additional 
cannabinoid targets that can modulate the EFS-evoked contractions of the MPLM.  
 
An investigation into the effects of the cannabinoids on the EFS-evoked release of 
ACh from the MPLM in response to the EFS parameters used for eliciting the twitch 
and rebound contractions would confirm the ability of the cannabinoids to modulate 
the EFS-evoked contractions by a modulation of ACh release. The effects of a 
cannabinoid on [3H]-ACh release could be studied from [3H]-choline pre-incubated 
MPLM strips as described by Mang et al., (2001). In this method, samples of the 
Krebs-Henseleit solution bathing the electrically stimulated MPLM strips can be 
collected at intervals in the absence and presence of cannabinoids. The radioactivity 
content of the samples can be quantified by liquid scintillation spectrometry to give a 
measure of the change in the outflow of the evoked [3H]-ACh in the presence of the 
cannabinoid. Alternatively, both ACh release and muscle contraction can be studied 
simultaneously using the cascade super-fusion technique (Finkleman, 1930; Gaddum, 
1953). In this technique, two MPLM strips can be suspended one below the other 
between isometric transducers and superfused with Krebs-Henseleit solution in the 
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absence and presence of cannabinoids. EFS of only the top i.e. donor MPLM strip 
would cause a contraction and the release of ACh of this strip. The ACh released from 
the donor strip would then contract the second i.e. recipient MPLM strip being 
superfused by the superfusate. The release of ACh can be easily verified by the 
inclusion of atropine or TTX in the superfusing Krebs-Henseleit solution. The 
inclusion of a cannabinoid agonist in the superfusing Krebs-Henseleit solution would 
inhibit the contractions of both MPLM strips. The inhibition EFS-evoked contractions 
of the donor strip would be explained with the same reasons as mentioned above for 
the organ baths studies. The attenuation of the contractions of the recipient MPLM 
strip would be indicative of the inhibition of ACh release from the donor MPLM strip 
because, as shown in the organ baths studies, cannabinoids do not interact with the 
muscle mACh receptors. 
 
To date, in vivo intestinal transit studies have not analysed the motility patterns of the 
small intestine following administration of cannabinoids.  The collective in vivo data 
suggests that activation of the CB1 receptor causes an inhibition of the propulsive 
patterns of contractile activity such as peristalsis as has been observed in vitro. In 
vitro functional studies with the rat ileum MPLM may be useful in characterising the 
mechanism of the action of the cannabinoids on different EFS-evoked cholinergic and 
non-cholinergic-non-adrenergic motility patterns. These studies could be extended to 
the effects of cannabinoids on the MPLM preparation from rats with an inflamed 
ileum.   
 
An experiment investigating the effect of cannabinoid agonists and SR 141716 on 
ACh-mediated contractions of the rat ileum MPLM elicited by pharmacological 
stimulation of the myenteric plexus, such as with nicotine and veratridine would 
provide comparative data for the EFS experiments. These studies may also provide 
insights into the role of the different receptors in relating the difference in the 
receptors modulating the twitch and rebound contractions of the MPLM. 
 
The ability of SR 141716, AM 251 and O-2050 to increase the amplitude of the twitch 
contractions of the rat and guinea-pig ileum MPLM preparations was suggestive of 
inverse agonism at the CB1 receptor. This conclusion was supported by the failure of 
the inhibitors of FAAH and the endocannabinoid uptake transporter to inhibit the 
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twitch contractions. Compelling evidence for the absence of an endocannabinoid tone 
may be obtained by measuring the levels of AEA and 2-AG from samples of the 
Krebs-Henseleit solution bathing the MPLM strips in the absence and presence of 
EFS using liquid chromatography and mass spectroscopy techniques. These 
experiments could be performed in the absence and presence of inhibitors of FAAH 
or the endocannabinoid uptake transporter to complement the data from the organ 
bath studies. 
 
In experiments described in Chapter 4, the ability of AM 251 and O-2050 to augment 
the twitch contractions of the MPLM tissues was taken to be mediated by the CB1 
receptor. An estimation of the pKB values of these cannabinoids would be necessary 
to confirm their action at the CB1 receptor.  
 
A major experimental limitation of the studies on the colonic SPM preparation was 
the inability to wash the capsaicin and nicotine after each response. A modification of 
the perspex Ussing chambers by including ports for draining the Krebs-Henseleit 
solution from the chambers may allow repeated secretory responses to be evoked in a 
single preparation. An examination of the interaction between a range of 
concentrations of the cannabinoid agonists and SR 141716 would allow precise 
characterisation of the CB1 receptor. These studies could be extended to inflamed 
colonic SPM preparations.  
 
The cannabinoids used in the present study represent a small fraction of cannabinoids 
that have been assayed in vivo. Little is known about the pharmacology of the many 
other endocannabinoids and phytocannabinoids and their interaction with other 
receptor systems that modulate intestinal motility and secretion. The rat ileum MPLM 
and colonic SPM preparations may also prove useful in characterisation of the 
pharmacology these cannabinoids and their interactions with other receptor systems. 
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